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Abstract 
Dyslipidemia and obesity are associated with an increased risk of breast cancer. Several 
obesity-related host factors involved in systemic metabolism can influence tumor 
initiation, progression, and/or response to therapy. 
 Insulin like growth factor (IGF) signalling and levels of cholesterol, particularly low-
density lipoprotein cholesterol (LDL-C) and its oxysterol metabolite 27-
hydroxycholesterol (27OHC) are frequently up-regulated in obese women. Although high 
expression of LDL and 27OHC have been reported in breast cancer, their role remains to 
be elucidated.  Triple negative breast cancer (TNBC) accounts for 50% of all deaths as they 
have a high affinity to metastasize to other organs. TNBC are associated with a poorer 
outcome because there is no specific target for therapy, such as progesterone receptor (PR), 
the estrogen receptor (ER)-α, or human epidermal growth factor receptor 2 (HER-2) 
receptor, that are expressed by other sub-types of breast cancer. The major problem for the 
failure of breast cancer treatment in TNBCs is the development of resistance to 
chemotherapy.  
In this study, we examined the effect of cholesterol and its metabolite on breast cancer cell 
proliferation, migration and invasion and the association of the IGF axis and cholesterol 
metabolism. Human epithelial like estrogen receptor-α (ERα)-positive MCF-7 and T47D 
and ERα-negative MDA-MB-231 and Hs758T, breast cancer cells were used in this study. 
Crystal Violet (CV) proliferation assays were employed to detect cell growth and the 
changes in cell migration were determined using a trans-well migration assay followed by 
crystal violet staining. Western immunoblotting was used to determine changes in protein 
abundance. Secreted levels of IGF-I were measured using a radioimmunoassay. 
 We found that LDL promotes cell growth and migration, and this action was mediated 
through CYP27A1 in both ERα-positive and ERα-negative breast cancer cells. Treatment 
with 27OHC also increased cell growth in ERα-positive breast cancer cells and this effect 
was mediated through ERα. 27OHC was able to promote breast cancer cell migration and 
invasion in all cell lines, and in the ERα-positive cells, silencing the ERα did not affect this 
and we found that in ERα-negative cells this action was mediated through estrogen receptor 
β (ERβ). The addition of LDL increased the production of IGF-I and the abundance of the 
IGF-IR in MCF-7 and MDA-MB-231 cells. Inhibition of the insulin-like growth factor 
receptor using a tyrosine kinase inhibitor, AG1024, blocked the effects of cholesterol on 
cell growth and migration of MCF-7 and MDA-MB-231 cells. The inhibition of insulin-
like growth factor-1 receptor attenuated cholesterol-induced AKT and MAPK activation. 
We also found that chemotherapy treatment such as doxorubicin was less effective in 
inducing cell death in the presence of 27OHC or LDL in, MDA-MB-231, TNBC cells.  
In conclusion, 27OHC functions as a biochemical mediator of the effects of LDL on breast 
cancer cell growth and migration. 27OHC promotes cell proliferation through ERα, but 
increased cell migration and invasion through ERβ, and this resulted in intrinsic activation 
of oncogenes such as IGF-1, which can bind to the IGF-1R and activate MAPK/ PI3K/AKT 
signalling pathways.  Our data also suggest that 27OHC or LDL can act as survival factors 
in TNBC. The results suggest that using cholesterol lowering drugs such as, statins, may 
sensitize  cells to existing targeted therapies and  improve the effectiveness of 
chemotherapy. 
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1.1 Breast cancer 
1.1.1 Breast cancer epidemiology  
Breast cancer is the most common cancer worldwide in women and the leading cause of 
death (Bray et al., 2018).  The incidence rate of breast cancer currently represents one in 
four cancer cases and is expected to reach 3.2 million by 2050 (Bray et al., 2018; 
Hortobagyi et al., 2005). Although cancer exists worldwide, the incidence rate is greater in 
developed countries. Additionally, the incidence rate of breast tumour largely differs with 
ethnicity and race, which differs between every region in the globe differing from 27 per 
100,000 in East Asia and Middle Africa to 96 per 100,000 in Western Europe (Ferlay et 
al., 2015).  However, the survival rate of breast cancer is lower in less developed countries 
in comparison to developed regions, and this can be explained by the lack of screening and 
treatment options (Torre et al., 2015). Breast cancer is responsible for around 626,679 
deaths globally each year (Bray et al., 2018), and in the UK breast cancer is the fourth 
cause of cancer mortality among women (“UK Breast Cancer Statistics | Breast Cancer 
UK, 2020). In recent years, the American Cancer Society proposed that the incidence rate 
of breast cancer has increased slightly by 0.3% per year (How Common Is Breast Cancer? 
| Breast Cancer Statistics, 2019). Since 2007, breast cancer mortality rates have been 
steady in women less than 50 years but have continued to decline in women older than 50. 
Between 2013 to 2017, the death rate has decreased by 1.3% per year (How Common Is 
Breast Cancer? | Breast Cancer Statistics, 2019). Decreased mortality rates are thought to 
be the result of detecting breast cancer earlier through improved methods of early detection 




Survival rates for breast cancer significantly reduce according to stage at diagnosis, with a 
5-year survival rate of 26.2% for stage 4 breast tumours, compared with 97.9% for stage 
one early breast cancer (CRUK, 2019). The incidence of late stage diagnosis has 
significantly reduced due to increased campaigns that encourage self-examination  and 
promote awareness to increase the chance of early detection (Wang, 2017). Understanding 
the underlying biological mechanisms of carcinogenesis and the pathophysiology of the 
different subtypes of breast tumours have led to the identification of novel molecular 
targets and major advances in the improvement of targeted therapy (Feng et al., 2018). 
Such targeted therapies, have enhanced both survival with metastatic disease and 
recurrence-free interval in the same patients including longer survival after recurrence 
(Perez et al., 2011). 
 
1.1.2 Normal breast development and the progression to breast cancer  
The human mammary gland is an apocrine gland made of 12–20 lobes, which are made up 
of smaller lobules connected by a milk duct embedded in a fat pad, formed from adipocytes, 
immune cells and fibroblasts and infiltrated by vascular endothelial cells (Deugnier et al., 
2002; Macias and Hinck, 2012). The mammary epithelium consists of a basal outer layer 
of myoepithelial cells and a bilayer of inner luminal cells which reside on a basement 
membrane, and collectively these tissues are arranged as a series of branched ducts that 
drain alveolar structures during pregnancy, as outlined in figure 1.1A. The ducts have an 
outer basement membrane on which there is an outer layer of basal myoepithelial cells 
needed for milk ejection and a bilayer of inner luminal cells needed for milk production as 




pregnancy and puberty, the mammary glands are subjected to fundamental changes 
(Macias and Hinck, 2012b), induced by hormonal fluctuations, notably progesterone and 
estrogen, that orchestrate a series of paracrine interactions between stromal and epithelial 
cell types to elicit phenotypic changes in the mammary gland (Sreekumar, Roarty and 
Rosen, 2015a). 
It has been noted that the microenvironment of the breast tissue plays an important role in 
supporting normal breast tissue development, while restricting tumour formation; breast stroma 
releases regulatory signals created by extracellular matrix components. For example, laminin 
to enhance the formation of the normal breast architecture and cell differentiation  (Silberstein, 
2001).  
Breast cancer is characterised by abnormal and uncontrolled growth in lobular and/or 
ductal epithelial cells of the breast, which can migrate to other tissues and metastasise into 
secondary tumours (Ingber, 2008). Cancer progression is a multistep process involving 
genetic alterations causing an over-proliferation of cells, which become transformed and 
initiate the development of solid tumours (Hanahan and Weinberg, 2011). Much work has been 
performed to molecularly characterize breast tumours to help understand its progression and 
formation (Harbeck et al., 2019). Mutation and abnormal amplification of both tumour 
suppressor genes and oncogenes, besides the tumour microenvironment, play important roles 
in breast cancer progression and initiation (Bombonati and Sgroi, 2011; Hanahan and 






Figure 1. 1: Structure of the mammary gland. 
 (A) The human breast consists of lobules connected by a ductal network to the nipple, 
which are immersed in the stroma. Most breast cancers begin from the ducts or lobules of 
the breast. In more advanced breast cancer, the tumour penetrate the skin or components 
of the chest wall for example the pectoralis muscles (Sun et al., 2017). (B) The ducts are 
circled by an outer basement membrane which is bound by an outer layer of basal 
myoepithelial cells needed for milk ejection and a bilayer of inner luminal cells needed for 




1.1.3 Diagnosis and screening of breast cancer  
Early diagnosis of breast cancer is critical to ensure treatment starts as soon as possible. 
The primary aim of screening is to reduce the mortality rate and the number of women 
presenting with late stage cancer (Saadatmand et al., 2015). A meta-analysis study of 11 
randomized control trials with a 13 year follow up reported a 20% reduction in death from 
breast cancer among women who had been invited for screening (Bleyer and Welch, 2012). 
Several methods have been decided as breast cancer screening tools, such as 
mammography, ultrasound, magnetic resonance imaging (MRI), breast self-examination 
and clinical breast examination. Mammography uses low-dose Xray imaging to detect 
abnormalities in the breast. A secondary prevention strategy of population screening for 
breast cancer using mammography is proposed for diagnosing the disease at an early stage 
of breast cancer to allow effective treatment (Bleyer and Welch, 2012).  
The UK national screening program strategy to detect breast cancer through the detection 
of micro calcifications and characteristic masses, is inviting women between the ages of 
50-71 every 3 years for screening mammography(Marmot et al., 2013). The World health 
organization (WHO) advise the mammography screening approach in women with age 40-
49 years or 70-75 years only in the situation of careful research and in well-resourced 
settings (‘WHO | Breast cancer’, 2018). 
Breast ultrasonography is widely available and cost-effective, and measures the acoustic 
waves reflected from the breast (Wang, 2017). It helps to detect cysts and solid masses, but 
is less efficient compared to mammography, and recommended for screening women with 
high density breast tissue (Hooley, Scoutt and Philpotts, 2013). In addition to using 




BRCA1/BRCA2 and is the suggested screening application for BRCA mutation carriers and 
women with an individual history of breast cancer and those with high density breast tissue 
(Saslow et al., 2007). The treatment decisions are taken after evaluating the grade/stage of 
the cancer and biological characteristics, menopausal status, the patient’s age and 
preferences and the risks and benefits associated with the particular option. However, the 
early management plan in breast cancer is based on loco-regional tumour load, molecular 
subtype, and patient decision (Harbeck and Gnant, 2017). 
 
1.1.4 Breast cancer grading and staging  
Cancer cells are given a grade and stage, which is used to predict prognosis. Histological 
grading depends on the microscopic appearance of cancer cells, which measures the 
percentage of the degree of nuclear pleomorphism, tubule formation and numbers of 
mitotic figures (Harbeck and Gnant, 2017). A score of 1 to 3 is provided based on the 
degree of abnormality of the breast tumour cells for each criteria; the scores are then added 





Table 1. 1: Breast cancer grading, adapted from (Elston and Ellis, 1991; Bloom and 
Richardson, 1957). 
Feature graded  Clinical feature  Score  
Tubule formation  > 75%  1  
  10-75%  2  
  < 10%  3  
Nuclear polymorphism  
  
  
Small, regular uniform 
cells  
1  
Moderate increase and 
variability  
2  
Marked variation  3  
Mitotic figures  




0- 5  1  
6- 10  2  






Breast cancer is graded based on histological features; then combined the score for each 
of these and add this score to the final grade as described.  
From 1959, seven editions of the tumor-node-metastasis (TNM) system have been 
established for tumour staging from the American Joint Committee on Cancer (AJCC). The 
8th edition was published in 2017, as outlined in table 1.2. The fundamental changes focus 
on breast cancer as a group of diseases including multiple molecular characteristics that 
demonstrate patterns of recurrence, various prognoses, and sensitivities to available 
therapies (Elston and Ellis, 1991). The committee integrated biomarkers (hormone 




anatomic TNM staging. Breast cancer is then categorised into four stages 1-4 dependent 
on the TNM criteria (Koh and Kim, 2019). Following staging and grading of breast 
tumours, histological examination of the excised tumour is required for evaluation of the 
subtype of breast cancer to decide the appropriate treatment (Koh and Kim, 2019).  Breast 
cancer is staged depending on the guidelines of the American Joint Committee on Cancer 
(AJCC), following the TNM evaluation of primary cancer size (T), degree of lymph node 
involvement (N) and extent of metastasis (M) (Ravaioli and Tassinari, 2000) as outlined in 






Table 1. 2: Staging criteria for breast cancer tumours: adapted from (Egner, 2010; 
Koh and Kim, 2019).   
 
Breast cancer is staged based on the amount of invasion/migration to lymph nodes (N), 
tumour size (T), and surrounding tissues (M). According to TNM classification, and these 





1.2 Breast cancer subtypes  
The two major approaches in the management of breast tumour are systemic therapy and 
locoregional treatment; the molecular alterations and histological characteristics of breast 
cancer dictate breast cancer management and treatment (Sims et al., 2007). There are 
several molecular pathways that are involved in the development of breast carcinogenesis 
and establish various categorisations. The intrinsic classification, reported in 2000 by 
Perou, categorised subtypes of breast cancer into luminal-A and -B (having high expression 
of the estrogen receptor (ER), basal-like and human epidermal growth factor receptor 2 
(HER2)-positive (without ER expression) (Perou et al., 2000; Sørlie et al., 2001). This 
classification shifted clinical diagnosis from being dependent on tumour burden to being 
dependent on the biology of the tumour. Nowadays, clinical practice classifies tumours 
based on five subtypes, that encompass the histological and molecular characteristics. 
Tumours expressing a progesterone receptor (PR) and/or estrogen receptor or/and HER2 
are classified as hormone receptor-positive breast cancers: two ER-positive (ER-positive; 
luminal A and luminal B), two ER-negative (ER−; ERBB2 and basal subtypes), and triple-
negative breast cancer (TNBC: that do not express PR, ER or HER2) (Perou et al., 2000). 
Women with the ER-positive or PR-positive /HER2-positive subtype have better survival 
outcomes than those with the ER-negative or PR-negative /HER2-negative 
subtypes (Howlader et al., 2018).   
The best survival rate was between women with the ER+ or PR+/HER2+ subtype, whilst 
the shortest survival rate was between women with ER- or PR-/HER2- breast tumor 




 The inadequate approach to molecular genetic tests in addition to their high costs limits its 
use in clinical practice, therefore, other more feasible approaches such as 
immunohistochemical (IHC) markers are used to predict breast cancer subtypes (Reis-
Filho and Pusztai, 2011). Tumour growth marker is a nuclear marker, Ki-67, that is 
expressed in all phases of the cell cycle, except G0.  Ki-67 is a crucial determinant of breast 
tumour prognosis and staging system, as an algorithm is used to decide the most 
appropriate medication for patients with breast cancer.  Ki67 is only applicable for ER+, 
HER2- breast tumours, since HER2+ breast tumours and TNBC subtypes require 
chemotherapy treatment, and assessment of Ki67 does not contribute to medical treatment 
decision-making comparing to other breast cancer subtype.  
The tumour grade is determined by evaluating morphological characteristics and by 
assessing Ki-67 expression. A cut-off point of 20% was determined to differentiate high 
Ki-67 from low Ki-67 to discriminate between luminal A-like and luminal B-like breast 
tumours and thereby the need for added chemotherapy, in the St. Gallen Consensus (Gnant, 
Harbeck and Thomssen, 2011). The low growth tumors were defined at Ki-67 value <20%, 
cut-off and the high growth tumours were defined at ≥20% Ki-67 value (Cheang et al., 
2009).  
Luminal A-like was categorised as ER+/HER2- with low Ki67 and PR ≥ 20%. Therefore, 
luminal B (HER2-) was categorised as ER+/HER2− with high Ki67 or PR < 20%. Ki67 
cut-off value 20% stained nuclei is the most widely used in invasive cancer cells and is 
considered low growth rate at a cut-off of <15% stained nuclei (Nielsen et al., 2020).  
Assessing Ki-67 is important in determining the best adjuvant chemotherapy treatment for 




1.2.1 Luminal breast cancer  
Luminal A breast cancers are characterised as a low risk group that reveal a good response 
to endocrine treatment, compared to luminal B subtype, which has a higher grade and 
higher expression of Ki-67 (Perou et al., 2000).  New definitions and guidelines for the 
management of luminal-A and -B were advised in St Gallen consensus 2011 (Goldhirsch 
et al., 2011). The cutoff point between high and low expression of Ki-67, which is the value 
of Ki-67 of 14% was the one best associated with the gene expression that related to luminal 
A type, whereas the high value for Ki-67 >14 was used as new definition for the HER2-
negative luminal-B subtype. In the ST. Gallen, 2013, consensus meeting, another new 
surrogate definition, reduced PR expression, was added for the HER2-negative luminal-B 
subtype, with a PR expression cutoff point of >20% related to luminal A 
subtype(Goldhirsch et al., 2013), as described in table 1.3 (Perou et al., 2000) such as, ER- 
and PR- related genes, lack of gene expression of HER2, and low expression of 
proliferation-related genes (Bombonati and Sgroi, 2011). Luminal A are the most frequent 
type of breast cancer, with a frequency 28-31% (Sotiriou et al., 2003).  
 Luminal B breast cancers are defined by ER positivity, higher expression of Ki-67 and the 
HER2 gene and a lower expression of different luminal-related genes, such as estrogen 
receptor 1 gene (ESR1) or Forkhead Box A1 (FOXA1)  (Prat et al., 2015), compared to 
luminal-A type.  
Subtype Characteristic  Treatment  
Luminal A  ER(+) &PR(+) & HER2(-) Hormonal therapy  
Luminal B  ER(+) & PR(+) & HER2 (-/or +) Hormonal and /or chemotherapy  




Luminal B tumours are linked with a poorer prognosis and are likely to have a greater risk 
of a recurrent cancer than that of luminal A (Perou et al., 2000). The two luminal A and B 
are categorised with positive gene expression of the hormone receptors, ER and PR, 
although a portion of luminal B subtype also express HER2, as described in table 1.3 (Ahn 
et al., 2015). Furthermore, the two ER-positive breast cancer subtypes, are correlated with 
long term survival and a good prognosis, in comparison to ER-negative subtypes (HER2-
positive and basal-like) that are linked with poor prognosis, and this difference is due to an 
individual response to antiestrogen treatment (Cheang et al., 2009). 
1.2.1.1 Estrogen receptors: 
Estrogen plays a crucial role in the development of the normal reproductive system: being 
involved in regulation of the immune system, bone, brain, reproduction, cardiovascular 
system, breast, prostate, and inflammatory processes (Minutolo et al., 2011). Estrogen is 
also a promotor of breast cancer, through its binding to the ER (encoded by estrogen 
receptor 1(ESR1)), which dimerises and translocates to the nucleus, where it binds to ER 
elements (EREs), to regulate the expression of various genes (Osborne et al., 2001), such 
as those linked with cell proliferation, survival and growth including cyclin D1, insulin-
like growth factor-1 receptor (IGF-1R) (Yu et al., 2012), anti-apoptotic B-cell lymphoma- 
2 (BCL-2) protein and vascular endothelial growth factor (VEGF) (Fotovati et al., 2006; 
Kousidou et al., 2008). Additionally, the ER also regulates non-genomic effects, by binding 
to cell surface receptors and activating cell signalling pathways. G-protein coupled 
estrogen receptor 1 (GPER) has been proposed to initiate non-genomic actions of estrogens 
in the cytosol. This leads to activation of several signalling pathways; phosphatidylinositol-




mitogen activated protein kinases (MAPKs)(Kleuser et al., 2008), to modulate various 
functions within the cell, such as, cell proliferation and survival (Lipovka and Konhilas, 
2016), explained in figure 1.2. During normal breast development, the hormones 
progesterone and estrogen are mainly responsible for coordinating the changes that occur 
in females through the activation of different transcription factors responsible for cell 
growth and differentiation (Sreekumar, Roarty and Rosen, 2015b). However, during the 
menstrual cycle the imbalance between progesterone and estrogen enhances the 
constitutive activation of the estrogen signalling cascades along with acquired mutations 
of oncogenes, that may promote the uncontrolled or abnormal growth of mammary 
epithelial cells and enhance the development of cancer cells (Feitelson et al., 2015). 
Furthermore, there is a strong correlation between postmenopausal women and the 
development of ER-positive breast cancer, that is thought to be due to the effects of high 
estrogen levels in obese women which leads to increased breast cancer progression and 
growth (Omoto et al., 2002; Murillo-Ortiz et al., 2008; Cheng et al., 2013). In post-
menopause women, the main source of estrogen modulation is the adipose tissue. 
Therefore, dysregulation of ER signalling is linked with progression and initiation of 
several cancers, including breast cancer. 
The action of estrogen is predominantly regulated via its two receptors: ERβ and 
ERα, which have different transcriptional activities in normal breast development and 
breast tumour progression (Osborne et al., 2001). The effects of estrogen are mediated 
through activation of various genes that are regulated by ligand‐modulated transcription 




ERα is expressed in 50–80% of breast cancers and is a significant indicator for breast 
tumour survival and the efficacy of hormone therapy. ERα is expressed less in normal 
human mammary epithelial cells of postmenopausal women, approximately by 10%, whilst 
ERβ expression level is higher; approximately by 50% in normal mammary epithelial cells 
of postmenopausal women, but not for premenopausal women. Nuclear ERβ but not ERα 
expression is found in stromal cells in postmenopausal women (Omoto et al., 2002; 
Murillo-Ortiz et al., 2008; Cheng et al., 2013). In breast cancer patients, loss of ERα 
indicates invasiveness and poor prognosis (Cheng et al., 2013).  
The primary function of ERβ in breast cancer progression is still being investigated 
(Lipovka and Konhilas, 2016). ERβ is expressed more than the ERα in mouse mammary 
glands and normal mammary epithelium (Roger et al., 2001). ERβ is also found in both 
myoepithelial cells and surrounding endothelial and stromal cells of the breast. It is 
purported that the role it plays depends on the relative ratio of expression of ERα to ERβ, 
and recent data suggests that ERβ has a pro-tumourigenic role in ERα-negative breast 
cancers (Leygue and Murphy, 2013). Several studies have reported on the expression of 
ERβ in patients samples, and some of these studies have found a link between high ERβ 
expression level and good prognosis in breast cancer(Järvinen et al., 2000; Hopp et al., 
2004; Esslimani-Sahla et al., 2005; Miller et al., 2006; Gruvberger-Saal et al., 2007; 
Sugiura et al., 2007a; Bozkurt and Kapucuoĝlu, 2012). Additionally, current pre-clinical 
studies in breast tumour animal models and cell lines propose a beneficial impact of ERβ 




The importance of ERβ in breast cancer progression and development is still ambiguous, 
as ERβ plays various functions based on the presence or absence of ERα (Haldosén, Zhao 
and Dahlman-Wright, 2014a). In fact, approximately 60% of all subtypes of breast 
tumours, that tested positively for high ERβ expression, do not have ERα expression 
(Skliris et al., 2006a). Previous studies proposed that ERβ is thought to act as a 
carcinogenic factor in breast tumours (Haldosén, Zhao and Dahlman-Wright, 2014b). 
Notably, in recent studies ERβ is defined as a predominant negative regulator of estrogen 
pathway, hence ERβ restrained ERα regulated transcription through creating heterodimers 
with ERα (Girgert, Emons and Gründker, 2019). The nuclear ERβ is expressed in 44.4% 
of TNBCs (Matthews and Gustafsson, 2003; Marotti et al., 2010).  ERβ has five different 
isoforms, therefore these multiple isoforms complicate the investigation of the function of 
ERβ and its participation in breast cancer carcinogenesis (Girgert, Emons and Gründker, 
2019). The role of ERβ in TNBC is not yet clear. A study analyzed 442 tissue samples from 
women with breast cancer administered with tamoxifen for the effect of ERβ1 expression 
on overall survival rates (Honma et al., 2008). Those groups with ERβ1-positive tumors 
demonstrated a significantly better overall survival rate in comparison to women with 
ERβ1-negative group in postmenopausal women, but not premenopausal women (Honma 
et al., 2008). Patients with progesterone-receptor negative, ERα-negative breast cancer 
expressing ERβ1 displayed a better prognosis regardless of whether the tumors with HER2-
positive or not (Zhang et al., 2012).  
The remaining four isoforms of ERβ (ERβ2, ERβ3, ERβ4, and ERβ5), do not bind to 
estrogen (Honma et al., 2008; Zhang et al., 2012). Several reports explored the influence 




been proposed that a better overall survival rate for breast cancer patients is evident with a 
high expression of both ERβ1 and ERβ2, and that ERβ1 expression is strongly associated 
with ERβ2 expression (Sugiura et al., 2007b). Interestingly, it has been proposed that 
nuclear ERβ1 and ERβ5 correlated with better overall survival rates in a study of 880 breast 
cancer patients (Shaaban et al., 2008).  
In contrast, Novelli  and their collogue  indicated that ERβ expression is a biomarker 
related to more aggressive proliferation in lymph node-positive breast cancer patients and 
indicated a higher chance of relapse (Novelli et al., 2008a).  Additionally, ERβ inhibits 
estrogen-induced proliferation by preventing ERα activation of the cyclin D1 gene, a 
major modulator of entry into the proliferative step of the cell cycle, when both receptors 
were expressed in Hela cells. This suggests that ERβ is capable 
of regulating the growth effects of 17β-estradiol binding to ERα (Liu et al., 2002). A recent 
study has been reported that ERβ2 is associated with growth and invasion of TNBC through 
the regulation of HIF-1 pathway (Bialesova et al., 2017).  
In TNBC, high expression of the epidermal growth factor (EGF) receptor is considered as 
one hallmark of high proliferation rates in these cancer types (Chen and Russo, 2009). 
Studies have reported a correlation between ERβ and the insulin-like growth factor (IGF) 
and EGF signalling pathways (Thomas et al., 2012). Knocking down ERβ in TNBC cell 
lines reduced cell proliferation, invasion and migration that were linked with down-







Figure 1. 2:  A diagram of estrogen signaling pathways, including genomic and non-
genomic response structures, adopted from (Tsuji and Plock, 2017). 
The arrow indicates the direction of the reaction. (ER) estrogen receptor, (ERE) estrogen 
responsive elements, (E) estrogen, HER, human epidermal growth factor receptor; 
(MAPK) mitogen-activated protein kinase, SRC proto-oncogene, non-receptor tyrosine 
kinase, P, protein; PI3K phosphatidylinositide 3-kinase, AKT protein kinase B; mTOR, 
mammalian target of rapamycin;(TF) transcription factor. 
1.2.1.2 Targeted therapy for ERα-positive breast cancer 
Targeted therapy for ER-positive breast cancer includes tamoxifen, an ER antagonist, that 
prevents estrogen-induced effects by inhibiting estrogen receptors in breast tissues 
(Piperigkou et al., 2016). Aromatase inhibitors (AIs) have been used as targeted therapy 
for ERα-positive breast cancer, which prevent the conversion of androgens, such as 
testosterone, to estrogen, and result in a reduction of estrogen production and ER activation 
(Miki et al., 2007). Intra-tumoural production of estrogen can be increased by cancer cells 




estrogen synthesis and present in breast adipose stroma and epithelium, which activates 
estrogenic signalling pathways (Brown and Simpson, 2010). Preclinical studies have 
advocated that aromatase inhibitors are likely to be more effective than tamoxifen in the 
treatment of ER-positive breast tumours in postmenopausal women, due to the serious and 
long-term side effects of tamoxifen in the treatment of advanced breast tumours (Xu, Liu 
and Li, 2011; C. Y. Liu et al., 2017). Significantly, these endocrine targeted therapies for 
ER-positive breast cancer have decreased mortality rates, by approximately 25-30% 
(Haque and Desai, 2019). However, about 30% of women treated with endocrine targeted 
therapy, in particular tamoxifen, develop the risk of recurrence, resistance in the next 
decade and long-term toxicities such as thromboembolic events and endometrial cancer, 
and this causes increasing use of alternative hormonal therapies such as aromatase 
inhibitors (Dowsett et al., 2010; Xu, Liu and Li, 2011). However, not all ER-positive breast 
cancer patients respond to targeted therapy for ER-positive breast tumours, and even those 
that are initially responsive ultimately become resistant as the disease progresses (Haque 
and Desai, 2019). 
Emerging evidence suggests several pathways can contribute to endocrine therapy 
resistance by ligand-independent activation of ER, such as growth factor activated 
pathways, PI3Kinase/AKT and MAP kinase, and G-protein coupled receptor pathways 
(Haque and Desai, 2019). Furthermore, ER-positive breast cancers which overexpress 
growth factors like HER2 and EGFR are more likely to become resistant to hormone 
therapy (Haque and Desai, 2019). Clinical trials suggested that using PI3K/AKT inhibitors 
combined with aromatase inhibitors resulted in promising targeted therapy for ER-positive 




understanding the involvement of metabolic proteins in growth factor signalling, in 
addition to ER, is a developing strategy to stop the development of resistance to endocrine 
therapy.   
Preclinical models using a CDK4/6 inhibitor, Palbociclib, in hormone receptor positive 
breast cancer studies indicated high sensitivity and a good response rate. The cyclin-
dependent kinases 4 and 6 (CDK4/6) are major promoters of cancer proliferation that 
regulate cell cycle progression in hormone receptor-positive breast tumours, correlating 
with estrogen receptor signalling pathway stimulation (Turner et al., 2018). Palbociclib 
when added to the endocrine therapy letrozole (O’Leary et al., 2018) and fulvestrant for 
cure of hormone receptor positive and HER2-negative metastatic breast tumour increased 
progression free survival (Cristofanilli et al., 2016). 
1.2.1.3 HER2-positive breast cancer: 
HER2-positive breast cancer is defined by loss of expression of PR and/or ER gene, HER2 
amplification and the low expression of basal and luminal clusters as described in table 4 
(Lee, Loh and Yap, 2015). HER2 (named ERBB2) is one member of the epidermal growth 
factor (EGFR) family of receptor tyrosine kinases (RTK) along with HER1, HER3 and 
HER4 (Perou et al., 2000; Kondov et al., 2018). HER2 signalling is a crucial mediator of 
cell differentiation and proliferation during normal breast development. However, 
amplification of HER2, leads to increased expression of the receptor which is linked with 
the development of HER2-positive breast cancer (Yarden and Pines, 2012) through the 
activation of downstream signalling cascades, such as the PI3K and MAPK signalling 




cases are diagnosed with HER2-positive breast tumours and are largely correlated with 
more aggressive breast diseases, shorter disease-free survival and higher recurrence rates 
(Cho et al., 2003; Iqbal and Iqbal, 2014).  
 
1.2.1.4 Targeted therapy for HER2 breast cancer 
Trastuzumab (Herceptin) is a targeted therapy, that is used to target HER2 genes for HER2-
positive breast cancer, which prevents the dimerization and activation of HER2, as 
described in table 4 (Vu and Claret, 2012). Trastuzumab results in the inhibition of the 
downstream PI3K and MAPK signalling cascades, which leads to the suppression of cell 
growth and proliferation (Vu and Claret, 2012). Pertuzamab is a targeted therapy, which 
inhibits the dimerization of HER3 and HER2 receptors and is also used for HER2-positive 
breast tumours in combination with trastuzumab to inhibit the HER2 signalling cascade 
(Vu and Claret, 2012), which has significant results with HER2-positive metastatic breast 
cancer (Capelan et al., 2013). A clinical study found that IGF-1R expression increased with 
trastuzumab resistance (Kast et al., 2017). Hence, understanding the molecular 
mechanisms underlying resistance to therapy may reveal novel targets to improve 
therapeutic benefit.  
Table 1. 4: Breast cancer molecular sub-types and treatment 
Subtype Characteristic  Treatment  







1.2.2 Triple-negative breast cancer (TNBC) 
 The TNBC subtype is defined as ER-negative, HER2-negative, PR-negative with high 
expression of Ki-67, as described in table 1.5 (Vu and Claret, 2012; Harbeck and Gnant, 
2017). TNBC accounts for approximately 20% of all diagnosed breast cancers, but is 
responsible for roughly 50% of all breast cancer mortalities as they have a high propensity 
to metastasize to the critical visceral organs (Chavez, Garimella and Lipkowitz, 2010). 
Patients with TNBC have a poorer outcome in comparison with the other diagnosed sub-
types of breast cancer principally due to no specific targetted therapy for TNBC (Chavez, 
Garimella and Lipkowitz, 2010). 
TNBC is more common in women less than 40 years of age, in women with BRCA1 gene 
mutations and among African-American women (Gonzalez-Angulo et al., 2011; Allison, 
2012).  In TNBC, high expression of epidermal growth factor (EGF) is one hallmark for 
increasing proliferation of these tumors. TNBC at diagnosis is more likely to be T2 or T3, 
and have already metastasised to the lymph nodes and are more aggressive than other breast 
cancer subtypes (Girgert, Emons and Gründker, 2019). TNBC are difficult to detect by 
screening methods like mammography because of the higher breast tissue density or rapid 
growth rate leading to late detection (Dent et al., 2007).  
The lack of a specific target is the major issue for the development of specific treatments 
against TNBC (Dent et al., 2007). Approximately 70% of TNBC subtypes are classified as 
basal-like tumours because both are heterogeneous subgroups which illustrate the poorest 
prognosis of this subtype (Lachapelle and Foulkes, 2011). Basal-like tumours are more 
likely to be characterised by the expression of individual genes of the epithelial cells in the 




(Shah et al., 2012). Upregulation of basal marker genes such as cytokeratin 5 and 17 result 
in deregulation of genes involved in the cell cycle pathway, alteration of growth factor 
signalling and DNA damage response pathways leading to a promotion of cell proliferation 
and tumour progression (Lehmann et al., 2011).  
Table 1. 5: Breast cancer molecular sub-types and treatment 
Subtype Characteristic  Treatment  
Triple-negative/basal- like  ER-, PR- and HER2-  Chemotherapy  
 
1.2.2.1 TNBC management 
Since TNBCs lack druggable targets, such as HER2 and ER,  chemotherapy is still the 
main choice of treatment for this sub-type of breast cancer (Lebert et al., 2018). 
Neoadjuvant chemotherapy results in higher rates of pathological complete response for 
localised early-stage TNBC compared with hormone-positive breast cancers (28% vs. 
6.7%) (Nakai, Hung and Yamaguchi, 2016). In particular, patients who have defective 
DNA repair mechanisms for example those with high expression of BRCA1/BRCA2 
mutations, respond positively to chemotherapy (Lebert et al., 2018). Although, TNBC 
indicates a favourable clinical response to chemotherapy, overall and cancer specific 
survival rates are lower than the other breast tumour subtypes, which is largely attributed 
to their more aggressive phenotype (Wahba and El-Hadaad, 2015). Although, it has been 
demonstrated that the EGFR signalling pathway plays an important role in TNBC 
progression, the results from clinical studies in breast cancer of EGFR-targeted therapy 
have been disappointing  due to low response rates (Masuda et al., 2012). Another factor 




down-stream signalling-independent of EGFR activation (Nakai, Hung and Yamaguchi, 
2016). 
 Furthermore, the most promising clinical target for TNBC is poly (ADP-ribose) 
polymerase (PARP). Inhibitors of PARP induce synthetic lethal actions in breast cancer 
patients with high BRCA mutations and interfere with the repair of single-stranded DNA 
breaks leading to tumour cell apoptosis (Nakai, Hung and Yamaguchi, 2016).  
1.3  The insulin-like growth factor system  
The insulin-like growth factor (IGF) system is a complicated network which plays an 
important role in the regulation of cell growth, and survival. It is essential in embryonic 
and postnatal development, as it influences almost all organ systems. IGFs were discovered 
in the early 1950s as somatomedins, however, when their insulin-like actions were 
identified later, the term insulin-like growth factors was then introduced in 1976 (Steck 
and Murphy, 2019) 
The IGF ligands, IGF-I and IGF-II, have high structural similarity to insulin. 
The physiological responses to specific receptor activation is still under investigation. In 
general, binding to the IGF-1 receptor (IGF-IR), is thought to mediate mitogenic effects, 
with the insulin receptor (IR) mediating metabolic actions. Each ligand has higher affinities 
for their corresponding receptors but can also bind to other receptors with lower affinity.  
IGF-II is able to bind to the IGF-IR receptor (6 fold lower affinity than IGF-I) and to the 
IR with different affinity.  The IGF-IR is thought to mediate most of their biological 




The IGF system also has six high affinity IGF binding proteins (IGFBP-1 to 6) that can 
have effects that are dependent or independent of IGF binding (Rinderknecht and Humbel, 
1976; Baxter, 2014).  
 
1.3.1 Insulin like growth factors–I (IGF-I &-II)  
IGF-I has 50-70% similarity to the structure of insulin. This enables IGF-I to bind (with 
low affinity) to the IR (Cox et al., 2015). IGF-I is primarily secreted by the liver into the 
blood circulation (Rechler, 1993). IGF-I is also expressed in most tissues including breast 
tissue. IGFs consist of the insulin growth factors (IGF-I and IGF-II), and their cell 
membrane receptors (IGF-IR, IGF-IIR, and IR) and six high-affinity binding proteins 
(IGFBP-1 to -6) which act primarily as carriers for IGFs. Most tissues can make IGFs and 
IGFBPs.  
The predominant regulator of IGF-I is growth hormone (GH) and it generally is involved 
in cell proliferation, migration and apoptosis, therefore affecting organisms longevity and 
size (Rechler, 1993).  
Although IGF-I is mainly considered a key factor in postnatal growth, which stimulates the 
growth of several cell types, it has other significant metabolic effects, such as direct effects 
on specific tissue or not direct effects by mediating the actions of GH. Additionally, IGF-I 
reduces blood glucose levels by enhancing tissue glucose uptake in muscle and blocking 
glucose production from the liver and it helps to increase insulin sensitivity (Zapf, Schmid 
and Froesch, 1984) and to promote protein synthesis. IGF-I serves as a mediator of 
mammary branching and ductal formation, which is implicated in the pathogenesis of 




effect in cancer progression, including breast cancer and in addition in contributing to 
resistance to targeted therapies (LeRoith and Roberts, 2003; Christopoulos, Corthay and 
Koutsilieris, 2018a).  
IGF-II is a 7.5 kDa peptide primarily secreted by the liver, with 62% homology with IGF-
I and consists of 67-amino acids. Serum levels of IGF-II are stable in adults, with a mean 
concentration of 700 ng/ml and a minimal decline with ageing (Humbel, 1990). IGF-II 
serum levels are correlated to the nutritional habits of the individual, as its levels have been 
shown to decrease with malnutrition (Wolf et al., 1994) and increase in overweight 
individuals, (Buchanan, Phillips and Cooper, 2001) both total and free IGF-II (Frystyk et 
al., 1999); this alteration in serum levels being reversible with weight loss (Belobrajdic et 
al., 2010). The physiological role of IGF-II is less well understood during adult life, but in 
comparison with IGF-I, IGF-II is more abundant in the blood serum and remains stable 
during pregnancy as a regulator of fetal development and growth (Frasca et al., 1999). The 
lack of clear understanding of the role of IGF-II may be due to its overlapping effects with 
IGF-I (Frasca et al., 1999). IGF-II is an important factor for normal embryonic growth but 
not important for postnatal development in mice (DeChiara, Efstratiadis and Robertsen, 
1990). Several studies have shown that IGF-II plays a role in intra-uterine proliferation in 
humans, as it is plentifully secreted by the placenta; IGF-II also helps to promote the 
formation of mesoderm cells, trophoblast invasion and growth, survival of 
cytotrophoblasts, enhance organ development and improve nutrient transport. IGF-II 
promotes angiogenesis through its regulation of vascular endothelial growth factor 
(VEGF), which can stimulate differentiation of endothelial cells (Irwin et al., 1993; 




in growth promotion in humans after birth (Begemann et al., 2015) and in postnatal bone 
development and cartilage proliferation (Uchimura et al., 2017). 
 
1.3.2 IGF-I receptors 
The mitogenic actions of IGF-I are modulated primarily via the IGF-IR receptor (Ward et 
al., 2013). IGF-I receptor activation affects cell proliferation, migration, survival and 
invasion (Arcaro, 2013). The IGF-IR and IR belong to the tyrosine kinase family of 
receptors and they share almost 84% structure similarity. These two cell membrane 
receptors consist of α and β subunits connected by disulphide bonds to form homodimers 
(Laron, 2001). The α subunit is the ligand binding site and located extracellularly, while 
the β subunits are transmembrane and contain tyrosine kinase domains (Werner, Weinstein 






Figure 1.  3: Structure of the IGF receptors  
The insulin structure, IGF-I structure, insulin/IGF-I hybrid receptors structure. IGF-I and 
IR are similar in structure and both belong to the tyrosine kinase receptor family. They 
exist at the cell surface as hetero-tetramer receptors comprised of two α and two β subunits 
connected by disulfide bonds. The IGF-I/IR hybrid receptor consists of IGF-I α, β and 
insulin α, β hemi-molecules. The binding affinity of IGF-I/insulin/ IGF-II to each of the 
four receptors vary from each other, as illustrated, (adapted from (Hawkes and Kar, 2004)) 
The IGF-IR is thought to mediate mitogenic effects whilst the IR has more metabolic 
actions, although each can exert similar effects depending upon the context (Lu et al., 2001)  
Each receptor has higher affinity for their corresponding ligand, additionally they bind with 




IGF-I) and to IR with different affinities based on the isoform of the IR present (Werner, 
Weinstein and Bentov, 2008).  
Activation of the IGF-IR and the IR leads to phosphorylation of two different pathways. 
Ligand binding via initial autophosphorylation, leads to multiple substrate molecules like 
IRS-1, 2 and Src homology 2/collagen alpha proteins (SHC) to bind, and then activate 
intracellular signalling cascades: the PI3K pathway, which mainly activates  metabolic 
activity (Ahmad, Singh and Glazer, 1999), and the MAPK pathway, which involved in 
cellular growth and differentiation (Pouysségur, Volmat and Lenormand, 2002), as 
illustrated in Figure 1.3. 
PI3K activation results in the conversion of phosphatidylinositol 4,5 bisphosphate (PIP2) 
to phosphatidylinositol 3,4,4-triphosphate (PIP3), resulting in the activation of protein 
kinase B (AKT) causing an elevation of glucose uptake. Additionally, activation of the 
PI3K pathway promotes phosphorylation of 4E-binding protein 1(4EBP-1), resulting in the 
release of eukaryotic translation initiation factor 4E (eIF4E) and enhancing protein 
synthesis (Morita et al., 2015). In addition, mTOR leads to ribosomal protein S6 kinase 
(S6Ks) phosphorylation, which promotes protein synthesis, and activates anti-apoptotic 
transcription factors causing  lower cellular apoptosis (Morita et al., 2015). 
Conversely, the MAPK pathway is correlated with Src homology and collagen protein 
(SHC) phosphorylation, and the initiation of the growth factor receptor-bound protein 2 
(GRB2) and mammalian son-of-sevenless (SOS) complex that activates Ras, MAP kinases 
and Like-1 protein (ELK1) leading to mitogenic signalling and regulation of apoptosis 






Figure 1. 4: The signalling pathways of the IGF-IR and IR (adapted from (Pollak, 
Schernhammer and Hankinson, 2004a)):  
Ligand attachment is linked with activation of two downstream signalling pathways; PI3K 
pathway (left) which participates in metabolic functions, and the MAPK pathway (right) 
which participates in growth related functions. 
1.3.3  IGF axis and breast cancer  
Recent epidemiological study indicates that the association between overweight 
individuals, people with type 2 diabetes and high risk of different kinds of cancer mortality, 
when compared with those of a normal body weight who are not diabetic (Frystyk, 2004). 




type 2 diabetes. Therefore, insulin resistance and a compensatory hyperinsulinemia 
develops. Consequently, insulin indirectly increases hepatic IGF-I production and the 
quantity of bioavailable IGF-I, in a direct or indirect action via reducing the levels of 
IGFBPs -1 and -2. Due to the poor levels of binding proteins, there is more free IGF-I to 
bind to the IGF-IR (Coughlin et al., 2004; Gallagher and LeRoith, 2011). 
In vitro studies have reported that the IGF-IR is necessary for the expression of genes that 
modulate tumour cell survival, the cell cycle, attachment, motility and metastasis (Lopez 
and Hanahan, 2002; Yakar, LeRoith and Brodt, 2005a). In breast tumour, the IGF-IR 
expression is frequently high and can play additional roles in cell transformation, cancer 
cell growth and metastasis, while reducing IGF-IR expression, results in reduced cancer 
growth in the majority of tumours  (Lopez and Hanahan, 2002; Loughran et al., 
2005).  Furthermore, high expression of the IGF-IR appears to be associated with 
radiotherapy resistance and lower patient survival (Jones et al., 2009). It has been shown 
that the IGF system increases breast cancer growth and survival through different 
signalling cascades, such as PI3K/AKT and MAPK (Martin et al., 2012). Furthermore, 
ERK (MAPK44/42) plays a crucial effect in the resistance of ER-positive , MCF-7,  breast 
cancer cells, to cell apoptosis, that suggests the significance of ERK cascade in the 
continued survival of breast tumour (Kang, 2010).  IGF-1R knockout mice exhibit a 
decreased rate of cancer proliferation and migration, suggesting a major effect of the IGF-
IR in the growth of  breast cancer cell (Yakar, LeRoith and Brodt, 2005b).  
IGFBPs play an important role in the regulation of IGF-I bioavailability and may promote 
the effects of IGF-1 signalling in the tumour. It has been shown that both endogenous and 




in vitro and in athymic mice (Sachdev and Yee, 2007). On the other hand, IGFBP-2 is 
reported to function with oncogenic activities in breast cancer (Pickard and McCance, 
2015), and may be involved in breast cancer metastasis.  
 Therefore, understanding the molecular mechanisms that lead to increases in the level of 
IGF-I signalling may reveal novel targets to improve therapeutic benefit and prevent breast 
cancer.  
Patients with TNBC have a much poorer outcome in relation to other sub-types of breast 
cancer principally because there is no specific target for therapy. Roughly 41–46% of 
TNBC individuals express the IGF-IR (Bahhnassy et al., 2015). Recent evidence indicates 
that IGF-I/IGF-IR level may be associated with TNBC patients and also with lower 
response and outcome, decreased survival and higher recurrence (Hartog et al., 2011). It 
was suggested that targeting IGF-I signalling in TNBC may serve as a promising therapy 
(Bahhnassy et al., 2015). A recent study has indicated that inhibiting the IGF-IR by using 
OSI-906 (Linsitinib) can increase the sensitivity of  TNBC cells to PI3K inhibition and that 
IGFBP-3 levels may be used as predictor for sensitivity to PI3K/IGF-IR inhibitor therapy 
(De Lint et al., 2016). It has been found that IGF gene was increased in TNBC cell lines 
and xenografts, and anti IGF-IR/IR therapy (inhibitor BMS-754807) in combination with 
chemotherapy, docetaxel, significantly increased TNBC cell sensitivity to chemotherapy 





1.4  Risk factors of breast cancer  
1. Genetic predisposition 
Roughly 10% of diagnosed breast tumours are correlated with a family history and 
inherited disease (Shiovitz and Korde, 2015). Some studies suggest that breast cancer can 
be caused by two high penetrance cancer suppressor genes, BRCA1 and BRCA2, that 
normally function as tumour-suppressor genes and participate in DNA damage 
recombination and repair, apoptosis, cell-cycle checkpoint control and transcriptional 
regulation of DNA damage (Dine and Deng, 2013). A meta-analysis in in women aged 70 
years or older proposed that the breast cancer risk ratio carrying BRCA1 was 57% or 
BRCA2 genes was 49% (Chen and Parmigiani, 2007).  The prevalence of BRCA1/BRCA2 
genes differs between race groups, being less in Asian (0.5%) and high in Ashkenazi 
(10.2%) Jewish women (Daly et al., 2016). 
2. Lifestyle and other environmental factors 
Women who have first-degree relative diagnosed with breast tumour can raise the risk of 
obtaining the disease (Feng et al., 2018). The risk of breast tumours also raises with age 
due to the accumulation of random mutations in breast cells, which results in their 
transformation into cancer cells if/when sufficient mutations accumulate (Sun et al., 2017) 
and the environment is conducive. Furthermore, it has been shown that early pregnancies 
and high levels of estrogen midst pregnancy decrease breast tumour risk (Britt, Ashworth 
and Smalley, 2007).  
Other risk factors for breast cancer include obesity (Mcdonnell et al., 2014), increased 




contraceptives or hormone replacement therapy (Mørch et al., 2017; Busund et al., 2018), 
and late menopause (Harbeck et al., 2019).  
 
3. Obesity 
Obesity is an important risk factors for cancers, including breast. In the USA, overweight 
among women may cause 20% of cancer deaths and 14% of cancer deaths in men (He and 
Nelson, 2017). Evidence supports a link between obesity and insulin resistance with 
increased probability of various cancers including breast cancer (Martinez-Outschoorn et 
al., 2017; Picon-Ruiz et al., 2017). An epidemiological study by the International Agency 
for Research on Cancer (IARC) Working Group, found that overweight is linked with an 
increased risk of cancer for at the minimum 13 types of cancer, including breast (Lauby-
Secretan et al., 2016).  
The biological correlation between obesity and cancer risk, may be linked to tissue lipid 
metabolism and circulating lipid levels (Korea et al., 2014). Cancer cells demonstrate 
alterations in several conditions of lipid metabolism, which can promote the biological 
availability of lipids for the contribution of lipid to energy homeostasis, the synthesis of 
membranes and lipid signalling pathway functions, such as the activation of inflammation-
related signalling cascades. These alterations are correlated to substantial cellular 
processes, such as cell differentiation, growth, and motility  (Korea et al., 2014). 
Moreover, a meta-analysis study reported that increased daily fat intake is associated with 
increased risk of breast cancer (Mourouti et al., 2015). There is a strong association 




precursors to estrogen through high aromatase activity in adipose tissue (Matthews and 
Thompson, 2016). Specifically, obesity raises the risk by 50% in post-menopausal women 
with ER-positive breast tumour (Dalamaga, Christodoulatos and Mantzoros, 2018).  
Increased body weight and excess fat tissue are factors that contribute to epigenetic changes 
that affect gene expression. These can mediate several actions such as an increase in 
adipose tissue stores, which can lead to fat accumulation as ectopic fat tissue leading to 
increased risk for several diseases (Avgerinos et al., 2019). Ectopic fat deposition is 
defined as the pathological growth of white adipose tissue in areas where it should not be 
(e.g. intra-abdominally, intrahepatic, intramyocellular, etc.). Also, fat accumulation may 
influence different pathways such as inflammatory, metabolic, and immunologic 
alterations changing gene function, deoxyribonucleic acid (DNA) repair and cell mutation 
rate, along with epigenetic changes allowing tumour progression and transformation 
(Avgerinos et al., 2019).  
The association of high levels of insulin and insulin-like growth factors in response to 
obesity can promote the proliferation of breast cancer cells (Picon-Ruiz et al., 2017). The 
main regulator of glucose homeostasis is insulin. Chronic obesity can lead to insulin 
resistance due to hyperinsulinemia (Kahn and Flier, 2000).  
IGFs synthesized by almost every tissue in the body, are important for development, 
proliferation, and survival, being associated with tumour pathogenesis (Moschos and 
Mantzoros, 2002).  
Although, the role of obesity in cancer is not fully illuminated, the main pathways that link 
obesity to cancer include abnormalities in the IGF axis and hyperinsulinemia/IR signalling 




levels of fasting insulin were correlated with lower outcome and mortality (Goodwin et al., 
2002).  
Cells utilise glucose for energy, which is required for growth and maintenance in normal 
and cancer cells. In the presence of oxygen, under normal conditions cells metabolise 
glucose to pyruvate via glycolysis, then pyruvate is converted into acetyl-coenzyme A 
(Acetyl-coA) in the mitochondria which is catalysed by the tricarboxylic acid (TCA) cycle 
and then enters oxidative phosphorylation (OXPHOS), which leads to the net production 
of 36-ATPs compared with 2-ATPs released by glycolysis alone (Zheng, 2012). However, 
a general phenomenon of tumours, is increased glucose catabolism via glycolysis into 
lactate even under normal oxygen conditions, instead of maximising ATP generation 
through OXPHOS. This phenomenon was first observed by Otto Warburg, and has since 
been termed the Warburg effect (Person, 1957)  Despite early preconceptions tumour cells 
do not completely bypass the TCA cycle, particularly those with tumour suppressor gene 
expression and dysregulated oncogenes,  but also rely on the TCA cycle which is supported 
by functional mitochondrial activity in cancer cells (Anderson et al., 2018). Although 
glycolysis produces less ATP than OXPHOS, the rate of ATP generation by glycolysis is 
much higher than by OXPHOS, which is more appropriate to the energy demands of 
malignant cells (Pfeiffer, Schuster and Bonhoeffer, 2001). Enhanced glycolysis also 
provides tumour cells with biochemical precursors needed for the synthesis of larger 
molecules such as proteins, lipids, and nucleic acids (Heiden, Cantley and Thompson, 
2009). This remodeling of cell metabolism in breast tumours is mediated through the 
activation of oncogenes and tumour suppressor genes that cause changes to multiple 




biosynthesis, protein synthesis and the pentose phosphate pathway (PPP) (Cairns, Harris 
and Mak, 2011). Obesity is related to essential metabolic alterations that enhance tumor 
growth, such as adipose tissue dysfunction, high blood levels of insulin and IGF-I, 
inflammation, and nutrient availability (Fallone et al., 2018). These studies illustrate the 







Figure 1.  5: Modulation of cancer metabolism by obesity-related growth factors.  
Insulin and IGF-I promote the PI3K signalling pathway, which in turn upregulates several 
pathways such as glycolysis and metabolic to produce energy which can achieve the 
biosynthetic demands of growth. (IGFBPs) IGF-binding proteins, (IR) insulin receptor, 
(IGF-IR) IGF-I receptor, (AMPK) AMP-activated protein kinase, (HIF-1α) hypoxia-
inducible factor 1-alpha, (SREBP) sterol regulatory element-binding protein, (mTOR) 
mammalian target of rapamycin, (OAA) oxaloacetate, (GSR) glutathione reductase, , 
(G6PD) glucose-6-phosphate dehydrogenase, , (ACLY) ATP citrate lyase,  (GSX) 
glutathione peroxidase, (LDHA) lactate dehydrogenase A (ACC) acetyl-CoA carboxylase, 
(FAS) fatty acid synthase, (HK2) hexokinase 2, (ECM) extracellular matrix, (PFKFB3) 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3, (PEP) 
phosphoenolpyruvate,(PKM2) pyruvate kinase M2, (PDH) pyruvate dehydrogenase, 
(PFK1) phosphofructokinase-1, (CS) citrate synthase, (DCA) dichloroacetate (PDK) 




1.5  Cholesterol and breast cancer pathogenesis 
Recently, altered cholesterol metabolism, was positively and independently correlated with 
risk factors for breast tumour in post-menopausal women (Mcdonnell et al., 2014). Data 
from the Canadian National Cancer Surveillance System study states that postmenopausal 
women with high cholesterol levels had a 48% increase in the risk of breast tumour (Danilo 
and Frank, 2012).  Investigating the biological mechanisms by which high cholesterol 
metabolism impacts on breast cancer risk and progression may lead to novel therapeutic 
targets.  
1.5.1 Cholesterol function and metabolism  
Diet is a confirmed risk factor for different cancers. Several mechanisms have been 
investigated to underlie the link between different dietary patterns and the risk of cancer, 
including epigenetics, gut microbiota and their metabolites, immune function, 
inflammation, and metabolic or hormonal disruption (Cedó et al., 2019). Recent studies 
indicate a positive association between high fat and cholesterol diets and cancer 
progression and metastasis(Pelton et al., 2014).  
Cholesterol is an essential molecule, that maintains the integrity and fluidity of the cell and 
organelle membranes. It plays an important role in maintaining cell homeostasis and acts 
as a building block for steroid hormones, oxysterols, bile acids and vitamin D  (Hu et al., 
2012). Cholesterol is insoluble in plasma, and requires transporters known as lipoproteins, 
which are made up of a hydrophobic core, containing a hydrophilic coat, cholesteryl esters 
and triglycerides consisting of free low-density lipoprotein (LDL) cholesterol, 
phospholipids and apolipoproteins, as outlined in fig 1.5. There are several categories of 




(ULDL, also  known as chylomicrons) and very low density (VLDL) (Röhrl and Stangl, 
2018).   
The main cholesterol-carrying lipoproteins are LDL and HDL (Röhrl and Stangl, 2018). 
Therefore, excess cholesterol from tissues and peripheral cells is transferred directly to 
HDL, which accepts excess cholesterol and transports it back to the liver for disposal in 
bile acids. This pathway ensures that cholesterol is removed from the body by the 
gallbladder or redistributed to other tissues, as outlined in figure 1.5 (Shahoei and Nelson, 
2019). 
All cells can synthesize cholesterol, and 50% of total cholesterol synthesis in humans body 
occurs in the liver (Luo, Yang and Song, 2020) by highly orchestrated cholesterol transport 
molecules that release and absorb cholesterol from the diet (Azrolan and Coleman, 1989). 
Indeed, the rate limiting step for the regulation of the cholesterol biosynthetic pathway is 
the endoplasmic reticulum (ER) enzyme 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMG-CoA reductase), that is responsible for converting the acetyl-CoA to 
HMG-CoA to mevalonate. The latter is converted to iso-pentenyl pyrophosphate, next 
converted to farnesyl-pyrophosphate (farnesyl-PP), which is modified to form  cholesterol, 
as outlined in figure, 1.6 (Baek and Nelson, 2016). The accumulation of cholesterol lowers 
the activity of HMG-CoA reductase and a variety of other enzymes, thereby limiting the 





Figure 1.  6: Describe A) lipoprotein structure and B) cholesterol metabolism and 
transport, adapted from (Leon et al., 2015). 
 
 The lipoprotein consists of triglyceride (TG), free cholesterol (FC), free fatty acids FFA, 
and phospholipid (PL). B) cholesterol synthesis occurs in hepatocytes and is transported 
by two ways: first as VLDL to the blood circulation and the VLDL contain fatty acids, TG, 
free cholesterol and phospholipids. VLDL particles are transported by apolipoproteins. 
Then, VLDL is remodeled and transformed into IDL and LDL by the action of LPL in the 
blood circulation.  Second way to transport cholesterol, is transported by chylomicrons 
from intestine to the circulation by the action of LPL. LDL particles are removed from 





Figure 1.  7: Cholesterol biosynthesis pathway: 
A biochemical signalling pathway demonstrating the key steps by which cholesterol is 
synthesised from acetyl-CoA. HMG-CoA reductase is the rate limiting step. adapted from 






1.5.2 Cholesterol processing  
The bile acid synthesis pathway is the main pathway, in which cholesterol is converted into 
oxysterols through enzymatic and nonenzymatic pathways. The replacement pathway is 
the acidic bile acid synthesis pathway, identified by the hydroxylation of cholesterol by 
CYP27A1, producing  27-hydroxycholesterol (Brown and Jessup, 1999).  
 
1.5.3 Regulation of intracellular cholesterol homeostasis  
Homeostasis of intracellular cholesterol is controled by complex and highly regulated 
signalling cascades that depend on both short negative feed-back loops and longer loop 
feed-forward mechanisms (Goldstein and Grown, 1997). In brief, the level of intracellular 
cholesterol is maintained at a low level by being incorporated into membranes, being stored 
as a cholesterol-ester in the cytoplasm or being exported out of the cell (Chang et al., 2009). 
In an acute need for increased intracellular cholesterol, as happens during cell division, the 
cell depends on de novo synthesis, decreased efflux, and/or increased uptake of cholesterol 




   
Figure 1.  8:  Cholesterol biosynthesis pathway:  
cholesterol biosynthesis (intracellular) is dysregulated in cancer cells due to increased 
acetyl CoA levels via glycolysis, fatty acid biosynthesis and HMG-CoA reductase activity, 
which is the major regulator of cholesterol homeostasis is sterol regulatory element-
binding proteins-2 (SREBP2), adapted from (Huang, Song and Xu, 2020). 
1.5.4 Role of cholesterol in the development of breast cancer 
The link between a high cholesterol diet and the risk of breast cancer was first discovered 
in the 1950s. Circulating levels of cholesterol are approximately 453 µg/ml or less for 
healthy adults (Baek and Nelson, 2016). A meta-analysis proposed that dietary cholesterol 
intake increased the risk of breast cancer (Li et al., 2016). Preclinical studies strongly 
demonstrate that cholesterol can influence cancer pathophysiology and is an important 




cholesterol occurs via the mevalonate pathway. Clinical and experimental evidence 
supports that cholesterol biosynthesis (intracellular) is dysregulated in many cancer cells 
due to increased acetyl CoA levels via glycolysis, fatty acid biosynthesis or HMG-CoA 
reductase activity (Kwan et al., 2008; Ahern et al., 2011), as described in figure 1.7.  
 
An imbalance in cholesterol levels is triggered by increased food consumption or genetic 
factors for instance, ATP-binding cassette subfamily A member 1 (ABCA1) gene and other 
genes as myosin regulatory light chain interacting protein (MYLIP, also defined as IDOL), 
which leads to an accumulation of cholesterol in peripheral tissue (Hegele, 2009). 
Furthermore, it’s a precursor to steroid hormones and bile acids, which can initiate or 
enhance breast cancer (Finlay-Schultz and Sartorius, 2015). Cholesterol is important for 
the fluidity and integrity of the cell and cellular organelle membranes, thus high levels of 
cholesterol are required for cells that have a high proliferative rate for membrane 
biogenesis. In addition, the cholesterol-derived metabolite 6-oxo-cholestan-3β,5α-diol, is 
found to be increased in patients with breast tumour, binds glucocorticoid receptors, the 
nuclear receptor of endogenous cortisol, and subsequently promotes cancer growth (Voisin 
et al., 2017). In general, cholesterol metabolism associates with cancer growth, migration 
and invasion (Liu et al., 2018; Chimento et al., 2019a). An increase in cholesterol 
biosynthesis is one of the hallmarks of cancer. In particular, when oxygen and/or lipids are 
limited, for example in the glioblastoma microenvironment, the key transcription factor 
SREBP2 and its downstream targets genes, in addition to mevalonate-pathway enzymes, 




SREBP, RAR-related orphan receptor gamma (RORγ), promotes the cholesterol-bio-
synthesis pathway and mediates progression of TNBC (Cai et al., 2019). 
As a vital component of the cell membrane, cholesterol may be related to membrane 
receptors which can activate oncogenic signalling pathways such as MAPK (Chun Wang 
et al., 2017) and  Notch (Levental and Veatch, 2016; Kim, 2019). Thus, the activation of 
signalling pathways resulting in cell differentiation, cell proliferation and tumour 
formation (Ding et al.,2019). Cholesterol can activate the PI3K/Akt and Wnt/β-catenin 
pathways which are related to cell proliferation and tumour formation (Lee, Loh and Yap, 
2015), and in prostate cancer cells it has been shown that the activation of PI3K/Akt leads 
to the accumulation of cholesterol esters through increasing LDL uptake and causing 
further esterification (Yue et al., 2014).  Besides the cell membrane, cholesterol can 
function in the cytoplasm. It has been shown that lysosomal cholesterol activates 
mTORC1, mammalian target of rapamycin complex 1, which is responsible for cell 
growth, invasion and metastasis of breast cancer cell lines (Ricoult et al., 2016; Kim, Cook 
and Chen, 2017). It has been found that cholesterol accelerated renal cancer cell invasion 
and migration mediated through KLF5/miR-27a/FBXW7 pathway, which plays a crucial 
role in epithelial-mesenchymal-transition, chemoresistance, and regulating cancer immune 
response(Liu et al., 2018). 
In contrast, statin treatment inhibits de novo cholesterol synthesis and decreases tumour 
growth rates. A recent meta-analyses reported that targeting the mevalonate pathway by 
statins, specifically lipophilic statins show improved recurrent-free, overall survival in 
breast tumour patients (Manthravadi, Shrestha and Madhusudhana, 2016; B. Liu et al., 




of cell membranes that are rich in cholesterol sphingolipids. The function and structure of 
the lipid rafts depends on the composition of cholesterol and related phospholipids, which 
are platforms for cellular signal transduction (Chimento et al., 2019a).  Consequently, 
upregulation of cholesterol levels may lead to structural damage in lipid rafts, which may 
inhibit the function of raft-related proteins, such as tyrosine protein kinases (Src and c-
Met,), death receptor proteins and calcium channels(Zeng et al., 2018). Using a lipid raft 
inhibitor methyl-β-cyclodextrin (MβCD) reduced the migration of lung cancer cells by 
63.1-83.3%, indicating that cholesterol reduction in lipid rafts could inhibit the 
phosphorylation of lipid-raft associated proteins, Src and c-Met which could lead to a 
reduction in tumour formation, migration and invasion (Zeng et al., 2018). Clinical 
evidence also supports that cholesterol metabolism is important for cancer progression 
(Guan et al., 2019). On the other hand, a cholesterol-rich diet in a mouse model of 
hepatocellular carcinoma, increased membrane cholesterol levels, and consequently 
enhanced CD44 , a gene on chromosome 11q13 that encodes cell-surface glycoprotein 
participated in cell–cell interactions and invasion, migration, relocation into membrane 
lipid rafts and decreased the interaction between CD44 isoforms and ezrin complex, which 
are important for cell migration and cancer metastasis (Yang et al., 2018). This study 
suggests that high cholesterol level decrease hepatocellular carcinoma invasion and 
metastasis.  
 1.5.5  Epidemiological studies on cholesterol and breast cancer  
LDL and HDL are the main transporters for cholesterol, and there are several clinical 
studies that associate high circulating levels of LDL with breast cancer risk (Guan et al., 




treatment with adjuvant chemotherapy resulted in elevated levels of total cholesterol, 
LDL-C, triglycerides and Apo B, and a decrease in Apo A1 and HDL-C (Li et al., 2018).  
Additionally, a systemic LDL-C level of more than 117 mg dL−1 was proposed to be a 
prognostic factor of cancer stage, and it was significantly correlated with worse prognosis 
due to a higher proliferative rate, a higher histological grade, and a more advanced clinical 
stage. Also, patients with high LDL-C <144 mg dL−1 were found to have lymph node 
metastases (Rodrigues dos Santos et al., 2014).   
 1.6 Low density lipoprotein (LDL) 
1.6.1 The effects of LDL-cholesterol on breast cancer progression  
LDL-c is frequently up-regulated in obese women (Luo et al., 2014). Treatment with LDL-
cholesterol (100ug/ml) for 48 hours in vitro was found to increase breast cancer cell 
proliferation, migration and loss of  adhesion (Rodrigues Dos Santos et al., 2014), Using 
in vivo mouse models of breast cancer, LDL-c treatment was shown to increase breast 
cancer growth together with a higher frequency of lung metastasis compared to untreated 
conditions (Rodrigues dos Santos et al., 2014). Fast proliferating breast tumour cells have 
an increased requirement for cholesterol and this is met via increased uptake of LDL-c 
from the blood stream in breast cancer tissue through increased LDL-R expression  (Pires 
et al., 2012). LDLR gene mutation and protein expression is found to be high in ER-
negative, MDA-MB-231, versus ER-positive, MCF-7, breast cancer cells (Cedó et al., 
2019). In ER-negative breast cancer cells LDL increased their growth (Gallagher et al., 
2017a), and migration (Gallagher et al., 2017a) but not in ER-positive. This demonstrated 




higher abilities of TNBC to store, take up, and utilise exogenous free cholesterol, and this 
was thought to be associated with the high activity of acyl-CoA:cholesterol acyltransferase 
1 (ACAT1) (Antalis et al., 2011). LDL-c promoted the proliferation of ER-positive breast 
cancer cells BT-474, because BT-474 also overexpress the HER2 (ErbB2) receptor (dos 
Santos et al., 2014). Furthermore, it has been reported that high plasma levels of LDL-C 
were related to HER2-positive breast tumours (Rodrigues Dos Santos et al., 2014).  Several 
studies have explained the association between LDL and cancer to be due to LDL induced 
phenotypic changes in ERK/MAPK (Danilo et al., 2013), PI3K/AKT (Khaidakov and 
Mehta, 2012; Alikhani et al., 2013), JNK and ErbB2, down-regulation of adhesion 
molecules cadherin-related family member3, CD226, claudin7 (Rodrigues dos Santos et 
al., 2014) and integrin β receptors (β1, β2 and β3)(Pan et al., 2012). The PI3K/Akt pathway 
has also been identified as a mediator of the tumour inducing activity of 
hypercholesterolemia in breast cancer  (dos Santos et al., 2014).  
A high-fat/high-cholesterol (HFHC) diet in a mouse model of breast cancer (MMTV 
polyoma middle T (PyMT) oncogene transgenic mice) was shown to enhance tumour 
progression (Cedó et al., 2019). Another study showed that a HFHC diet significantly 
increased circulating cholesterol levels, induced angiogenesis and the growth of ER-
negative (MDA-MB-231) human breast cancer cells in an orthotopic mouse model of 
breast cancer (Llaverias et al., 2011).  
1.7   Oxysterols and cholesterol metabolism 
Cholesterol molecules generate oxidized metabolites, defined cholesterol oxidation 




enzymatic or non-enzymatic oxidative processes, such as 24-hydroxycholesterol, 25-
hydroxycholesterol, 27-hydroxycholesterol (27OHC), or other products 6-
hydroxycholesterol , 7α/β-hydroxycholesterol and 7-ketocholesterol, and act by binding 
nuclear receptors such as liver X receptor (LXR) and related orphan receptor (ROR) as 
described in figure 1.8 (Kloudova, Guengerich and Soucek, 2017). At a physiological 
concentration, oxysterols are natural constituents of the human body and modulate several 
important functions. The regulation of cholesterol synthesis is mediated by both oxysterols 
and cholesterol, as described in figure 1.9. Oxysterols affect different signalling cascades, 
membrane fluidity, and the activity of several membrane proteins (Fig. 1.9)(Kloudova, 
Guengerich and Soucek, 2017). Several clinical and experimental studies have suggested 
a role for 27OHC in cancer (Nelson, 2018; Jiao et al., 2020).  
The sterol regulatory element-binding proteins (SREBPs) function as major regulators of 
cholesterol biosynthesis and regulate the genes encoding cholesterol synthesis enzymes 
(Horton, Goldstein and Brown, 2002). SREBPs enhance the transcription of cholesterol-
associated molecules, down-regulating genes that excrete or catabolize cholesterol and 
upregulating cholesterol synthesis genes. They are also associated with cholesterol uptake 
for example LDLR (Horton, Goldstein and Brown, 2002). SREBPs regulate cholesterol 
synthesis: when cellular cholesterol is high, SREBPs are found in the membrane of the ER 
where they produce a complex with SREBP-cleavage stimulating protein (SCAP) (Brown, 
Radhakrishnan and Goldstein, 2018). On the other hand, when the cellular cholesterol is 
low, the SREBP–SCAP complex moves to the Golgi apparatus, where it is cleaved and 
SREBP goes to the nucleus and activates the expression of associated genes, such as, 




persists in the ER. However, cholesterol and oxysterols together regulate activation of 
SREBP: oxysterol by interaction with Insig protein and cholesterol through binding 
together with SCAP (Kloudova, Guengerich and Soucek, 2017).  
Cholesterol metabolism is also modulated via HMGCR, a major enzyme of the cholesterol 
biosynthesis pathway. HMGCR has a sterol-sensing domain and therefore directly bind to 
the Insig protein, inducing degradation of the HMGCR (Gill, Chow and Brown, 2008).  
Cholesterol levels are also regulated by LXRs, which can activate gene expression of sterol 
transporters, ATP-binding cassette subfamily A member 1 (ABCA1). In addition, 
oxysterol-binding proteins (OSBPs) participate in the downregulation of the ABCA1 
transporter via modulation of protein destabilization and gene expression (Gill, Chow and 
Brown, 2008).  
1.7.1  27-Hydroxycholesterol  
The most abundant oxysterol in human plasma is 27OHC, which in human plasma ranges 
from 0.2-0.8 µM. High circulating levels of 27OHC are associated with 
hypercholesterolemia, and with increasing age (Russell, 2000).  27OHC is a selective 
estrogen receptor modulator (SERM) and is also a modulator of LXR. In an acidic pathway 
through hydroxylation, 27OHC is synthesised from cholesterol by the mitochondrial 
resident cytochrome P450 enzyme, CYP27A1 (sterol 27 hydroxylase, cholesterol 27-
hydroxylase) (Clai et al., 1991).  
CYP27A1 is a ubiquitous mitochondrial enzyme, overexpressed in the liver, and expressed 
in the intestine, macrophages, brain and vasculature. 27OHC is principally transported, 




27OHC catabolism occurs when 27OHC is hydroxylated by CYP7B1 oxysterol 7α-











Figure 1.9: Cholesterol oxidation products;  
generated by both non-enzymatic and enzymatic reactions. The enzymatic pathway is 
modulated by enzymes from the cholesterol-25-hydroxylase (CH25H) and cytochrome 
P450 (CYP) family.   
1.7.2  27-Hydroxycholesterol metabolism 
Oxysterols, modulate several different signal transduction pathways that regulate many 
biochemical and physiological effects, as shown in (fig 1.9). The bioavailability of 27OHC 
at the tumour site can be totally different from its level in the plasma, and this may be more 
critical in the context of tumour progression. The content of 27OHC in ER-positive breast 
cancer cells is 2.5- 3-fold higher than in normal breast cells (Wu et al., 2013). At very low 




physiological functions; they regulate cholesterol metabolism, influence signalling 
molecules such as MAPK, insulin-induced gene (INSIG); SREBP- SCAP cleavage 
activating protein, and the activity of some membrane proteins such as ABCA1, ABCB1, 
Na+/ K+ ATPase and also affect membrane fluidity (fig. 1.9) (Russell, 2000). However, 
oxysterol metabolism is also connected with different human diseases, like Parkinson’s 
disease, Alzheimer’s, and atherosclerosis. Recent evidence shows that oxysterols influence 
cancer progression and carcinogenesis (Kloudova, Guengerich and Soucek, 2017).   
 
 
Figure 1.  10: The physiological role of oxysterols in cellular processes:  
Oxysterols mediate many physiological functions; they regulate cholesterol metabolism, 
influence signalling molecules such as MAPK, INSIG, SREBP- SCAP, and the activity of 
some membrane proteins such as ABCA1, ABCB1, Na+/ K+ ATPase and affect membrane 




1.7.3  27-Hydroxycholesterol and breast cancer    
Oxysterols may modify cancer risk in different ways. There are several studies indicating 
the proliferative and the pro-cancerous role of oxysterols (Nelson et al., 2013b; Raza et al., 
2017) , which could explain observations such as, higher circulating 27OHC correlated 
with aggressive cancer biology and late lethal disease of ER-positive  breast cancer in 
postmenopausal women (Kimbung et al., 2020) (Fig 1.10). Many studies investigated the 
mechanisms involved in the effects of 27OHC on promoting breast cancer development. 
A role for 27OHC in the regulation of p53 activity and proliferation has been reported via 
the E3 ubiquitin ligase Mouse Double Minute 2 protein (MDM2) in ER-positive (MCF-7) 
breast cancer cells. P53 is a tumour suppressor protein which plays a crucial role in 
apoptosis, senescence, and cell cycle. Also, the level of p53 is regulated by MDM2. 
However, 27OHC-induced an increase in the p53 regulator MDM2 and activates the 
interaction between p53 and MDM2. This suggests that 27OHC increased the proliferation 
through MDM2-mediated p53 degradation (Raza et al., 2015). Another study investigated 
the role of 27OHC on MYC protein (a proto-oncogene and encodes a nuclear 
phosphoprotein) in MCF-7 breast cancer cells. MYC is a critical oncogene protein involved 
in the proliferation, migration and invasion of different types of cancers (Xu, Chen and 
Olopade, 2010). This study found that 27OHC increased MYC stability through 
transcriptional repression of protein phosphatase 2A (PP2A), F-box and WD repeat domain 
containing 7 (FBW7) and small C-terminal domain phosphatase 1(SCP1), in ER-positive 
breast cancer cells (Ma et al., 2016).  
As a result, Shen et al realized that 27OHC is a risk factor in both ER-positive and -negative 




has been shown that 27OHC promotes proinflammatory processes mediated through ERα 
(Umetani et al., 2014); therefore, suggesting the link between 27OHC, inflammation and 
cancer development. However, the mechanisms involved in 27OHC enhanced 
development of breast cancer are complicated and require further study (Umetani et al., 
2014).   
 
Figure 1.  11:  The cholesterol metabolite 27OHC influences breast cancer cell biology 
as a modulator of the LXR and ER: 
The cholesterol metabolite 27OHC promotes breast cancer cell progression via its actions 
on the LXRs and ER. CYP27A1, the enzyme that converts cholesterol to 27OHC, is highly 
found in macrophages, liver, and in stromal cells within breast cancer. Under normal 
physiologic circumstances, 27OHC might be converted to polar bile acids by the enzyme 
CYP7B1 and/or might play a role as an agonist ligand of LXR to regulate cholesterol 
homeostasis in cells. 27OHC can act through the ER and promote breast tumour 




1.7.3.1  27-Hydroxycholesterol as a modulator of the estrogen receptor (ERα)  
Since researchers discovered that 27OHC was a SERM of the ERα, a number of studies 
have described, that activation of the ER is increased by 27OHC in breast cancer (DuSell 
et al., 2008; Umetani and Shaul, 2011). 27OHC is synthesised through CYP27A1 enzyme 
and catabolised by CYP7B1 into bile acid. SERMs are characterized as compounds that 
suppresses or stimulate ERα activity and their action is dependent on the tissue type 
(Wardell, Nelson and McDonnell, 2014) , as illustrated in figure 1.10. 27OHC levels are 
increased within breast cancer tissue compared to normal breast tissue, and this was 
correlated with a higher tumour grade, and circulating 27OHC levels were increased in 
women treated with an aromatase inhibitor (Nelson et al., 2013b; Wu et al., 2013), which 
culminates in increased cell proliferation and consequently promoted ER-positive breast 
cancer progression (DuSell et al., 2008). 
The exposure to 27OHC is correlated with the development of breast cancer and this action 
is mediated through the ER in a mouse model of breast cancer (Nelson et al., 2013b).  
The effect of 27OHC on the growth of MCF-7 cells at a concentration of 1–2 µM was 
comparable to that of 1–2 nM of 17β-estradiol, and they suggested that 27OHC promotes 
breast cancer growth through binding to ER (Cruz et al., 2010). The proliferative role of 
27OHC has been confirmed in vitro, MCF-7, and in vivo, PyMT mice and murine human 
cancer cell xenografts (Umetani and Shaul, 2011; Nelson et al., 2013b).  
Elevated 27OHC can increase the metastasis of breast cancer in murine models, and as 
such was able to promote the myeloid immune cell functions through the interaction with 
the number of γδ-T cells and polymorphonuclear-neutrophils cells, resulting in a decrease 




hydroxycholesterol on metastasis as this needs myeloid immune function (Baek et al., 
2017). Several clinical studies indicate that 27OHC works as a biochemical mediator of 
the metastatic impact of hypercholesterolemia, as 27OHC was found to increase markers 
of EMT and consequent lung metastases in MMTV-PyMT mice (Nelson et al., 2013a; Wu 
et al., 2013). Furthermore, 27OHC promoted invasion and migration in both ER-positive 
and ER-negative breast cancer cells through elevated EMT and activated, Signal transducer 
and activator of transcription 3, STAT-3 (Shen et al., 2017). However, the discovery of 
27OHC as a selective endogenous modulator of the ERα that promotes ER-positive breast 
cancer proliferation could help to explain why some breast cancer patients have resistance 
to aromatase inhibitors, where 27OHC, in a low-estrogen environment, may act as an 
alternate estrogenic ligand (Simigdala et al., 2016). 
1.7.3.2  27-Hydroxycholesterol as a modulator of the LXR  
LXR is a group of proteins affected by the level of oxysterols in the plasma (called 
oxysterol receptors) – LXR-α and LXR-β form heterodimers with retinoid X receptors 
(RXR) (Wu et al., 2016a). It has been demonstrated that LXR plays a significant role in 
ERα-positive breast cancer cells, such as arresting cell cycle progression and reducing cell 
proliferation (Wu et al., 2016b). Moreover, 27OHC plays a role as a positive regulator of 
LXR activity in breast cancer (Bovenga, Sabbà and Moschetta, 2015). It has been 
demonstrated that the synthetic LXR agonist reduces cell proliferation but increases EMT 
markers in MMTV-PyMT mice, such as Vimentin, Snail Family Transcriptional Repressor 
1( Snail1) and Fibroblast Activation Protein Alpha (FAPa) (Hassan et al., 2015).  A recent 
study illustrated that in an ER-independent and LXR-deficient breast cancer cell line, 




migration and invasion not only in ER-positive breast cancer cells but also ER-negative 
cell lines that involved STAT3 activation (Shen et al., 2017). It has also been observed that 
27OHC increased breast cancer proliferation through ER transcriptional activity and that 
the ER may inhibit the protective effects of LXR in ER-positive breast cancer (Nelson et 
al., 2013a) 
1.7.4 The impact of high cholesterol on the IGF axis 
As a growth factor, IGF-I plays a key factor in lipid metabolism (Aguirre et al., 2016). 
IGF-I knockout mice exhibited dysregulated expression of genes encoding enzymes and 
lipid-related genes involved in cholesterol synthesis in the liver (Ita et al., 2015). Data from 
the large-scale, community based Framingham Heart Study, illustrated that lower IGF-I 
levels are correlated with metabolic syndrome (Lam et al., 2010; Zelazowska-Rutkowska 
et al., 2018). A recent cross-sectional study indicated that IGF-I levels associate with LDL-
C levels in short-stature children and adolescents (Zhao et al., 2019), and they suggested 
that IGF-I plays an important role in regulating the LDL-C concentration in serum. In 
oligodendrocyte progenitor cells, long‐term suppression of cholesterol biosynthesis 
inhibited IGF‐I stimulated AKT/PI3K phosphorylation and cell survival. They explained 
that adding 25hydroxycholesterol to cells in culture inhibited cholesterol synthesis which 
then depleted lipid rafts and this prevented IGF-I activation of the IGF-IR (Romanelli et 
al., 2009). Additionally, IGF-1 induces different expression of fatty acid and cholesterol 
biosynthesis signalling genes in murine C2C12 myoblasts (muscle cells) which was 
explained by IGF-1 treatment upregulating 19 genes that are correlated with cholesterol 
synthesis and five genes with fatty acid biosynthesis and they suggested that IGF-I induces 




SREBP transcription factor (Bhasker and Friedmann, 2008). Depletion of cellular 
cholesterol also impacts on the pathways activated by IGF and EGF, through blocking 
activation of the PI3K/AKT pathway. Cholesterol lowering treatment inhibits the IGF-IR 
in bile duct cancer cells (Laurentiis, Donovan and Arcaro, 2007; Lee et al., 2016).  
1.8  The role of cholesterol-lowering treatments on breast cancer 
Studies have concluded that cholesterol and its major metabolite, 27OHC, may promote 
breast tumour progression, development and metastasis and in support of this several 
studies have shown that cholesterol-lowering drugs may be a potential therapy to reduce 
cholesterol and reduce the risk and progression of breast cancer.   
 
1.8.1 Statins 
Statins are cholesterol lowering therapies, that inhibit the rate limiting enzyme of 
cholesterol synthesis, HMGCR, which converts HMG-CoA to mevalonate 
(Nelson et al., 2013b). In humans, the use of cholesterol-lowering treatments, especially, 
statins have been shown to have a protective effect against breast tumour deaths and 
recurrence in older women (Anothaisintawee et al., 2016; Borgquist, Giobbie-Hurder, 
Thomas P. Ahern, et al., 2017).  A recent meta-analysis demonstrated that breast tumour 
patients who regularly use statins, particularly lipophilic statins, display significant 
improved recurrent-free, overall and cancer- specific survival (Manthravadi, Shrestha and 
Madhusudhana, 2016; B. Liu et al., 2017). Furthermore, a retrospective cohort study was 
done in 20,559 Swedish breast cancer patients who use statin, was linked with improved 




and lower risk of breast cancer mortality (95% CI 0.75–0.93, P = 0.001) in patients with 
inflammatory breast cancer (Borgquist, Giobbie-Hurder, Thomas P Ahern, et al., 2017). 
Furthermore, the use of cholesterol lowering drugs, such as, fluvastatin was found to 
decrease breast cancer metastasis in a murine breast cancer metastasis model (Vintonenko 
et al., 2012). Importantly, atorvastatin was also reported to reduce serum levels of 27OHC 
and CYP27A1 expression in patients who had been diagnosed with breast cancer 
(Kimbung et al., 2017a), and thus, suggested this as one mechanism by which statins could 
reduce breast cancer progression. Another is the ability of the cholesterol lowering drug, 
simvastatin to increase expression of the PTEN gene, the anti-proliferative tumor 
suppressor gene, which reduces the phosphorylation of the Akt signalling pathway, 
eventuating in reduced cancer cell survival and growth in the MDA-MB-231 xenograft 
breast tumor model (Ghosh-Choudhury et al., 2010). The same results were found in vitro, 
the antiproliferative effects and cytotoxic effects of statins in breast tumour cells by 
elevating autophagy, cell cycle arrest and apoptosis(Brewer et al., 2013; Afzali, Vatankhah 
and Ostad, 2016)(Brewer et al., 2013).  
 
1.8.2 Plant phytosterols 
Phytosterols are plant sterols, which can reduce intestinal cholesterol leading to lower 
serum cholesterol levels of LDL-C, and have anticancer effects which may be explained 
by preventing oxidative damage (Llaverias et al., 2013). Several studies in vivo have tested 
the role of phytosterols on breast cancer progression. In mice injected with breast cancer 
cells MDA-MB-231, supplemented with 2 % phytosterols, it was observed that 




reduced tumour size was also reported in female mice received carcinoma MCF-7 cells 
injection and supplemented with β-sitosterol, the most widespread phytosterol (Awad, 
Williams and Fink, 2001). The ability of phytosterols to prevent lipoprotein oxidation was 
suggested as a potential mechanism to explain a reduction in both the progression of 
tumour burden and mammary hyperplastic lesions in PyMT mice fed a high fat, high-
cholesterol diet (Llaverias et al., 2013). The results from different studies confirmed that 
phytosterols affect the tumour by inhibiting  tumour metastasis, slowing cell cycle 
progression, altering signal transduction, inducing apoptosis and inhibiting  angiogenesis 





1.9 Hypothesis and aims  
 
1.9.1 Hypothesis:   
Cholesterol and 27OHC promote breast cancer cell growth, migration and invasion and 
this is associated with modulation of the IGF system.  
  
1.9.2 Study aims and objectives:   
- To confirm the effect of LDL on cell proliferation, migration, invasion, and 
resistance to chemotherapy in breast cancer epithelial cell lines. 
- To assess the effect of 27OHC on cell proliferation, migration and invasion in 
breast cancer epithelial cell lines. 
- To investigate the involvement of the ERβ in the role of 27OHC on breast cancer 
cell migration/invasion, and its regulation of IGF and EGF receptors.  
- To delineate the involvement of the IGFs/IGF-IR in the effects of cholesterol on 










2.1  Cell culture techniques  
2.1.1.  Cell lines    
Human breast cancer cell lines MCF-7, T47D, MDA-MB-231 and Hs578T were purchased 
from ATCC (American Type Culture Collection) (Teddington, Middlesex, UK).  
MCF-10A cell line: this a non-tumorigenic epithelial cell line that was derived from 
fibrocystic mammary gland of a 37 year old Caucasian female. 
MCF-7 cell line: This cancerous breast epithelial cell line was derived in 1970 from the 
pleural effusion from a metastatic site of a 54 year old Caucasian female. 
T47D cell line:  This cancerous breast epithelial cell line was derived from the pleural 
effusion from a metastatic site of a ductal carcinoma of a 69 year old Caucasian female. 
MDA-MB-231 cell line: This cancerous breast epithelial cell line was derived from the 
pleural effusion from a metastatic site of a carcinoma of a 51 year old Caucasian. It is a 
highly invasive, aggressive, and poorly differentiated TNBC.  
Hs578T cell line: This cancerous breast epithelial cell line was derived from metastatic 





Table 2. 1: The receptor status of each breast cancer cell lines:  
Cell Line  ERa HER2 PR ERb 
MCF-10A - - - + 
MCF-7 ++ - + + 
T47D + - + + 
MDA-MB-231 - - - ++ 
Hs578T - - - + 
This table indicates receptor status of each cell line- ERa and -b, PR and HER2 
2.1.2.  Equipment 
General sterile cell culture plastics were acquired from Greiner Bio-One (Gloucestershire, 
UK), pasteur pipettes from Fisher Scientific (Loughborough, UK), serological pipettes 
from Corning Incorporated (Amsterdam, Netherlands), syringes from Terumo (Leuven, 
Belgium), and 0.2μM filters from Appleton Woods (Birmingham, UK). The 
haemocytometer was from Hirschmann (8100104) and cryogenic vials were purchased 
from NUNC (Roskilde, Denmark). The hoods were obtained from BIOMAT (Class II, 
Medical Air Technology, Manchester, UK), incubators were from SANYO (MCO-
18AIC), and the centrifuge was from MSE (Centaur2).  
2.1.3.  Stock solutions   
• Growth Media (GM): MCF-7, T47D, MDA-MB-231 and HS578T cell lines were 
seeded in Dulbecco's modified Eagles Medium (DMEM, BioWhittaker, Verviers, 
Belgium) enriched with 10% fetal bovine serum (FBS, Gibco, Paisley, UK).  
• Serum Free Media (SFM): DMEM was supplemented with 50 µg/ml 
streptomycin (Celltech Pharmaceuticals, Slough, UK), 5% L-glutamine(LG), 50 
IU/ml penicillin (Britannia Pharmaceuticals, Redhill, UK), 10mg/L apo-transferrin 
(Sigma Aldrich), 1.2g/L sodium bicarbonate (Sigma Aldrich) and 0.2% bovine 
serum albumin (BSA) (Sigma Aldrich).  
 
69 
•  Phosphate Buffered Saline (PBS)-PBS was prepared by dissolving one tablet 
(Oxoid Ltd., Basingstoke, UK) per 200ml of deionized H2O; the pH was adjusted 
to 7.4 and the solution was autoclaved and stored at room temperature.   
• Paraformaldehyde in 4% PBS (PFA), (Alfa Aesar)- It is fixation solution for 
cells and is a ready-to-use solution. It is stored at 4°C.  
• Trypsin-EDTA (TE)- (ethylenediaminetetraacetic acid) (TE)-10 x (Lonza); to 
make a 1 x solution, trypsin was diluted 1:10 with sterile PBS and stored at -20oC 
in 5ml aliquots.   
• Trypan Blue Dye (TB)-TB stain (Sigma Aldrich) was used for assessing the 
viability and number of the cells: TB was diluted from 0.4% to 0.165% in PBS and 
mixed with a cell suspension at a 1:1 ratio.  
• 27- hydroxycholesterol (27OHC)- Santa Cruz Biotechnology (Santa Cruz, CA, 
USA) the stock solution 1000 µM was prepared in 100% ethanol and stored at -
80°C. The stock solution was dissolved in growth media to give a range of 
concentrations from 0.1-1 µM. 
• Erteberel (LY500307), Cat# B1518-5m (Sigma Aldrich) - it has selective 
binding affinity for estrogen receptor β (Erβ). The stock solution (10mM) was 
prepared in 1.77 mL DMSO and stored at -20°C. The stock solution was dissolved 
in growth media to give a range of concentrations from 0-10µM.  
• Lipoprotein, low density from human plasma (LDL)- was bought from Thermo 
Fisher Scientific (Waltham, MA, USA). The stock solution was dissolved in growth 
media to give a range of concentrations from 0-100µg/ml. 
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• 4-[2–phenyl-5,7–bis (trifluoromethyl) pyrazolo [1,5-a]-pyrimidin-3-yl] phenol 
(PHTPP) (SML1355-5MG), (Star lab), it is a selective ERβ antagonist. The stock 
solution was prepared in DMSO: 5 mg/mL, and stored at -20°C. The stock solution 
was dissolved in growth media to give a range of concentrations from 0-10µM. 
2.1.4.  Resuscitation of cells from liquid nitrogen  
Cells stored in cryovials were taken from liquid nitrogen and placed briefly in a water bath 
at 370C to defrost. GM (1ml) was added to the tube and the cells were placed into a 
universal tube containing 9ml of GM.  The cells were spun gently at 1,000 rpm for 3-5 
minutes. The supernatant was removed by suction and the cell pellet was re-suspended in 
5ml of GM using a syringe and 21G needle (Terumo). 
2.1.5.  Cell counting for seeding experiments 
50µl of cell suspension were added in a 1:1 ratio with TB;0.165%). 50 µl of this mixture 
were added to the top and bottom counting chambers of a haemocytometer. The cells 
included within the chambers were counted using a light microscope. The non-viable cells 
stained blue whereas the viable cells were colourless.  During cell death, the cell membrane 
becomes permeable that enables the TB dye to enter the cell and stain it blue. This does 
not occur in viable cells. The cells in both chambers were counted and multiplied by 1 x 
104 to calculate the number of cells per ml. 
 
2.1.6.  Cell passaging    
Cells were trypsinised when they reached ~80-90 % confluence, (1ml/T75 flask, 5ml/T175 
flask). Growth media was removed, and cells were washed with PBS which was then 
aspirated and discarded. The cells were incubated with 1ml of 0.25% TE for 5 minutes at 
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37°C, 5% CO2. The flask was firmly tapped to detach the cells from the bottom of the 
flask. To deactivate the TE, 10ml of GM were added to the flask. The cell suspension was 
transferred to a universal container and centrifuged at 1200 rpm for 3-5 minutes, and then 
the supernatant was discarded.  GM (5ml) was added to the pellet and the cells were re-
suspended using a needle and syringe.  50µl from the cell suspension was added to an 
eppendorf for cell counting (section 2.1.5) to estimate the number of cells in the 5ml 
suspension prior to re-seeding. Depending on the cell type (Table 1), the cells were seeded 
with varying densities depending upon the vessel being used:  T25, T75, or T175 flasks, as 
described in table 1.1.  Media was changed every 2-3 days.  
 Table 2.2: Cell densities for T25, T75 and T175 flasks for each cell line.     
Flask Cell line Cell density 
(x 106) 
Company 
T25 MCF-7/MDA-MB231/T47D/HS578T 0.2-0.3 Greiner BioOne 
T75 MCF-7 /T47D 0.5 Greiner BioOne 
MDA-MB231/HS578T 0.8 Greiner BioOne 





2.1.7.  Cell freezing    
A cell suspension was prepared with 3x106 cells for MCF-7 and MDA-MB-231 cells and 
6x106 cells for the HS578T cells in 500µl of growth media, and added to a cryogenic vial 
(Starlab, E3110-6122): a freezing mixture (500 µl) containing100µl of 10% 
dimethylsulfoxide (DMSO, Fisher Scientific, D/4121/PB08), 350µl of 85% GM, and 50µl 
of 5% FBS were added dropwise after it had cooled. Cryogenic vials were left in an 
insulating freezing container that would reduce the temperature in a controlled manner and 
kept at -800C overnight. After 24 hours the cryogenic vials were transferred to the liquid 
nitrogen tank and their position recorded in a log-book. 
2.2.  Experiment seeding densities  
Seeding density for each experiment varied depending on the seeding plate/flask capacity 
and on the difference in cell size for each cell line. The following table 1.2 shows the 
different densities used for each experiment: 
Table 2.3: Cell densities for specific assays 






MCF-7 & T47D T75 flask 4.5 x106 
Proliferation Assay 
Crystal Violet(CV) 
MCF-7 & T47D 96 well plate 10000 
Proliferation Assay (CV)  HS578T & MDA-MB-
231 
96 well plate 5000-8000 
Any other experiment  MCF-7, T47D & 
H578T 




2.3.  Cell treatments & dosing protocol 
Cells were seeded in GM for 24 hours, before being transferred to SFM for a further 
24 hours, after which the cells were dosed. To assess the effects of 27OHC and LDL, cells 
were treated with 0-0.1µM, and 0-100µg/ml respectively for 48 hours. While the 
concentration of the ERβ agonist and antagonist ranged from 0-10µM for 24 hours. 
Following treatments, cells were harvested using trypsin, then cells were centrifuged, and 
cell pellets were washed with PBS. Following cells were applied to different protocols such 
as the protein extraction, cell counting and sometimes reseeded for migration assays 
2.4.  Cell counting for experiments 
2.4.1.  Counting and viability assay using the Muse cell analyzer (Merck Millipore)   
The media from each well was removed and added to a universal tube. Trypsin-EDTA 
(300µl) were added to each well and the plates were placed in the incubator at 370C for 5 
minutes. The collected media was spun down at 10,000 rpm for 3 minutes to collect dead 
cells in a pellet and the resulting cell-free supernatant was collected in 7ml bijous and 
frozen for later use. After the 5-minute incubation, 1ml of GM was added to each well of 
the plates to neutralize the trypsin. The cell suspension was added to the universal tubes 
containing the pellet of dead cells, then spun down at 10,000 rpm for 5 minutes to form a 
pellet of live and dead cells. The pellet was re-suspended in 1ml of GM and 20 µl in 
triplicate of cell suspension were mix with 180 µl of Muse cell count and viability solution 
(1:20) to stain cell samples. After a 5-minute incubation, sample was loaded onto the Muse 
cell analyzer to read the results. For each condition, one sample at a time both viable and 




2.4.2.   Crystal Violet (CV) assay for determining viability of cultured cells with CV 
staining 
The cells in 200μl GM were seeded into 96 well plates with 3-10 replicates per each 
condition for 24 hours. Then, the GM was removed and added 200μl SFM for a further 24 
hours, and the cells were dosed with specific treatment such as, LDL, 27OHC. After 
incubation, the plate was fixed by applying 100μl 4% PFA for 20 min. The fixative was 
removed and added PBS. Then, the cells were washed two times with PBS followed by the 
addition of 100μl CV solution (0.05% in PBS) and then incubated for 30min. After that, 
the plate was washed three times with 200μl/well PBS. The last step was replaced the PBS 
with 100μl/well of 1% SDS/PBS. To solubilize the CV the plate was placed on a rocker 
for 1 hour and read using a plate reader (FLUOstar Optima, BMG LABTECH). 
2.5.  Transfection with siRNA  
Table 2.4: Reagents: 
ERα siRNA (20nM) 
ERβ siRNA (20nM) 
Dharmacon 
CYP27A1 siRNA (20nM), Thermo Fisher Scientific 
AllStars Neg. Control siRNA 
(20nM) 
Qiagen 
siRNA Transfection Reagent 
saint red 
Synvolux 
Growth media DMEM 5mM glucose 
 
Lyophilised siRNA was resuspended with an appropriate amount of siRNA suspension 
buffer to make a 20μM stock solution, which was aliquoted and stored at -20°C. The 
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transfection master-mix depended on its required concentration: for example, a 20nM 
solution for ERα siRNA was prepared, as illustrated in table 2.4, followed by 20 minutes 
incubation period at the room temperature. The stock cells were trypsinised when 70-80% 
confluent, counted and then seeded into 6-well plates (0.1X106/cells in 800µl /well of GM). 
200 µl of the transfection master-mix were added gently drop-wise. The cells were then 
incubated for 24 hours before changing the media to SFM for a further 24 hours at 37°C in 
5% CO2. The transfection efficiency was assessed by western immunoblotting.  












Buffer 20ul 20ul 20ul 
siRNA transfection reagent Saint-
RED 9ul 9ul 9ul 





Growth media (DMEM) 
Top up to 200ul 
total volume per 
well 











2.6  Development of stable transfection of ERβ using shRNA  
Transduction with lentiviral vectors is defined as a highly efficient method capable of 
transducing cells to adjust expression of target genes (Blömer et al., 1997).  Short hairpin 
RNA (shRNA) applied to target the human ERβ gene (ESR2) (ERβ shRNA (h) Lentiviral 
Particles: (sc-35325-V) were obtained from Santa Cruz Biotechnology, Inc. ERβ shRNA 
(h) lentiviral particles is a combine of concentrated, transduction prepared viral particles 
including three target-specific constructs that encode (19–25 nucleotide sequences in 
length, plus hairpin) shRNA designed to silence gene expression. As a negative control, 
control shRNA lentiviral Particles-A (sc-108080) that encode a mix-up shRNA sequence 
were used in this model.  
MDA-MB-231 (high metastatic potential, ERβ- positive), were harvested by trypsinization 
and seeded into 6-well plates. Infections of MDA-MB-231 cells were performed with two 
volumes (15-20μl) of shRNA target-specific human ERβ or non-targeting shRNA control.  
Polybrene solution (5μg/mL) (sc-134220; Santa Cruz Biotechnology, Inc) were used to 
optimise transfection efficiency, following the manufacturers protocol.  
After 24h incubation time, the medium was changed to complete medium without 
polybrene. After a further 24h, the transfected cells were split 1:3 and incubated for 48h in 
complete medium.  
Puromycin kill curve experiments were performed with 0.2-1μg/mL to assess the 
appropriate concentration of puromycin to kill 100% of untransfected cells in one week 




For the development of stable clones that express shRNA, puromycin dihydrochloride 
selection (sc-108,071; Santa Cruz Biotechnology, Inc) 0.8μg/mL was supplemented in the 
culture media, changing it with fresh puromycin-containing media once every 3–4 days. 
Transfection efficiency was assessed by western blotting and qPCR.  
2.7.  Trans-well migration/invasion assay using crystal violet staining  
Cells were seeded and following treatment were trypsinised and resuspended in SFM in 
preparation for the migration/invasion assay. Trans-well inserts containing polycarbonate 
filters (8 µm pores-transwell) (Millipore) were used in 24-well plates. To detect invasion, 
the inserts were coated with 10µg/ml collagen-I for 24 hours before cell seeding at room 
temperature. Cells (5×105) / per well were seeded in the upper chamber of the inserts in 
triplicate in SFM-DMEM and incubated at 37oC. DMEM containing 5% FBS was used in 
the lower chambers to act as a chemoattractant for the cells. Cells migrated against the 
chemoattractant medium in the lower chambers for 24 h (MCF-7) or 6 h (MDA-MB-231).  
 The cells that had passed through the membrane to the bottom side were fixed using 300µl 
of 4% paraformaldehyde for 15 minutes. The membrane was washed with PBS 
permeabilized with triton X, stained with crystal violet, incubated for 20 minutes and 
washed with PBS. Cotton buds were used to remove any non-migrated cells from the top-
side of the membrane. The stain was then dissolved in 1% SDS on a plate shaker for one 




The traditional method for assessing cell migration/invasion is counting the cells that have 
migrated/invaded through the membrane, but more recently dye extraction methods have 
been employed.   
The trans-well migration assay was performed using MCF-7 cells to examine changes in 
cell migration, after which the migration rate was assessed using both techniques for 
comparison. Figure 2.2. confirms that the techniques are comparable and overall dye 






Figure 2.  1: Trans-well migration assay using crystal violet staining.  
 
  
Figure 2.  2: Optimization of migration and invasion in MCF-7 cells using a trans-
well migration assay and assessing using two techniques: counting 
invading/migrating cells and a dye extraction method  
Cells were treated with LDL (80μg/ml) for 48 hours. A trans-well assay was used to detect 
cell migration and invasion after 24hours. The migrated cells were stained with crystal 
violet and quantified by  A) analysis of extracted stain using a microplate reader at an OD 
at 595 nm and B) by  count the stained, migrated cells. Data are representative of the mean 
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2.8.  Western immunoblotting (WB)   
2.8.1.  Preparation of cells lysates 
The preparation of the lysis buffer is described in table 2.6. 10μl/ml of the protease inhibitor 
cocktail and 10μl/ml of the phosphatase inhibitor cocktail were added to the lysis before it 
was used. An appropriate volume of lysis buffer (depending upon the number of cells/sizes 
of the pellet) was added to each cell pellet. It was, re-suspended, centrifuged for 5 minutes 
at 15,000 x g at 4°C. The supernatant (containing the proteins) was transferred to a fresh 




Table 2. 6: Ingredients of lysis buffer and protein standards concentration range  
Lysis Buffer Quantity 
Tris HCL (Sigma) 1.576g/L 
Sodium Chloride (Sigma) 2.92g/L 
EDTA (Sigma) 1.86g/L 
Sodium Pyrophosphate (Sigma) 6.66g/L 
Sodium Fluoride (Sigma) 2.1g/L 
Sodium Orthovanadate (Sigma) 100μM- (10mls of 100x solution)  
Triton X-100 (Sigma) 1%- 1(10mls/L) 
 Standard concentration BSA (µl)  Lysis buffer  
A 2000μg/ml 300μl of stock 0 
B 1500μg/ml 375μl of stock 125 
C 1000μg/ml 325μl of stock 325 
D 750μg/ml 175μl of stock B 175 
E 500μg/ml 325μl of stock C 325 
F 250μg/ml  325μl of stock E 325 
G 125μg/ml 325μl of stock F 325 
H 25μg/ml 100μl of stock G 400 
 
2.8.2.  Protein quantification   
To assess the total protein in the cell lysates, protein concentration was observed using the 
Pierce bicinchoninic acid (BCA) protein assay kit, containing BCA reagent A and B, 
(Pierce Biotechnology, Cheshire, UK) according to the manufacturer's instructions. Protein 
standards, stock standard of 2mg/mL, containing BSA in 0.9% saline and 0.05% sodium 
azide in lysis buffer, was used to make a variety of concentrations from 0.025-2.0mg/ml, 
as described in table 2.6. Into a 96 well plate, 5μl of the protein standards with 5μl of each 
sample were placed in duplicate. Then, reagents A and B from the protein assay kit, were 
combined in a ratio of 50:1 and 200µL were placed to each of the targeted wells. Then the 
plate was left for 30 minutes. After the incubation period the plate was read utilizing a plate 
reader at a wavelength of 590nm using the Bio-Rad software package. The concentration 




2.8.3.  Sample preparation and gel electrophoresis 
Samples were prepared by diluting to a correct concentration according to the measured 
protein concentration in PBS. Protein samples were resuspended in 2X Laemmli Sample 
Buffer, containing glycerol to increase the density of sample, anionic detergent (SDS), and 
bromophenol blue dye to allow visualization, and denatured by boiling for five minutes at 
95°C.  
Table 2. 7: Western blotting reagents: 
Reagents Description 
30% Acrylamide/ BIS (N,N'-methylene 
bis acrylamide). (Severn Biotech) 
4°C storage degree.  
1.5 M Tris Base (Sigma), (18.16g) pH 8.9 The reagents made up in 70mls of 
distilled water (dH2O) with pH adjusted 
and the solutions were added to 100mls 
and stored at 4°C. 1.1 M Tris HCL (Sigma) (17.33g) pH 6.8 
10% Sodium dodecyl sulphate (SDS), 
pH 7.2 (Sigma) 
50g Electrophoresis grade SDS was 
dissolved in 400mls dH2O and heated to 
68°C with pH adjusted before the 
solution was added to 500mls. The 
solution was filter sterilized and stored at 
room temperature 
10% Ammonium persulphate (APS) 
(Sigma) 
1g made up in 10mls of dH2O and stored 
at 4°C.  
TEMED (N,N,N,N- 
tetramethylethylenediamine) (Sigma) 
Stored at room temperature. 
10x Tris-buffered saline TWEEN 20 
[TBS-T] 
50 mM Tris base pH 7.5, 5ml 0.1% 
Tween-20 and 150 mM NaCl, dissolved 
in 500ml dH2O. The solution was 
calibrated with HCl and NaOH for a pH 
value of 7.6. 





Table 2. 8 : Chemicals and buffer for western blotting.  
SDS polyacrylamide gel 
electrophoresis 
 




40% acrylamide 37.5:1 37.5:1 
Triss buffer  1.5 M pH 8.8  
 




0.1% 0.1%  
10% APS 
 
0.1% 0.1%  
0.0006% TEMED 0.06% 0.1% 
1X Running buffer 25 mM Tris Base tris-HCl pH 6.8 
0.1% SDS 
192 mM Glycine 
10X Transfer buffer 25 mM Tris-HCl pH 8.3 
192 mM  glycine 
20% methanol 
 
The resolving and stacking gels were prepared as described in Table 2.7. The resolving 
solution portions are applied between glass plates (1.5mm apart|) and enabled to 
polymerise under a layer of butanol, which makes sure a smooth interface and speeding up 
the polymerisation process. After the gel has set, the gel was washed with dH2O before 
adding the stacking gel and inserting a comb(10-well). Once the stacking gel has 
polymerised, the comb was pulled out and the gels was transferred to the running tank. The 
electrode chambers and tank were topped up with running buffer before loading with the 
samples. Samples were allocated in SDS polyacrylamide gel electrophoresis (SDS-PAGE), 
then the gel was run at (125–200V) according to the number of gels in the tank, for 45–90 
minutes depending upon the separation required and protein size, and filled with 1x running 




2.8.4.  Wet transfer western blot 
The separated proteins were transferred to a western blot membrane (nitrocellulose 
membrane, PVDF (polyvinylidene difluoride).  The membrane was pre-soaked for 10 
minutes in 1X transfer buffer along with the gel, sponge and thick paper. A transfer 
sandwich was made of sponge – thick paper – gel – membrane – thick paper – sponge, and 
placed in a transfer tank, loaded with 1x transfer buffer, and run by limited volts (90V) for 
90 minutes at 4°C.  After the proteins had transferred from the gel to the membrane, the 
membrane was washed in tris buffered saline tween (TBST) for 3 x 5minute washes before 
being blocked for 1 hour at room temperature with blocking solution (5% non-fat dried 
milk or 3-5% BSA in TBST) with gentle agitation. The primary antibody solution was 
prepared with blocking solution containing 5% non-fat dried milk or 3-5% BSA in TBST 
(according to the manufacturer’s specification) as indicated in Table 2.9 and the 
membranes were incubated for 18 hours at 4°C.  
Membranes were then washed with TBST for 3 x 10 minute at room temperature and 
incubated with secondary antibody diluted (1:3,000 for anti-rabbit and 1:1,000 for anti-
mouse) at room temperature in fresh blocking solution for 1 hour, then the membrane was 
washed three times with TBST for 5 minutes each at room temperature.  
The membrane was incubated for 5 minutes with Clarity Luminata Forte ECL substrate 
(Bio-Rad) or Femto (Pierce, Rockford, IL) before being visualized by using Bio-Rad 
ChemiDoc (system and Image lab software). Image J 1.46r software (National Institutes of 





Table 2.9 : Western blotting antibodies 
Antibody  Company Concentrations 
Anti-Liver-X-Receptor (LXR-β) Cell Signalling Technology 
 
1:1000 
Anti-Insulin Growth Factor I -β 
(IGF-IRβ) 




Anti-Phospho-IGF-I Receptor β 
(pIGF-IRβ) 
Thermo Fisher 1:1000 
β 1 integrin Merck Millipore 1:1000 
Anti-Estrogen receptor β (ERβ) Merck Millipore 1:2000 
Anti-Estrogen receptor β (ERβ) ABCAM 1;1000 
Anti-Estrogen receptor β (ERβ) Thermo Fisher 1:1000 
Anti-Estrogen receptor α (ERα) Santa Cruz Biotechnology 1:1000 
Anti-Fibronectin BD Transduction 1:1000 
Anti-E-cadherin Cell Signalling Technology 1:1000 




Anti-MAPK Thermo fisher 1:1000 
Anti-Phospho-MAPK Thermo fisher 1:1000 
Anti-AKT Cole-Parmer Scientific 
experts 
1:1000 






Anti-α Tubulin Sigma 1:5000 
Anti-β Actin Sigma 1:10,000 





2.9.  Quantitative real-time polymerase chain reaction (qRT-PCR) 
2.9.1.  RNA extraction and quantification  
- Solutions and reagents 
• Isopropanol  
• Ribozol extraction reagent  
• 99.8+% Chloroform  
• 70% ethanol, prepared by mixing 35ml 99.8% ethanol and 15ml molecular biology 
grade, nuclease-free water 
• Trizol  
• Molecular biology grade, Nuclease free water  
- Materials and equipment 
• Refrigerated centrifuge (PrismR, Labnet International) 
• Greiner 1.5ml Microcentrifuge Tubes (Greiner Bio-one, 616201) 
• Nanophotometer (Implen, Munich, Germany) 
• The autoclaved tubes. 
- Procedure 
 Cells were lysed by adding 1ml of Trizol directly to the culture dish for 5 minutes at room 
temperature. Cell lysates were transferred to sterile 1.5ml microcentrifuge Eppendorf tubes 
and incubated at room temperature for 5-7 minutes to dissociate nucleoprotein complexes. 
Chloroform was added (0.2ml per 1ml of the cell lysate). Each eppendorf was shaken for 
15-seconds and was incubated for 10-15 minutes at room temperature. These samples were 
centrifuged at 40C 12000xg (PrismR, Labnet International) for 15 minutes, to separate the 
sample into 3 layers of an aqueous layer containing RNA (clear top), interphase layer 
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(middle white layer), and phenol/chloroform/DNA/protein mixture (pink bottom layer). 
The aqueous phase containing RNA was transferred to a 1.5ml eppendorf tube and 
incubated with 0.5ml isopropanol (Fisher Scientific, 10284200) at room temperature for 
10 minutes. Samples were centrifuged at 12000xg for 10 minutes at 4oC. The supernatants 
were carefully discarded, and the RNA pellet was washed with 1ml of 70% ethanol (Fisher 
Scientific, 10437341). The RNA pellet was centrifuged at 8600x(rpm) for five minutes, the 
ethanol was discarded, and the pellet left to air dry. The RNA pellet was dissolved in 10-
12µl of RNase-free water and vortexed to dissolve the RNA. The amount of RNA extract 
was quantified using a nanophotometer (Implen, Munich, Germany). The sample purity 
was read at the ratio of 260 to 280 with a ratio of between of 1.8-2.0. 
2.9.2.  RNA purification 
Deoxyribonuclease I (DNase I) was added to extracted RNA, to eliminate any genomic 
DNA contamination, using a DNase I Kit (Thermo Fisher Scientific, 18047019) according 
to the manufacturer’s instructions. Briefly, the sample was diluted with 8μl of DNase-free 
water and mixed with 2μl of the master-mix, which was prepared by adding 1μl of DNase 
(volume/reaction) and 1μl of 10x reaction buffer, and incubated at room temperature for 
15 minutes, followed by the addition of 1μl DNase stop solution. After incubation of the 
RNA samples for 10 minutes at 70oC, the samples were placed on ice in preparation for 
the reverse transcription step.  
2.9.3.  Reverse transcription 
- Solutions and reagents 
• Molecular biology grade, nuclease free water (Thermo Scientific, SH30538.01) 
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• High-capacity RNA-to-cDNA kit (Applied Biosystems, P/N 4387406). The kit 
contains; 
o 2X RT Buffer mix (includes dNTPs random octamers and oligo dT-16) 
o 20X RT Enzyme mix (MuLV reverse transcriptase and RNase inhibitor 
protein) 
- Materials and equipment 
• Refrigerated centrifuge (PrismR, Labnet International) 
• Thermal cycler PTC-200 Peltier Thermal Cycler (MJ Research, Waltham, MA) 
• PCR tubes (Alpha laboratories) 
• Vortex mixer (Vortex genie, Scientific Industries Inc.) 
- Procedure 
The cDNA was created by using the high-capacity RNA-to-cDNA kit reagents prepared as 
listed in the table 2.10.  (Applied Biosystems, P/N 4387406). 
 Table 2.10: Preparation of the master-mix used for reverse transcription, as 
manufacture instruction. 
Component Volume per reaction (μl) 
2X reverse transcriptase (RT) Buffer 
(includes dNTPs, random octamers, and Oligo 
dT-16) 
10μl 
20X RT Enzyme 
(MuLV and RNase inhibitor protein) 
1μl 
 
1μl of RNA sample was diluted with 9μl DNase/RNase-free water and mixed with 11μl of 
the master-mix generated on ice using the ingredients listed in Table 2.10. The tubes were 
briefly centrifuged. The samples were added to the PTC-200 Peltier Thermal Cycler (MJ 
Research, Waltham, MA), with a negative control (RNA treated as described but with no 
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addition of the reverse transcriptase buffer). The program was set to incubate RNA samples 
at 37oC for 60 minutes, heated up to 95°C and cooled down to 4°C, this allowed the reaction 
to stop. The samples were stored at -20°C for further use.  
2.9.4.  Quantitative PCR (qPCR) 
- Solutions and Reagents 
• SYBR Green Jumpstart™ Taq Readymix™ (Sigma, S4438) containing 20 mM tris-
HCl, pH 8.3, 7 mM MgCl2, 100 mM KCl, 0.4 mM each dNTP (dATP, dCTP, 
dGTP, TTP), stabilizers, 0.05 unit/ml taq DNA Polymerase, JumpStart Taq 
antibody and SYBR Green I. 
• 100X Internal Reference Dye (Sigma, R4526) 
• ERβ primer pairs (Sigma) 
Forward: AAGTTGGCCGACAAGGAGTT 
Reverse: ACAGGCTGAGCTCCACAAAG 
• GAPDH primer pairs (Sigma) 
Forward: CAATGACCCCTTCATTGACC 
Reverse: GATCTCGCTCCTGGAAGATG 
• Molecular biology grade, Nuclease free water (Thermo Scientific, SH30538.01) 
- Materials and equipment 
• StepOne Plus Real Time, PCR System (Applied Biosystems, Foster city, CA) 
• 96-well PCR plates (Sarstedt, 95.1994) 
• Plate centrifuge (MPS 1000 Mini PCR Plate Spinner) 
• PCR tubes (Alpha laboratories, LW2340) 




qPCR based on the detection of PCR products produced by reactions with a 
fluorescent molecule that reports a proportional elevation in the fluorescent signal with 
elevation in the amount of DNA. Using SYBR green, the master mixes were prepared as 
described in table 2.11, for each sample and a negative control. The mix was prepared in 
PCR tubes, by adding cDNA to the master-mix. The samples were vortexed and placed 
into a 96-well plate in duplicate. The negative control was prepared by adding water and 
cDNA (without the reverse transcriptase enzyme) in duplicate, to check for possible 
contamination. 
Table 2. 11: Preparation of qPCR master mix.  
Component Concentration per reaction  
2X SYBR green 1X 
100X Internal Reference Dye 0.1X 
Forward primer (10 µM) 0.2-1µM 
Reverse primer (10 µM) 0.2-1µM 
PCR water As required 
The 96-well plates were sealed and centrifuged for 10 seconds on a plate spinner to ensure 
the mixtures were at the bottom of each well. The plate was placed on the ABI StepOne 
Plus Real Time PCR System), and the program was set for the thermal cycling parameters 
as described in Table 2.12.  
Table 2. 12: qPCR thermal cycling parameters used in the protocol.  
 Temperature Duration 
Initial denaturation 95oC 120 minutes 40 cycles 
       Denaturation 95oC 30 seconds 
       Annealing 
       Extension     
       Recording fluorescence 
60oC 60 seconds 
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The target gene was normalized to a reference gene, GAPDH, and expressed as relative 
RNA levels against the control gene, calculated by using the 2-∆Ct method as previously 
described (Kondaveeti, Guttilla Reed and White, 2015). 
2.10  Radioimmunoassay (RIA) for IGF-I 
Table 2. 13: Reagents used for radioimmunoassay. 
Reagent  Description  
Assay buffer  Formed by 0.2g Protamine sulphate (Sigma – P4020), 0.03M 
sodium dihydrogen phosphate (BDH – 301324Q), (3mM) 
sodium azide (Sigma – S2002), (10mM) EDTA (Sigma – 
E5134), and (0.05%) TWEEN 20 (Sigma – P5927). Added to 
1L dH2O, adjusted to pH 7.5 and stored at 4°C. 
8M formic acid  Formed by 8M of neat formic acid added to 100ml of ddH2O, 
and 3–4 drops of TWEEN 20 were added to give approximately 
0.05% TWEEN (stored at room temperature).  
1M Tris base  Formed by adding 1M of Tris base to 100ml of ddH20, stored 
at room temperature.  
Acetone  (BDH, Poole, UK) 
 
An extraction procedure was carried out to release IGF-I from their endogenous binding 
proteins. 50μl of the sample and a control of normal human serum were aliquoted into 
1.5ml eppendorfs. 25μl of the formic acid/TWEEN solution were added to each sample 
and vortexed. 175μl of acetone were added to each sample, by using an acetone primed 
pipette tip. The samples were immediately capped, vortexed and centrifuged, for 30 
minutes at 4oC at a rcf of 3000g. In a fresh eppendorf, 100μl of supernatant were placed 
and mixed with 100μl of tris base. The conditioned media did not need dilution, therefore, 
the standards were added with 50μl of acid/ tris base solution /acetone, with 50μl of the 
conditioned media to make sure that all conditions were maintained. Normal human serum 
was used as positive control, which was diluted 1:80 (in assay buffer).  
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Recombinant human IGF-I standards were prepared in assay buffer to produce a standard 
curve with the following dilutions for IGF-I: 0, 0.25, 0.5, 1.0, 2.5, 5, 10, 25 & 50ng/ml.  
Freshly made radioactive tracer with I-125 labelled IGF-I was prepared by adding 25ml of 
assay buffer to 50μl of the labelled tracer. Using a bench-top gamma counter, 50μl of the 
mix solution were placed into a test tube and the number of counts were measured. The 
number of counts should be between 10,000-15,000 cpm per assay tube. 
IGF-I radioimmunoassay antiserum was a monoclonal antibody (Clone M23/ILG1-001, 
5345-0304) diluted with assay buffer at a 1:2000 dilution. 
RIA is very sensitive to residual binding proteins, therefore, an excess 200ng/ml of IGF-II 
peptide were added to the assay to removes any interference from them after the extraction 
procedure. The peptide will not change or affect the levels of the measured IGF-I because 
they would not be recognised by the very specific antibodies. Then, the tubes were labelled 
for total counts of the tracer (TC) in duplicates, non-specific binding (NSB), which 
demonstrated the level of iodinated peptide binding to the tube, usually less than 3% of 
TC, maximum binding (around 40% of TC), and each assay standard. Tubes were labelled 
for the samples and were set up in triplicate, as indicated in Table 2.14 for IGF-I.  
Each tube was vortexed (except for TC tubes), covered and incubated at 4°C (in the fridge) 
for 24h. 50μl of anti-mouse SAC-CEL (IDS Ltd., Bolden, UK) were added to tubes (except 
for the TC tubes). The tubes were vortexed, and incubated for 30 minutes at 4°C.  SAC- 
CEL is a solid-phase (covalent-coupled) secondary antibody coated cellulose suspension 
that pulls down the primary antibody after centrifugation and this step was performed with 
continuous stirring. Distilled water 1ml was added to tubes and centrifuged at 2000g at 4°C 
for 30 minutes (except the TC tubes). The IGF-I was then released from the SAC-CEL by 
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adding the acetic acid and the tubes then centrifuged again, as before. The generated 
supernatant was extracted and counted using the Gamma Counter. The concentration of 
IGF-I ligand was then calculated automatically according to the standard curve by a pre-
set computer program.  














TC - - - 50 - - 
NSB 400 - - 50 - 50 
Maximum 
binding  
350 - - 50 50 50 
Standards 300 - 50 50 50 50 






The effects of LDL on breast cancer cell 





3.1 Introduction  
Obesity has been identified as a leading risk factor for breast tumour incidence in post-
menopausal women and abnormal lipid accumulation and cholesterol may affect breast 
cancer progression and treatment (Bradley, 2018; F et al., 2018). Cholesterol associates 
with lipoproteins, to be transferred to several parts in the body. Lipoproteins include low-
density (LDL) and high-density lipoproteins (HDL) (Li et al., 2018). Several studies have 
evaluated the role of lipid accumulation with breast cancer risk, and found increased  levels 
of LDL, total cholesterol and triglyceride in breast cancer patients when compared with 
healthy women, with LDL cholesterol being significantly correlated with breast cancer 
progression (Rodrigues Dos Santos et al., 2014; Kumar et al., 2015).  
Cholesterol is also an important component for the cell membrane as well as for cell 
proliferation and differentiation (Silvente-Poirot and Poirot, 2014). Moreover, cholesterol 
is a crucial factor of lipid rafts, which are sphingolipid enriched domains of the plasma 
membrane (Park et al., 2010). Lipid rafts contain different cell signalling molecules, such 
as EGFR, Ras, FAS/CD95, and Wnt that contribute to the regulation of cell proliferation, 
mobility and survival (Park et al., 2010). Cholesterol accumulation has been demonstrated 
in breast cancer patients with higher levels in breast tumours compared to normal tissue 
(Silvente-Poirot and Poirot, 2014). Also, cholesterol accumulation may activate the 
interaction of key signalling molecules in lipid rafts and thus enhance cell growth and 
survival by activating the cell surface markers such as the EGFR and the IGF-IR in cancer 
(Laurentiis, Donovan and Arcaro, 2007) (Lee Seong-Hee et al., 2009). Additionally, a 
retrospective cohort study assessed the status of the serum lipids and lipoproteins in women 
breast cancer patients during chemotherapy at initial diagnosis. They found that 
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chemotherapy treatment caused significant changes in metabolic status, decreases in HDL-
C and apolipoprotein (Apo A1) and increases in total cholesterol, triglycerides, LDL-C and 
Apo B (Li et al., 2018).  
An epidemiologic study indicated that cholesterol and its metabolite contribute to the risk 
of breast cancer and overall survival (Dalenc et al., 2017; Kimbung et al., 2017a). (DuSell 
et al., 2008). Oxysterols, such as 27OHC, oxygenated derivatives of cholesterol, are also 
thought to play a role in the development of breast cancer as indicated in experimental 
animal models (Oguro, 2019). A prospective study in breast cancer patients found a 
significant increase in 27OHC in the patients’ blood serum in response to aromatase 
inhibitor (AI) treatment, and they suggested that 27OHC might be a marker of both poor 
prognosis and/or the efficacy of endocrine treatment (Dalenc et al., 2017). Another recent 
prospective study indicated no correlation between circulating 27OHC level and breast 
cancer risk in postmenopausal-women and no association with ERα breast cancer status 
(Lu Da-Lin et al., 2019). In vitro, whilst 27OHC alone increased cell proliferation through 
activation of the ER, administration of 27OHC decreased estradiol-induced proliferation  
(DuSell et al., 2008).  
Furthermore, it has been found that increased CYP27A1 levels, the enzyme that converts 
cholesterol to 27OHC, were observed in more aggressive mammary breast cancers (Nelson 
et al., 2013b; Wu et al., 2013). A study investigating the correlation between patients taking 
statins and risk of breast cancer are equally conflicting, with the meta analyses revealing 
that there is no correlation (Undela, Srikanth and Bansal, 2012). However, there is strong 
clinical data supporting a correlation between serum levels of total cholesterol and breast 
cancer survival and recurrence, with elevated total cholesterol correlating with increased 
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breast cancer recurrence (Bahl et al., 2005). A recent phase III, double-blind trial, found 
that cholesterol lowering treatment along with endocrine therapy was correlated with 
elevated recurrence-free survival time in 8010 invasive breast cancer postmenopausal 
women with hormone receptor positive (Borgquist, Giobbie-Hurder, Thomas P Ahern, et 
al., 2017).  
The anti-cancer drug doxorubicin has been widely used to treat different types of cancer 
including breast cancer, but its use is limited due to dose-dependent side effects 
(Doroshow, 1991). In cell line models, statins, influence the sensitivity of doxorubicin in 
ovarian cancer (Martirosyan et al., 2010), breast cancer (T47D, MCF-7 and MDA-MB-
231), and osteosarcoma (Werner, Sacher and Hohenegger, 2004; Fromigué, Hamidouche 
and Marie, 2008).  These studies suggest that high cholesterol levels may interfere with 






3.2 Aims  
In this chapter, we aimed to assess the effect of LDL on cell proliferation, migration, 
invasion, and resistance to chemotherapy in breast cancer epithelial cell lines. 
 
3.3 Specific aims  
Aim 1: To examine the effect of LDL on cell proliferation, migration, and invasion in both 
ERα-positive and ERα-negative breast cancer epithelial cell lines. 
Aim 2: To address the role of the CYP27A1 enzyme in the effects of LDL on cell 
proliferation and migration in both ERα-positive and ERα-negative cells, by silencing 
CYP27A1 using siRNA. 
Aim 3: To address the effects of LDL and its metabolite 27OHC on the survival of breast 




3.4. Methods  
 3.4.1. Cell culture:  
The human breast cancer cell lines MCF7, T47D, Hs578T and MDA-MB-231 were 
obtained from ATCC (Teddington, Middlesex, UK). Each cell lines were grew as described 
previously in section 2.1.1. 
3.4.2.  Cell counting:  
3.4.2.1. Optimising a crystal violet (CV) proliferation assay  
The crystal violet assay is a simple and reliable method, because it directly stains the 
attached cells with crystal violet dye, which binds to DNA and proteins (Feoktistova, 
Geserick and Leverkus, 2016a). We performed some optimisation steps to ensure that the 
CV assay performed sensitively and reliably for future experiments. The CV assay was 
performed using MCF-7 cells to examine changes in cell proliferation at different seeding 
densities: 500, 1000, 2000, 4000, 8000, and 16000 cells per well for 24, 48, 72, and 96 
hours, after which the proliferation rate for each density/time point was measured. 
3.4.2.2 LDL treatment 
For cell proliferation assays, cells were incubated in growth media DMEM for 24 hours, 
before being changed to serum-free media for a further 24 hours. The cells were then 
treated with different concentrations of LDL 0-100μg/ml. Crystal violet assay was used to 
determine the viability and proliferation of MCF-7 cells, as outlined in section (2.6).   
3.4.3 Western blot  
Western blot analysis was observed as described previously (2.10). In brief, protein cell 
lysates (30 μg), were allocated in SDS-PAGE gel, transferred to nitrocellulose membrane 
and immunoblotted with the targeted antibodies: anti-CYP27A1 (1:1000), GAPDH 
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(1:5,000; Millipore) and β-actin (1:10,000; Sigma-Aldrich). After that the membranes were 
incubated with particular secondary antibodies (anti Mouse or Rabbit) conjugated to 
peroxidase (Sigma), next proteins were detected by Clarity ECL substrate (BioRad) by 
using BioRad Chemidoc XRS + system and quantified by using Image J 1.46r software 
(BioRad). 
3.4.4 Optimizing the CYP27A1 antibody  
Antibody validation is critical to generate accurate, valid data. For experiments to 
investigate if the effects of LDL were through CYP27A1 (is the rate-limiting step in 27-
hydroxycholesterol biosynthesis), we first validated the CYP27A1 antibody as shown in 
Figure 3.1. We used western blotting technique to assess the protein abundance of 
CYP27A1 in different breast cancer cell lines. The CYP27A1 antibody detected a single 
band of the expected size following the manufacture protocol (the molecular weight; 




Representative images of western blotting for lysates from exponentially growing whole-
cell lysates from 4 cancerous cell lines ERα-positive; MCF-7 & T47D and ERα-negative; 
MDA- MB-231 & Hs578T were used for these experiments: showing the band was detected 
at the correct molecular weight of 60KDa and showing the level of CYP27A1 in different 
breast cancer cells. GAPDH was used as loading control protein. Data representative of 
(n=1). 
3.4.5 Targeted CYP27A1 gene knockdown, using siRNA knockdown 
For experiments investigating the effect of LDL on the cell proliferation and migration of 
MCF-7 and MDA-MB-231 cells in the presence or absence of CYP27A1, the optimum 
concentration of siRNA for silencing the CYP27A1 (Dharmacon) or non-silencing (NS) 
(AllStars) was investigated. The cell number for this experiment was assessed using a Muse 
cell analyzer, as described in section 2.5. 
 CYP27A1 siRNA was optimised using a range of concentrations (20, 30 and 40nM) for 
ERα-positive cells (MCF-7) and (20 and 40nM) for ERα-negative cells (MDA-MB-231) 
and the level of knockdown of CYP27A1 protein expression was assessed by Western blot 
 




analysis. The optimum concentration of siRNA for silencing the CYP27A1 was 40nM in 
MCF-7 (Fig. 3.2A) and MDA-MB-231 cells for 48 hours (Fig. 3.2B).   
 
Cells were treated with siRNA transfection for CYP27A1 knockdown with different 
concentration of siRNA (20,30, and 40nM) in MCF-7, and (20 and 40nM) in MDA-MB-
231. Western blotting analysis confirmed CYP27A1 knockdown in A) MCF-7 and B) MDA-
MB-231. GAPDH were used as loading control. Data representative of one experiment. 
  
 






3.4.6 Trans-well migration assay by crystal violet staining  
48 h post-treatment with or/without LDL and CYP27A1 siRNA, cells were seeded into 
transwell inserts to assess migration. The migrated cells were fixed and stained with crystal 
violet after 24 h for MCF-7 or 6 h for MDA-MB-231 cells. Further protocol details are 
described in section (2.9). 
 3.4.7  Statistical analysis  
The whole experiments were repeated in triplicate, and also each experiment was repeated 
three times. Using GraphPad Prism 8.0.1 software for windows (La Jolla, CA, USA), to 






3.5.1 Optimizing a crystal violet (CV) proliferation assay 
Figure 3.3 A and B show that at the 2000 to 16000 cell density, the proliferation 
rate increased in a time-dependent manner up to 96 hours. However, the cell growth rose 
most sharply at 2000-16000 cells between the time 48 to 96 hours in both MCF-7 and 
MDA-MB-231 cells (Fig. 3.3A and B respectively). We chose an optimal plating density 
of 5000-10,000 cells/well for 48hrs. This number of cells lay in between the lowest and 
highest densities that allowed the cell growth to be increased or decreased depending upon 
the treatment (Fig. 3.3). 
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The crystal violet assay was performed to assess the growth rate of A) MCF-7 and B) MDA-
MB-231 cells to compare the proliferation rates at different cell densities :500, 2000, 4000, 
10000 and 16000cells/well for 24, 48, 72 and 96 hours. Data representative of (n=1).  
3.5.2 Effects of LDL on cell proliferation, invasion, and migration  
To investigate the appropriate time point for dosing with LDL, we tested different time 
points: 24 and 48 hours. MCF-7 cells were treated with different concentrations of LDL 0-
100μg/ml for 24h and 48h. Figure 3.4 A and B show that the optimum time point for dosing 
 
 
Figure 3. 3: Crystal violet proliferation assay showing the growth rate of MCF-7 
and MDA-MB-231 cells  
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with LDL was 48 hours, as the growth was greatest at 48h in comparison with the 24h time 
period (Fig 4.3B).  
The CV assay was performed to assess the proliferation and viability of MCF-7 cells for 
A) 24h and B)48h with seeding density at 10,000 cells/well, after being dosed with 
increasing concentrations of LDL (0-100μg/ml). Absorbance values reflect the number of 
viable cells that have absorbed the crystal violet dye. Data representative of (n=3).  
Next, we investigated the effects of LDL on cell proliferation in a different ERα-positive 
cell line, T47Ds and two different ERα-negative breast cancer cell lines with different 
concentrations of LDL 0-100μg/ml. At 48hrs, the proliferation of ERα-positive MCF-7 
cells was greatest at 80μg/ml (p < 0.001) LDL in comparison with the control (Fig. 3.4B), 
whereas with T47D cells, a gradual increase in growth was found with increasing 
concentrations of LDL from 0-100μg/ml, with a significant increase at 80 and 100μg/ml 
(p < 0.001 for both) in comparison with the control (Fig. 3.5).   
 
 
Figure 3. 4: Optimization of cell proliferation at different time points, 24h and 
48h in response to LDL treatment, using a CV proliferation assay:  





























































Figure 3. 5: Assessment of proliferation in T47D cells using a crystal violet assay (CV) 
following LDL treatment 
  The CV assay was performed to assess the proliferation and viability of T47D cells with 
seeding density at 10,000 cells/well after being dosed with increasing concentrations of 
LDL (0-100μg/ml) for up to 48 hours. Absorbance values reflect the number of viable cells 
that have absorbed the crystal violet dye. Data representative of mean ±SEM (n=3). P-
values were determined by using GraphPad Prism one-way Statistical analysis: ANOVA 
test followed by least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, 
***p < 0.001).   
While with the ERα-negative cell lines, figures 3.6 A and B respectively, show a significant 
change in cell proliferation in response to LDL in MDA-MB-231(Fig. 3.6A) and Hs578T 
(Fig. 3.6B) cells. There was a dose-dependent increase in growth rate of MDA-MB-231 
cells in response to LDL in comparison with the control: a 22.2, 28.5, 31.8, 39.7 and 37.9% 
increase respectively in growth at 10-100μg/ml with p-values of (p<0.007, p <0.001, 
p<0.001, p<0.001 and p<0.001 respectively). A similar pattern of growth was observed in 
Hs578T with proliferation increasing from 60-100μg/ml LDL; a 16.7% (p<0.001), 28.6% 
(p<0.001) and 50.7% (p<0.001) increase respectively in comparison to control.  
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  The CV assay was performed to assess the proliferation and viability of A) MDA-MB-231 
with seeding density at 5,000 cells/well, and B) Hs578T with seeding density at 5000 
cells/well after being dosed with increasing concentration of LDL (0-100μg/ml) for 48 
hours. Absorbance values reflect the number of viable cells that have absorbed the crystal 
violet dye. Data representative of mean ±SEM (n=3). P-values were determined by using 
GraphPad Prism one-way statistical analysis: ANOVA test followed by least significant 
difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001).  
Migration and invasion were significantly increased by LDL treatment (80μg/ml) in both 
the ERα-positive, MCF-7 cells, with p-value of (p< 0.001 for migration and p < 0.01 for 
invasion) (Fig. 3.7A and B respectively), and ERα-negative, MDA-MB-231 cells, in 
comparison to control with a p-value of (p < 0.01 for both) (Fig. 3.7C and D respectively).   
 
Figure 3. 6: Assessment of proliferation in ERα-negative, A) MDA-MB-231and 
B) Hs578T cells using a crystal violet assay (CV) following LDL treatment 





















































Figure 3. 7: Assessment of migration and invasion in A& B) MCF-7 and C&D) MDA-
MB-231 cells using a trans-well migration/invasion assay following treatment with 
LDL  
Cells were treated with LDL (80μg/ml) for 48 hours. A trans-well assay was used to detect 
cell migration and invasion. The migrated cells were stained with crystal violet and images 
were taken (×20 magnification). Quantification of cell migration for A) MCF-7 after 
24hours and B) MDA-MB-231 after 6 hours, and cell invasion for C) MCF-7 after 24hours 
and D) MDA-MB-231 after 6 hours. Quantitative analysis of stained migrated/invaded 
cells using a microplate reading at an OD at 595 nm. Data representative of mean ±SEM 
(n=3). P-values were determined by using GraphPad Prism one-way Statistical analysis: 
ANOVA test plus least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, 
***p < 0.001), Scale bar represents 100μm.     
MCF-7 MDA-MB-231  
MCF-7 MDA-MB-231  
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3.5.3 Are the effects of cholesterol mediated via 27OHC in breast cancer cells? 
As LDL induced proliferation, migration, and invasion in breast cancer cells, we next 
examined if the effect of LDL actions were through CYP27A1 (is the rate-limiting step in 
27-hydroxycholesterol synthesis). MCF-7 and MDA-MB-231 cells were dosed with LDL 
in the presence or absence of CYP27A1, by using CYP27A1 siRNA.  
With MCF-7 cells, LDL increased proliferation and migration (p < 0.001 respectively), but 
with CYP27A1 silenced, these effects were blocked (Fig. 3.8A &B). The western blot 
shows effective silencing of CYP27A1 in MCF7 cells (Fig. 3.8b-E). Similarly, with MDA-
MB-231 cells, LDL promoted cell growth and migration (p < 0.001 respectively) and these 
effects were blocked with CYP27A1 silenced (Fig 3.8a-C&D). The western blot shows 




Figure 3. 8a: LDL increases proliferation and migration through 27OHC production 
in breast cancer cells: 
Using a Muse cell analyser, to assess the cell number for A) MCF-7 and C) MDA-MB-231 
after being transfected with CYP27A1 siRNA and non-silencing RNA and dosed with LDL 
(80μg/ml) for 48 hours. A trans-well assay was used to detect cell migration and invasion 
after being transfected with CYP27A1 siRNA and dosed with (LDL 80μg/ml). The migrated 
cells were stained with crystal violet and images were taken (×20 magnification). 
Quantification of migrated cells were assessed for B) MCF-7 after 24 hours and D) MDA-
MB-231 after 6 hours incubation time. Data representative of mean ±SEM (n=3).  P-values 
were determined by using GraphPad Prism one-way Statistical analysis: ANOVA test 
followed by least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, 
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Western blotting was conducted to show protein abundance of CYP27A1 for E) MCF-7 
and F) MDA-MB-231 with or without LDL and CYP27A1 silencing, and relative fold 
changes of CYP27A1 against loading control β-actin were measured. Data representative 
of mean ±SEM (n=3).  P-values were determined by using GraphPad Prism one-way 
Statistical analysis: ANOVA test followed by least significant difference (LSD) post-hoc 
test (*p < 0.05, **p < 0.01, ***p < 0.001).   
 
Figure 3. 9b: LDL increases proliferation and migration through 27OHC 
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3.5.4 Cholesterol and its metabolite increased survival in breast cancer cell lines  
To investigate the survival effect of LDL and 27OHC breast cancer cells were dosed with 
a chemotherapy drug, doxorubicin (DOX) to induce cell death. Cells were exposed to DOX 
treatment (0-20!M) in MDA-MB-231 cells to choose an appropriate concentration, which 
in this case killed approximately 46.1% of the MDA-MB-231 cells. The optimum dose was 
0.5uM for MDA-MB-231 (fig. 3.9B).  
 
Figure 3. 10:  Dose response to doxorubicin for 24hours in ERα -negative cells 
The CV assay was performed to assess the viability of MDA-MB-231 after being dosed 
with increasing concentration of doxorubicin (0-20μM) for 24 hours. Absorbance values 
reflect the number of viable cells that have absorbed the crystal violet dye. Data are 
representative of the mean ±SEM (n=3). P-values were determined by using GraphPad 
Prism one-way Statistical analysis: ANOVA test followed by least significant difference 
(LSD) post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001).  
Cells were either pre-exposed with 27OHC or LDL for 24 hours, followed by co-exposure 
with DOX for a further 24hrs. Pre-exposure to 27OHC and LDL significantly reduced 
doxorubicin-induced cell death. There was a significant increase cell viability and 
percentage of cell viability respectively with LDL (p < 0.001 for both) and 27OHC 
treatment (p < 0.001 for both) (Fig.3.10A &B respectively), and a significant decrease in 
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the percentage of cell death by 35.91% (p < 0.001) with LDL and 30.1% (p < 0.001) with 
27OHC treatment (Fig.3.10C), in compared to DOX. Doxorubicin is less effective in 
inducing cell death in the presence of LDL and 27OHC, therefore LDL and 27HC appear 
to act as survival factors. 
  
Figure 3. 11: Effects of LDL and 27OHC on the effect of doxorubicin on cell death in 
the ERα-negative cells:  
Cells were pre-incubated at least 24hrs with 27OHC(0.1μM) and LDL (80μg/ml) before 
adding doxorubicin (1μM) for 24hrs with/without 27OHC and LDL:  A) cell viability and 
proliferation assay (crystal violet staining assay) detects the cell viability of MDA-MB-231 
after 48hrs. Absorbance values reflect the number of viable cells that have absorbed the 
crystal violet dye. Muse cell counting was employed to detect B) the percentage of cell 
viability and C) the percentage of cell death in MDA-MB-231 cells. Data representative of 
mean ±SEM (n=3). P-values were determined by using GraphPad Prism one-way 
Statistical analysis: ANOVA test followed by least significant difference (LSD) post-hoc 
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3.5.5  The Cancer Genome Atlas (TCGA) data analysis to assess the expression of 
CYP27A1 in different types of breast cancer  
The Cancer Genome Atlas (TCGA) data analysis was used to assess the expression level 
of CYP27A1 in different types of breast cancer. The expression level of CYP27A1 mRNA 
is significantly increased in triple negative breast cancers (TNBC) compared with normal 
breast tissue (p value <10-6), whereas there is no difference found between the HER2-
positive group and luminal group compared with normal breast tissue (Fig. 3.11A). The 
protein expression of CYP27A1 is significantly increased in stage 2 and stage 3 breast 
cancer groups compared to normal breast tissue, while there is no differences found 
between stage 1 compared with normal breast tissue (Fig. 3.11B) 
 
Figure 3. 12: mRNA and protein expression of CYP27A1 in different subtypes of 
breast invasive carcinoma (BRCA) using the TCGA data:  
A) the expression of CYP27A1 in luminal, HER2-positive and TNBC compared to normal 
breast tissue. B)  Protein expression analysis using data form Clinical Proteomic Tumor 
Analysis Consortium (CPTAC) the protein expression of CYP27A1 in different breast 
cancer stages, stage 1, stage 2 and stage 4, compared to normal. Unpaired two-tailed 







 3.6 Discussion  
Obesity is correlated with an increase in breast cancer-specific mortality in women (Niu et 
al., 2013). The levels of cholesterol, specifically low-density lipoprotein cholesterol (LDL-
C) are frequently up-regulated in women with obesity (Gallagher et al., 2017a). 
Additionally, it was reported that a high fat diet and raised cholesterol decreased latency 
and promoted tumour growth and metastasis of breast cancers in mice (Llaverias et al., 
2011).  
Statins are 3-hydroxy-3-methylglutharyl-coenzyme-A reductase (HMGCR) inhibitors that 
block the rate limiting step in the production of cholesterol. Recent meta-analyses reported 
that the use of statins, specifically lipophilic statins in patients with breast cancer show 
improved overall recurrent-free and cancer- specific survival (Manthravadi, Shrestha and 
Madhusudhana, 2016; B. Liu et al., 2017). Additionally, similar results with in vitro studies 
found that fluvastatin reduced caveolin-1 (CAV-1) expression, and cerivastatin down-
regulated cyclin D1 in breast cancer cells (Denoyelle et al., 2001; Salis et al., 2014) 
We found that LDL drives the proliferation of ERα-positive and ERα-negative cells, and 
this is consistent with a previous study examining the importance of the LDL-R in the 
growth of TNBCs (Gallagher et al., 2017a). Although the differences in the optical density 
(OD) readings are small, the fold change is comparable to that seen with cell counting.  
A correlation between the circulating levels of 27OHC and hypercholesterolemia has been 
reported (Brown and Jessup, 1999; Burkard et al., 2007; Wu et al., 2016a). In our 
laboratory, we found that LDL increased the proliferation of ERα-positive and ERα-
negative cells and this was inhibited when CYP27A1 was silenced using siRNA, 
suggesting that cholesterol was metabolised to 27OHC that was responsible for increasing 
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the growth of the breast cancer cells. The phenotype that we observed has been confirmed 
by others (Nelson et al., 2013a; Wu et al., 2013). It has been reported that statin treatment 
significantly decreased serum 27OHC and may deregulate CYP27A1 expression in breast 
cancer (Kimbung et al., 2017a). According to our analysis of the “The Cancer Genome 
Atlas (TCGA)” data show that the expression of the enzyme that converts cholesterol into 
27OHC, CYP27A1, is the same in ER or HER2 positive breast tumour tissue in comparison 
with normal breast tissue, but its expression is significantly upregulated in TNBC tumour 
samples in comparison with normal breast tissue. Moreover, the protein expression of 
CYP27A1, is significantly increased in stage 2 and stage 3 breast cancer group in 
comparison with normal breast tissue, suggesting a potential role of disrupted 27OHC 
homeostasis in breast cancer development. This is consistent with previous work showing 
increased expression of CYP27A1 enzyme in higher grade tumours (Kimbung et al., 
2017a). Another study reported that a high fat diet significantly increased circulating levels 
of both total cholesterol, 27OHC and promoted tumour growth and this effect was 
decreased by treatment with a CYP27A1 inhibitor in mice with ER-positive breast cancer 
compared to mice on a control diet, and is thought to be mediated through the estrogen 
receptor (Nelson et al., 2013a). Exogenous 27OHC supplementation increased lung cancer 
cell proliferation (Hiramitsu et al., 2018), suggesting 27OHC signalling can mediate the 
effects of cholesterol.  
We have shown that the effects of cholesterol on the proliferation of ER-positive and ER-
negative breast cancer cells involves its conversion to 27OHC. It is important to mention 
that other metabolites of cholesterol, such as 25-hydroxycholesterol (25OHC), may also be 
involved and we have not yet explored how cholesterol treatment may alter other such 
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metabolites. 25OHC is generated from cholesterol via CH25H enzyme, CYP27A1 and 
cytochrome P450 3A4 (CYP3A4) and can be created by free radical oxidation (Yamauchi 
and Rogers, 2018).  
Interestingly, 27OHC promoted breast cancer metastasis and this effect was decreased with 
a CYP27A1 inhibitor in mice with ER-positive breast cancer compared to mice on a control 
diet (Nelson et al., 2013b). In our laboratory, we found that LDL promoted the migration 
and invasion of ERα-positive and ERα-negative cells and this was inhibited when 
CYP27A1 was silenced using siRNA, suggesting that the role of dietary cholesterol on 
migration and invasion requires the conversion of cholesterol to 27OHC via CYP27A1. In 
support of the mechanism that the 27OHC signalling pathway mediates the role of 
cholesterol, it was found that exogenous treatment with 27OHC induced lung cancer cell 
metastasis (Hiramitsu et al., 2018). In the next chapter we examine the effect of exogenous 
27OHC on proliferation, migration, and invasion to examine the role of endogenously 
produced 27OHC. 27OHC is an important biochemical mediator of the metastatic effects 
of high level of cholesterol through its interaction with immune cells γδ-T cells and 
polymorphonuclear-neutrophils (PMNs) and decreasing CD8+T cells (Baek et al., 2017).  
Although the exact signalling pathways involved are not yet known, 27OHC has been 
found to interact with nuclear receptors as the ERs and LXRs. Additionally, cholesterol 
was found as a ligand for the estrogen-related receptor alpha (ERRα), and it has been 
suggested that 27OHC might also interact with this receptor(Wei et al., 2016). In next 
chapter, we investigate the action of exogenous 27OHC on migration and invasion and 
through which receptors these actions might be mediated. 
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Anti-cancer, DNA-damaging agents, including doxorubicin have been widely used to treat 
different types of cancer.  Recently, it was found that doxorubicin significantly 
downregulates HMG-CR and this leads to a reduce in the level of the EGFR, and thus 
enhances doxorubicin-induced cell death. In addition, knockdown of HMG-CR in the 
presence of DOX promoted PARP cleavage, which is an indicator of consequent apoptosis 
and caspase-3 activation (Yun et al., 2019). Consistent with these observations, we found 
that doxorubicin was less effective in inducing cell death in the presence of 27OHC or 
LDL, suggesting they can act as survival factors in MDA-MB-231, ERα-negative breast 
cancer cell lines.  
These results are consistent with an animal model treated with doxorubicin, which 
demonstrated that the tumour growth was faster in mice fed with a high-cholesterol diet 
than on a normal diet and HMG-CR expression likely to be inversely associated with 
decreased overall survival and is increased in tumour than in normal tissues (Yun et al., 
2019). In vitro, 27OHC and 7-ketocholesterol increased doxorubicin resistance in MCF-7 
breast cancer cells and this might be mediated through the upregulation of P-glycoprotein 
in an ERα- and mTOR-dependent pathway (Wang et al., 2017). Our data suggest that 





 3.7 Conclusion  
In summary, our data support the clinical studies suggesting a link between obesity and 
high cholesterol with an increased risk of breast cancer progression: we found that LDL 
promotes cell proliferation, migration and invasion and chemo-resistance and that this may 






The effect of 27-Hydroxycholesterol on breast 
cancer cell proliferation, migration, and invasion 




4.1 Introduction  
Cholesterol molecules generate oxidized metabolites, defined cholesterol oxidation 
products (COP) or oxysterols, that mediate different signal transduction cascades. At very 
low concentrations, oxysterols play a vital role in the human body, mediating many 
physiological functions; they regulate cholesterol metabolism, influence signalling 
molecules such as MAPK (Caihua Wang et al., 2017), INSIG SREBP (LP et al., 
2005b), SCAP and the activity of some membrane proteins such as ATP-binding cassette 
transporters, ABCA1, ABCB1, Na+/ K+ ATPase to affect membrane fluidity (Ouvrier et 
al., 2009). Recent evidence shows that oxysterols influence cancer progression and 
carcinogenesis (Kloudova, Guengerich and Soucek, 2017). The most abundant oxysterol 
in plasma is 27OHC that is a SERM (He and Nelson, 2017) and is also a modulator of LXR 
(Fu et al., 2001).  In an acidic pathway through hydroxylation, 27OHC is synthesised from 
cholesterol by the mitochondrial resident cytochrome P450 enzyme, CYP27A1 (Russell, 
2000). 27OHC is a regulator of LXR activity in ERα-positive breast cancer cells, resulting 
in the arrest of cell cycle progression and a reduction of cell proliferation (Wu et al., 
2016a).  
The bioavailability of 27OHC at the tumour site can be totally different from its level in 
the plasma, and this may be more critical in the context of tumour progression. The 
abundance of 27OHC in ERα-positive breast cancer cells is 2.5- 3-fold higher than in 
normal breast cells. The concentration of 27OHC in healthy human plasma is 0.22 to 
0.60μM and 50–90% of 27OHC is esterified and thus, unesterified plasma levels around 
10−8M, and 10−8M was the threshold concentration for activation of breast cancer cell 
growth (Burkard, Rentsch and Von Eckardstein, 2004; Wu et al., 2013). The relative 
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contributions of the bioavailability of 27OHC at the tumour site is also regulated by intra-
tumoral expression level of the CYP27A1 enzyme that catalyses production of 27OHC 
from cholesterol (Kimbung et al., 2017a). High expression of CYP27A1 is associated with 
a higher grade of tumour in breast cancer patients (Kimbung et al., 2017a). Recently, 
CYP27A1 expression has been identified as an independent prognostic factor for overall 
and recurrence-free survival in ER-positive breast cancer women > 50 years of age 
(Kimbung et al., 2017a). 
 A recent report indicated that 27OHC activated the STAT signalling pathway that plays 
an important role in cell proliferation and migration (Jiao et al., 2020). Furthermore, 
oxysterols have been found to induce the activation of the JAK/STAT signalling cascade 
through LXR-dependent and LXR-independent mechanisms (Nelson et al., 2013b). 
Several studies have described that activation of the ER is increased by 27OHC in breast 
cancer cells, which culminates in increased cell proliferation and consequently promoted 
ERα-positive breast cancer progression and migration (DuSell et al., 2008; Wu et al., 2013; 
Nguyen et al., 2015; He and Nelson, 2017). Interestingly, 27OHC increased migration and 
invasion not only in ERα-positive breast cancer cells, but also in ERα-negative cell lines 
that involved STAT3 activation (Shen et al., 2017).  
Currently, the exact mechanism of action of 27OHC in ERα-positive and ERα-negative 
breast cancer cells and the role of these metabolites in breast cancer cell proliferation, 





 4.2  Aims  
In this chapter, we aimed to assess the effect of 27OHC on cell proliferation, migration, 
and invasion in breast cancer epithelial cell lines. 
 
 4.3 Specific aims  
Aim 1: To examine the effect of 27OHC on cell proliferation, migration, and invasion in 
both ERα-positive and ERα-negative breast cancer epithelial cell lines. 
Aim 2: To determine the roles of ERα in the effects of 27OHC on cell migration 




4.4 Methods  
 4.4.1 Cell culture:  
The human breast cancer cell lines ERα-positive; MCF7 and T47D and ERα-negative; 
MDA-MB-231 and Hs578T were obtained from ATCC (Teddington, Middlesex, UK). All 
cell lines were cultured as described previously in section 2.1.1. 
  4.4.2 Cell counting:  
For cell proliferation assays, cells were incubated in growth media DMEM for 24 hours, 
before being changed to serum-free media for a further 24 hours. The cells were then 
treated with different concentrations of 27OHC 0-0.1μM. Crystal violet proliferation assay 
was used to determine the viability and proliferation of MCF-7 and MDA-MB-231, as 
outlined in section (2.6).  
4.4.3 Western blot  
Western blot analysis was observed as described previously (2.10). In brief, protein cell 
lysates (30 μg), were allocated in SDS-PAGE gel, transferred to nitrocellulose membrane 
and immunoblotted with the targeted antibodies:  anti-estrogen receptor α (ERα) (1:1000; 
Santa Cruz Technology), anti-estrogen receptor β (ERβ)(1:1000; Thermo Fisher), 
fibronectin and vimentin (1;1000; BD Transductio), Low density Lipoprotein-Receptor 
(LDL-R) (1;1000; Merck Millipore), anti- Liver-X-Receptor (LXR-β) (1;1000;Cell 
Signalling Technology), GAPDH (1:5,000; Millipore) and β-actin (1:10,000; Sigma-
Aldrich). After that the membranes were incubated with particular secondary antibodies 
(anti Mouse or Rabbit) conjugated to peroxidase, next proteins were detected by Clarity 




4.4.4. Targeted estrogen receptor α (ERα) gene knockdown, using siRNA knockdown 
For experiments investigating the potential interactions of 27-OHC with the estrogen 
receptor, we investigated the effect of 27OHC in the presence or absence of ERα. As 
previously established in our lab by (Zielinska et al., 2018), the optimum concentration of 
siRNA for silencing the ERα is 20nM for 48 hours in ERα-positive cells . Transfection 
with siRNA was performed as described previously in section (2.7). 
4.4.5.  Trans-well migration assay by crystal violet staining  
48 h post-treatment with or/without 27OHC and ERα siRNA, cells were seeded into 
transwell inserts to assess migration. The migrated cells were fixed and stained with crystal 
violet after 24 h for MCF-7 or 6 h for MDA-MB-23. Further protocol details mentioned in 
section (2.9). 
4.4.6.  Statistical analysis  
The whole experiments were repeated in triplicate, and also each experiment was repeated 
three times. Using GraphPad Prism 8.0.1 software for windows (La Jolla, CA, USA), to 





4.5  Results 
4.5.1  Effects of 27OHC on cell proliferation 
In the previous chapter, we found that LDL promoted migration and invasion of breast 
cancer cells and that this was inhibited when CYP27A1 was silenced, suggesting that 
dietary cholesterol requires the conversion of cholesterol to 27OHC via CYP27A1 to exert 
its effects. To investigate this further, we examined the effect of exogenous 27OHC on 
proliferation, migration, and invasion.  We found that at 24hrs, the proliferation of ERα-
positive MCF-7 cells was greatest at 1μM 27OHC in comparison to control (Fig. 4.1A), 
whereas at 48hrs, peak growth in response to 27OHC occurred at 0.1μM (p < 0.001) in 
comparison to the control (Fig. 4.1B).  
Results from the MCF-7 cells indicated that the ideal incubation time for dosing with 
27OHC in ERα-positive cell lines was 48 hours. To confirm the results obtained using the 
CV assay, the effects of 27OHC on MCF-7 cell proliferation was also performed by MUSE 
counting assay at the same doses over 48hrs. A similar pattern of growth was observed 
with a peak in cell proliferation found at 0.1μM (p < 0.001) in comparison to control (Fig. 
4.1C). To confirm the results, we used another ERα-positive cell lines T47D cell and the 
same pattern was observed with a peak cell growth in response to 27OHC at 0.1μM 





Figure 4. 1: Assessment of proliferation in MCF-7 cells using a crystal violet assay 
(CV) and MUSE cell counting following 27OHC treatment: 
  The CV assay was performed to assess the proliferation of A) MCF-7 treated with 
increasing concentration of 27OHC (0- 1μM) for up to A) 24 and B) 48 hours. Absorbance 
values reflect the number of viable cells that have absorbed the CV dye. Muse cell counting 
was employed to confirm the CV assay results shown in C. C) Number of MCF-7 cells after 
being dosed with increasing concentrations of 27OHC (0- 1μM) for up to 48 hours. Data 
representative of mean ±SEM (n=3). P-values were determined by using GraphPad Prism 
one-way Statistical analysis: ANOVA test followed by least significant difference (LSD) 












































































Figure 4. 2: Assessment of proliferation in T47D cells using a crystal violet assay (CV) 
following 27OHC treatment 
 The CV assay was performed to assess the proliferation of T47D treated with different 
concentration of 27OHC (0-1μM for 48 hours, was assessed using a CV assay. Absorbance 
values reflect the number of viable cells that have absorbed the CV dye. Data 
representative of mean ±SEM (n=3). P-value were determined by using GraphPad Prism 
one-way Statistical analysis: ANOVA test followed by least significant difference (LSD) 
post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001).  
With the ERα-negative cell lines, figures 4.3A and B respectively, no significant changes 
in cell proliferation in response to 27OHC in either MDA-MB-231(Fig. 4.3A) or Hs578T 
(Fig. 4.3B) cells, were observed in comparison to control.  




























Figure 4. 3: Assessment of proliferation in MDA-MB-231 cells using a crystal violet 
assay (CV) following treatment with 27OHC 
A) Cell proliferation of MDA-MB-231 and B) Hs578T treated with different concentration 
of 27OHC (0-1μM for 48 hours and assessed using a CV assay. Absorbance values reflect 
the number of viable cells that have absorbed the CV dye. Muse cell counting was employed 
to confirm the CV assay results.  Data representative of mean ±SEM (n=3). P-value were 
determined by using GraphPad Prism one-way Statistical analysis: ANOVA test followed 
by least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001).  
4.5.2  Effects of 27-hydroxycholesterol on cell migration, invasion, and the abundance 
of EMT markers   
Migration and invasion were significantly increased by 27OHC (0.1μM) in both the ERα-
positive, MCF-7, (p < 0.001 for both) (Fig. 4.4 A+C) and ERα-negative, MDA-MB-231 
cells (Fig. 4.4B and D) (p < 0.001for both). 
















































Cells were dosed with different concentration of 27OHC (0.1μM) for 48 hours, a trans-
well assay was used to detect cell migration and invasion. The migrated/ invaded cells 
were stained with CV for A) MCF-7 after 24hours and B) MDA-MB-231 after 6 hours, and 
invaded cell for C) MCF-7 and D) MDA-MB-231 and images were taken (×20 
magnification).  Quantitative analysis of stained migrated/invaded cells were assessed by 
using a microplate reading at an OD at 595 nm. Data representative of mean ±SEM (n=3). 
P-values were determined by using GraphPad Prism one-way Statistical analysis: ANOVA 
test followed by least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, 
***p < 0.001).  
 
Figure 4. 4: Assessment of migration and invasion in MCF-7 and MDA-MB-231 cells 
using a trans-well migration/invasion assay following treatment with 27OHC  
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The effects of LDL, on migration and invasion were assessed in chapter 3 and in this 
chapter, we examined the effects of 27OHC and LDL on the abundance of EMT markers 
in both ERα-positive and ERα-negative breast cancer cell lines. After treatment with 
27OHC and LDL for 48hrs in MCF-7 cells, we found a significant increase in fibronectin 
(p < 0.001 for both) and a decrease in E-cadherin (p < 0.001 for both) (Fig. 4.5A), while in 
MDA-MB-231 cells, we found a significant increase in both fibronectin (p < 0.001 for 




Figure 4. 5: Abundance of EMT markers in MCF-7 and MDA-MB-231 cells using 
western blotting following 27OHC and LDL treatment. 
Western blotting was conducted to show protein abundance of EMT markers fibronectin 
and E-cadherin in A) MCF-7 and fibronectin and vimentin in B) MDA-MB-231 with or 
without 27OHC (0.1μM) and LDL (80μg/ml) treatment for 48 hours. C&D) Densitometry 
analysis of fold changes of fibronectin, E-cadherin, and vimentin expression relative to B-
actin normalized to control. Data representative of mean ±SEM (n=3).  P-value were 
determined by using GraphPad Prism one-way Statistical analysis: ANOVA test followed 
by least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001). 
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4.5.3.  Effects of 27-hydroxycholesterol on cell proliferation in the presence or 
absence of the ERα  
To address the potential interactions of 27OHC with the estrogen receptor, we investigated 
the effect of 27OHC in the presence or absence of the ER. As previously established in our 
laboratory, the optimum concentration of siRNA for silencing the ERα is 20nM for 48 
hours in ERα-positive cells (Zielinska et al., 2018). Figure 4.6A shows that 27OHC 
treatment increased MCF-7 proliferation (p < 0.001) in comparison to control, whereas 
with knockdown of ERα, 27OHC was unable to increase cell growth in comparison to 
control. Effective silencing of the ERα was shown by Western blotting (Fig. 4.6B & C). 
27OHC treatment increased the abundance of ERα significantly as shown in figure 4.6B 
and C. These data suggest that 27OHC interacts with the ERα to promote breast cancer cell 





Figure 4. 6: Effects of 27OHC on proliferation of MCF-7 cells in the presence or 
absence of the ERα. 
Muse cell counting was employed to assess the cell number of A) MCF-7 after being 
transfected with ERα siRNA (20nM) and non-silencing RNA (20nM) and dosed with 
27OHC (0.1μM) for 48 hours. B) Western blot analysis of the ERα. C) Densitometry 
analysis of fold changes of ERα levels relative to B-Actin normalized to control. Data 
representative of mean ±SEM (n=3). P-values were determined using GraphPad Prism 
one-way Statistical analysis: ANOVA test followed by least significant difference (LSD) 




















































NS siRNA ER-α siRNA




























































NS siRNA ER-α siRNA
✱✱✱
ns














NS siRNA ER-α siRNA














NS siRNA ER-α siRNA






























NS siRNA ER-α siRNA































NS siRNA ER-α siRNA



































































NS siRNA ER-α siRNA




























































NS siRNA ER-α siRNA
✱✱✱
ns














NS siRNA ER-α siRNA














NS siRNA ER-α siRNA




























NS siRNA ER-α siRNA






























NS siRNA ER-α siRNA



































NS siRNA ER-α siRNA
✱✱✱
ns
27OHC - + +-
 
136 
4.5.4.   Effects of 27-hydroxycholesterol on cell migration in the presence or absence 
of the ERα 
We silenced the ERα using siRNA in MCF-7 cells treated with 27OHC and then assessed 
changes in migration and invasion. The ability of 27OHC to increase cell migration and 
invasion was unaffected with the ERα silenced (Fig. 4.7A and B), suggesting that 27OHC-
induced migration and invasion of MCF-7 cells was not mediated via the ERα. Effective 





Figure 4. 7: Effects of 27OHC on migration and invasion of MCF-7 cells in the 
presence or absence of the ERα. 
Trans-well assay was used to detect cell migration for A) MCF-7 after 24 hours and B) 
invasion after24 hours after being transfected with ERα siRNA and dosed with 27OHC 
0.1μM. The migrated cell was stained with crystal violet and images were taken (×20 
magnification). Quantitative analysis of stained migrated/invaded cells using a microplate 
reading at an OD at 595 nm. C) Western blotting analysis of ERα knockdown and 
overexpression. C) Densitometry analysis of fold changes of ERα expression relative to B-
actin normalized to control. Data representative of mean ±SEM (n=3).  P-value were 
determined by using GraphPad Prism one-way Statistical analysis: ANOVA test followed 
by least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001). 
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4.5.5.  Role of other nuclear receptors in mediating the effects of 27OHC on cell 
migration and invasion 
In MCF-7 cells, we showed that the ERα only mediated the effects of 27OHC on cell 
proliferation but not its impact on cell migration and invasion. To try to determine which 
receptor might be involved, we knocked down the ERα using siRNA in ERα-positive cells 
and assessed the abundance of alternative receptors to which 27OHC can bind: LXR-β, 
ERβ and the LDL-R.  
Our preliminary data suggested that silencing ERα only increased the abundance of ERβ 
in ERα-positive cell lines, in comparison to LDL-R and LXRβ expression (Fig. 4.8 A).  
This suggested that perhaps the LDL-R and LXR- were not involved, but that ERβ may 





Figure 4. 8: Expression of nuclear receptors in MCF-7 cells in the presence or absence 
of the ERα using western blotting following 27OHC treatment. 
A) Western blotting analysis was performed to assess changes in the protein levels of ERα, 
LXR-β, ERβ and LDL-R. ;B) Densitometry analysis of fold changes of ERα, LXR-β, ERβ 
and LDLR expression relative to β-actin and GAPDH normalized to control. Data 
representative of mean ±SEM (n=3). P-value were determined by using GraphPad Prism 
one-way Statistical analysis: ANOVA test followed by least significant difference (LSD) 
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4.6   Discussion  
Estrogen is recognised as the main ligand of the ER that promotes ERα-positive breast 
tumour growth (Huang, Warner and Gustafsson, 2015a). Estrogen binds and activates the 
ER (encoded by ESR1) that then translocate to the nucleus, to regulate the expression of 
genes that are linked with cell proliferation and survival (Lipovka and Konhilas, 2016).   
Cholesterol and its metabolites are known risk factors for breast cancer progression 
(Mcdonnell et al., 2014) and it has been observed previously that 27OHC behaves as a 
selective estrogen receptor modulator (He and Nelson, 2017). Several studies indicate the 
role of cholesterol metabolites in enhancing tumour growth and invasion (DuSell et al., 
2008; Wu et al., 2013; Nguyen et al., 2015; He and Nelson, 2017). We show that 27OHC 
can promote cell growth in ERα -positive cell lines, but not in ERα-negative cell lines. This 
proliferative effect of 27OHC was mediated via the ERα.  
The proliferative effects of 27OHC on breast cancer is well established in the MCF-7 cell 
line (DuSell et al., 2008), in mice (Nelson et al., 2013a; Baek and Nelson, 2016) and in 
human breast tumour tissue (Shahoei and Nelson, 2019). Also, a recent report has proposed 
that 27OHC promotes MDM2-mediated p53 (tumour suppressor protein p53) inactivation 
through ERs which subsequently results in cell proliferation (Raza et al., 2015). 
Furthermore, 27OHC was found to have no effect on the proliferation of ER-negative 
breast cancer cells, SKBR3 and MDA-MB-231 (Cruz et al., 2010). The same observations 
were found for endometrial cancer cell lines with an effect on the proliferation of RL95 
and Ishikawa cells but not on low or poorly ERα -positive cell lines, MFE280 cells, 
agreeing with stated ER expression in these cell lines (Gibson et al., 2018). This evidence 
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is consistent with our findings suggesting that 27OHC only exerts a proliferative effect in 
ERα-positive breast cancer cell lines.  
Furthermore, we found that silencing the ERα blocked the proliferative effect of 27OHC, 
in-line with the evidence suggesting a role for cholesterol metabolites in promoting the 
growth of ERα-positive breast cancers through acting as endogenous SERMS (DuSell et 
al., 2008; He and Nelson, 2017; Starkey et al., 2018).  
Levels of 27OHC correlate with high grade breast cancers  (Nelson et al., 2013b) and have 
been shown to have metastatic actions (Baek and Nelson, 2016). Here, we show that 
27OHC promotes breast cancer cell migration, invasion and modulates EMT markers in 
both ERα-positive and -negative cell lines. 27OHC had previously been shown to interact 
with ERs and LXRs to induce migration and invasion of breast cancer cell (Shen et al., 
2017). This effect might be due to the metastatic actions of 27OHC reported to be mediated 
through the activation of STAT-3 by increasing matrix metalloproteinase 9 (MMP9) and 
generating EMT in ERα-positive (MCF-7 and T47D) and -negative cell lines (MDA-MB-
231) (Shen et al., 2017). These studies are consistent with our finding suggesting that 
27OHC induces migration/invasion and EMT in both ER-positive and ER-negative breast 
cancer cell lines.  
The phosphorylation of ERα in MCF-7 cells has been suggested to induce cell migration 
and invasion, suggesting the effect of 27OHC on cell migration and invasion may be 
mediated through ERα in MCF-7 (Huderson et al., 2012). However, we found that the ERα 
does not mediate the migration and invasion induced by 27OHC in ERα-positive breast 
cancer cells. However, there are several other nuclear receptors that may play a crucial role 
in oxysterol actions, such as, LXRs, ERs and the LDLR. 27OHC acts as a SERM and 
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oxysterols have been shown to indirectly modulate ERs through interaction with the 
nuclear receptor LXR-β  (Ishikawa et al., 2013)(Gallagher et al., 2017a). We elucidated 
that the proliferative effects of 27OHC involved the ERα.  
Caveolae have a specific requirement for free cholesterol which intercalates with caveolin-
1(CAV-1). It has been demonstrated that cerivastatin down-regulated cyclin D1 and 
decreased the cell growth in ERα-positive breast cancer cells; MCF-7, and this 
antiproliferative effects may be mediated through a reduction of caveolin-1 expression 
(Salis et al., 2014). This work further highlights the roles statin plays in ERα-positive breast 
cancer cells and can lead us to more promising therapeutics targeting cholesterol 





 4.7.  Conclusion  
27-hydroxycholesterol plays a role in breast cancer progression. In this study, we found 
that 27OHC induced proliferation in the ERα-positive tumour cells, but not in ERα 
negative cell lines. Furthermore, 27OHC induced migration and invasion, in both ERα 
positive and negative cell lines. Our data indicates that whilst the proliferative effects of 
27OHC were dependent on the presence of the ERα, its actions on migration and invasion 








The involvement of the ERβ in the role of 27OHC 
on breast cancer cell migration/invasion and its 




5.1   Introduction  
The estrogen receptors (ERs), ERα and ERβ play a crucial role in hormone-dependent 
breast cancer development and metastasis, by mediating the effects of estrogen(Osborne et 
al., 2001). ERs can also be regulated independently of estrogen, such as via activation of 
growth factor receptors (McDonnell and Norris, 2002). ERα expression was found to be 
10% in normal breast epithelial cells and 50–80% in breast tumors (Huang, Warner and 
Gustafsson, 2015b).  
While ERα is well recognized for contributing to breast cancer growth and development, 
the role of ERβ is less understood. In 1996, ERβ was discovered, and its function in breast 
cancer is still being elucidated (Haldosén, Zhao and Dahlman-Wright, 2014b). The 
activation of ERβ can form heterodimers and/or homodimers with the ERα (Paech et al., 
1997), thus modulating the activity of ERα. It has been demonstrated that the relative 
expression levels of ERβ and ERα are likely to influence cell growth and the activities of 
different signalling cascades in breast cancer cells (Chang et al., 2006). The dysregulation 
of ER signalling is linked with progression and initiation of several cancers, such as breast 
cancer as it affects a number of different molecules, such as cyclin D1, insulin-like growth 
factor-1 receptor (IGF-IR), vascular endothelial growth factor (VEGF) and anti-apoptotic 
BCL-2 protein, that impact on cell proliferation, survival and growth (Umetani, 2016).   
ERβ has five different isoforms, therefore these multiple isoforms complicate the 
investigation of the biological role of ERβ and its participation in the carcinogenesis of 
breast tumours (Girgert, Emons and Gründker, 2019). The five isoforms of ERβ (β1, β2, 
β3, β4, and β5), do not all bind to estrogen (Honma et al., 2008; Zhang et al., 2012). 
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Early studies proposed that ERβ is a risk factor linked with breast cancer (Haldosén, Zhao 
and Dahlman-Wright, 2014b). Furthermore, the estrogen receptor ERβ is found in 44.4% 
of TNBC (Matthews and Gustafsson, 2003).  A recent studies indicate elevated levels of 
ERβ targets genes that regulate cell survival/death, cell movement, growth and cell 
development, along with genes linked with the Wnt/β-catenin and G1/S cell cycle phase 
checkpoint pathways (Shanle et al., 2013; Hamilton et al., 2015).  
In recent years, 27OHC, an oxysterol has been identified as an agonist of ERα and an 
antagonist of ERβ (Herynk and Fuqua, 2007). The content of 27OHC in ERα-positive 
breast cancer cells is 2.5-3-fold higher than in normal breast cells (Wu et al., 2013). 27OHC 
may modify cancer risk in different ways, such as modulation of signalling (e.g., Wnt, 
Hedgehog) and inflammatory pathways (Kloudova, Guengerich and Soucek, 2017). The 
proliferative role of 27OHC has been confirmed in human cancer cells (Nelson et al., 
2013a) and in human breast cancer tissue, 27OHC concentrations and the levels of the 
enzyme, CYP27A1 were increased in higher grade tumours (Baek et al., 2017).  
Emerging studies illustrates that metabolic factors, for instance insulin-like growth factor 
(IGF-I and IGF-II) signalling pathways promote the development of breast cancer (Belardi 
et al., 2013; Sturtz et al., 2014). ER signalling pathways are known to intersect with IGF 
signalling cascades, with estrogen increasing breast cancer production of IGF-II (Westley 
and May, 1994). Aberrant EGF and IGF signalling is detected in TNBC tumours and is 
linked to higher rates of recurrence, poor response to therapy and reduced overall survival. 
Experimental and clinical evidence implicates the EGF and IGF systems in the progression 
of breast cancer (Samani et al., 2007; Voudouri Kallirroi et al., 2015; Christopoulos, 
Corthay and Koutsilieris, 2018b).   
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5.2   Aims  
In this chapter, we aimed to investigate the involvement of the ERβ in the effects of 27OHC 
on breast cancer cell migration/invasion, and its regulation of IGF and EGF receptors.  
 
 5.3   Specific aims  
Aim 1: To optimise shRNA-mediated knockdown of ERβ in MDA-MB-231 TNBC cells. 
Aim 2: To assess the role of the ERβ in the effects of 27OHC on cell migration and 
invasion. 
Aim 3: To establish a role for the ERβ in the regulation of IGF-I and EGF receptors and 





5.4.   Methods 
5.4.1.   Cell culture:  
The human breast cancer cell lines MCF7 and MDA-MB-231 were obtained from ATCC 
(Teddington, Middlesex, UK). All cell lines were cultured as described previously in 
section 2.1.1. 
5.4.2.   Western blot  
Western blot analysis was observed as described previously (2.10). In brief, protein cell 
lysates (30μg), were allocated in SDS-PAGE gel, transferred to nitrocellulose membrane 
and immunoblotted with the targeted antibodies: anti-ERβ (1:1000) (PPZ0506: Thermo 
Fisher; 14C8: Abcam, and 05-824; Merck Millipore), IGF-I Receptor β (1:1000; Cell 
Signalling), EGF Receptor (1:1000; Cell Signalling), GAPDH (1:5,000; Millipore) and β-
actin (1:10,000; Sigma-Aldrich). After that the membranes were incubated with particular 
secondary antibodies (anti Mouse or Rabbit) conjugated to peroxidase, next proteins were 
detected by Clarity ECL substrate and quantified using Image software 
5.4.3.   Optimizing an ERβ antibody  
Antibody validation is critical to generate accurate valid data as demonstrated in a recently 
published report where previous studies on ERβ were disputed (Andersson et al., 2017). 
ERβ antibodies for Western blotting were first validated by screening 3 antibodies, 
including the most commonly used ones (14C8; Abcam, PPZ0506; Thermo Fisher and 05-
824; Merck Millipore). Western blotting was used to assess the protein abundance of ERβ 
in different breast cancer cell lines. The PPZ0506 ERβ antibody displayed a single band of 
the expected size (the molecular weight; 59 kDa) in lysates from a panel of breast cancer 
cell lines (Fig. 5.3A), however the Merck Millipore ERβ antibody displayed a single band 
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below the expected size (57 kDa) (Fig. 5.3B). Using the Abcam ERβ antibody, multiple 
bands including a weak band at the correct size were seen (Fig. 5.1C). ERβ protein levels 
seemed to be higher in the normal like breast cancer cell line (MCF10A) and ERα-negative 
(MDA-MB-231) compared with ERα+ve (MCF-7 and T47D), as shown in (Fig. 5.1 A). 
We concluded that ERβ (PPZ0506; Thermo Fisher), is the most appropriate antibody to 
use for all further experiments. 
 
Figure 5.  1: ERβ antibody assessment using a panel of breast cancer cell lines:  
Representative images of western blotting: A) ERβ (PPZ0506; Thermo Fisher), B) 05-824; 
Merck Millipore, and C) 14C8; Abcam antibody in normal breast epithelial cell line, MCF-
10A, and 4 cancerous cell lines – ERα-positive (MCF-7 & T47D) and ERα-negative (MDA-
MB-231 and Hs578T). GAPDH was used as loading control protein. Data representative 
of (n=3). 
5.4.4.   RNA extraction and RNA-cDNA reverse transcription  
Trizol reagent (Invitrogen) was used to extract RNA as outlined in section (2.11.1).  
5.4.5.   Quantitative Polymerase Chain Reaction (qPCR)  
Quantitation of expression of ERβ mRNA was performed using SYBR green- based qPCR.  























    
    
    
    





















    
    
    
    




















    
    
    
    























      
      
      






























      
      
      





assessed using the 2−ΔCt method after normalization to the GAPDH reference gene as 
described previously in section (2.11.4) 
5.4.6.   Dosing with exogenous 27OHC, LDL and ERβ-agonist and antagonist:  
For proliferation assays, cells were incubated in growth media DMEM for 24 hours, before 
being changed to serum-free media for a further 24 hours. The cells were then treated with 
different concentrations of LDL and 27OHC and as described in chapter 3 and 4 
respectively. To investigate the optimum concentration of a selective ERβ antagonist, 4-
[2-phenyl-5,7- bis(trifluoromethyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenol (PHTPP), 
MDA-MB-231 and MCF-7 cells were treated with different concentrations ranging from 
0-5μM. Effective treatment of PHTPP was shown by a reduction in levels of ERβ protein 
by Western blotting. As shown in Figure 5.2A the levels of ERβ decreased gradually with 
increasing concentration of PHTPP compared with control in MCF-7 cells, with levels 





Cells were treated with increasing doses of a selective ERβ antagonist (PHTPP)(0-5μM). 
Western blotting was used to detect the abundance of ERβ with or without PHTPP in A) 
MCF-7 and B) MDA-MB-231. B-actin was used as loading control. Data representative 
of (n=1). 
To further investigate the role of ERβ, we activated ERβ in MDA-MB-231 cells using 
Erteberel (LY500307) that has selective binding affinity for ERβ. We treated MDA-MB-
231 cells with different concentrations of Erteberel ranging from 0-10μM for 24 hours. 
Effective concentrations of the ERβ were assessed by qPCR (Fig. 5.3). The expression of 
ERβ increased in comparison to control with a peak response observed at 2.5μM in MCF-




Figure 5.  2: The optimum concentration of ERβ antagonists in MCF-7 and 




Figure 5.  3: Assessment of ERβ mRNA expression using quantitative polymerase 
chain reaction (qPCR): 
 Cells were treated with different concentration of a selective ERβ agonist (0-10μM) for 24 
hours. The mRNA level of ERβ was quantified using qPCR in A) MCF-7 and B) MDA-MB-
231. Data representative of (n=1). 
5.4.7.   Cell proliferation  
This was determined using a CV proliferation assay (Feoktistova, Geserick and Leverkus, 
2016b), as described in section 2.6.  
5.4.8.   Targeted ERβ gene knockdown: 
5.4.8.1.   siRNA knockdown  
For experiments investigating the effect of 27OHC on the cell migration of MDA-MB-231 
cells in presence or absence of ERβ, the optimum concentration of siRNA for silencing the 
Erβ (Dharmacon) or non-silencing (NS) (AllStars) was investigated. MDA-MB-231 cells 
were transfected with different concentration of siRNA ranging from 0-60nM or non-
silencing (NS) (AllStars). Effective silencing of the ERβ was shown by Western blotting 
(Fig. 5.4 A) and qPCR (Fig. 5.4 B). Figure 5.4 A and B show effective silencing of ERβ at 





Figure 5.  4: Optimizing ERβ siRNA in MDA-MB-231 cell line: 
 MDA-MB-231 after being transfected with ERβ siRNA (20,40 and 60nM) and non-
silencing RNA.  A) Representative images of western blotting assess the protein abundance 
of ERβ expression. B-actin was used as loading control protein. B) mRNA expression of 
ERβ and melt curve of ERβ. GAPDH was used as a house keeping gene.  Data 



































5.4.8.1.   Development of stable knockdown of ERβ using shRNA in MDA-MB-
231 cell line: 
Transduction with lentiviral vectors is a highly efficient method to modulate expression of 
target genes (Blömer et al., 1997).  
To further understand the role of ERβ (ESR2) in TNBC, a stable transfection model for 
knockdown of ERβ was developed for further work. To perform the stable knock down, 
different concentrations of puromycin dihydrochloride, which kills cells that do not express 
resistance genes, ranging from 0.125–1 µg/mL were used for 7 days. The kill curve shows 
the optimal working concentration to be 0.8 µg/mL, which is the lowest puromycin 
concentration at which all available cells are dead after 7 days of puromycin selection (Fig. 




Cells were treated with increasing concentrations of puromycin (0.8, 0.4,0.60.8 & 1μg/ml) 
for168hrs. A) Representative images of MDA-MB-231 cells treated with puromycin after 
24hrs and 168hrs time points. B) Cell viability using Trypan blue staining, shows the 
puromycin kill curve from 0hrs-168hrs. Data representative of (n=1). 
Following several cell passages after transfection with two different amounts (shRNA1and 
shRNA2; 10 and 15µl/well respectively following the manufacture instruction) of ,1x 106 
infectious units of virus (IFU), shRNA against ERβ: shRNA target-specific human ERβ or 
non-targeting shRNA control, as described in section 2.8, a gradual decrease in ERβ 
expression was observed. The transfected cells with ERβ shRNA were followed by a final 
reduction in the ERβ protein expression at the level of 80.09% (p < 0.01) for and ERβ 
shRNA2, in comparison with the control shRNA2, lentiviral particles, transfected cells and 
empty control. Stable transfection of ERβ shRNA2 resulted in a 65.20% decrease of ERβ 
 































MDA-MB-231 Dosed with Puromycin 
dihyrochloride 







gene expression in comparison with the control shRNA (Fig. 5.6 A-B). This suppression 
was examined after four cell passages and remained constant in following cell passages. 
Cells were stably transfected with two different concentrations (shRNA1;5µl/well and 
shRNA2;15µl/well) of shRNA against ERβ or control lentiviral particles or negative 
control (empty). A) Western blotting was used to detect the abundance of ERβ with or 
without ERβ knockdown with two different concentration of ERβ shRNA (1&2) after the 
first and fourth passages. B) Densitometry quantification of ERβ was assessed after 
normalization to GAPDH. C) mRNA expression of ERβ, GAPDH was used as a house 
keeping gene. Data representative of mean ±SEM (n=3) except C) (N=1).  P-value were 
determined by using GraphPad Prism: one-way Statistical analysis: one-way ANOVA test 
flowed by Tukey’s post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
 
Figure 5.  6: ERβ Knockdown in MDA-MB-231 breast cancer cells: 




















































































5.4.9.  Transwell migration assay  
Cells were prepared to migrate into the chemoattractant serum in the lower compartment 
as described in section 2.9, for 24 h (MCF-7) or 6 h (MDA-MB-231) with or without the 
addition of 27OHC (0.1µM) or ERβ siRNA/shRNA. 
5.4.10.   Statistical analysis  
The whole experiments were repeated in triplicate, and also each experiment was repeated 
three times. Using GraphPad Prism 8.0.1 software for windows (La Jolla, CA, USA), to 





 5.5.   Results 
5.5.1. Is the effect of 27-hydroxycholesterol on the migration and invasion of MDA-
MB-231 breast cancer cells mediated by ERβ? 
ERβ protein levels were higher in the normal-like breast cancer cell line (MCF10A) and 
ERα-negative (MDA-MB-231) cells compared with ERα-positive (MCF-7 and T47D) 
cells, as shown in the methods (Fig. 5.1A).  
To assess whether the ERβ played a role in the actions of 27OHC on breast cancer cell 
migration and invasion, MDA-MB-231 cells were selected as these possess abundant ERβ 
but lack ERα as shown in figure 5.7.  To understand the role of ERβ, we inhibited ERβ in 
MDA-MB-231, using three different strategies (siRNA, shRNA or an ERβ inhibitor, 
PHTPP). 
 
Figure 5.  7: ERα antibody assessment using a panel of breast cancer cell lines:  
Representative images of western blotting: A) ERα antibody in 4 cancerous cell lines – 
ERα-positive (MCF-7 & T47D) and ERα-negative (MDA-MB-231 and Hs578T). and B) 
ERb antibody in 4 cancerous cell lines – ERα-positive (MCF-7 & T47D), ERα-negative 
(MDA-MB-231 and Hs578T) and a normal epithelial breast cell line (MCF10A). GAPDH 
was used as loading control protein. Data representative of (n=1). 
The results showed that 27OHC (0.1μM) increased cell migration (p <0.001) and invasion 
(p <0.001) and these effects were blocked with ERβ silenced using siRNA (Fig.5.8A, B & 















PHTPP: where 27OHC was similarly unable to increase migration in the presence of 
PHTPP (Fig. 5.8 D). Interestingly, using the publicly available METABRIC gene 
expression database, it was observed that the breast cancer patients who had high mRNA 
levels of CYP27A1 (and thus expected elevated 27OHC) also had increased expression of 
ERβ mRNA levels (p<0.001) when compared to normal breast tissue (Fig.5.8E). 






Figure 5.  8a: 27OHC increases cell migration/invasion in ERα-negative breast cancer 
cells via ERβ: 
 A trans-well assay was used to detect A) migration and B) invasion after 6 hours for MDA-
MB-231 after being transfected with ERβ siRNA (40nM) and non-silencing RNA (40nM) 
and dosed with 27OHC (0.1μM). C) Western blotting was used to detect the abundance 
of ERβ with or without ERβ silencing. Densitometry quantification of the ERβ was assessed 
after normalization to β- actin. D) Quantification of cell migration after being dosed with 
27OHC (0.1μM) and PHTPP (5μM). The migrated and invaded cells were stained with 
crystal violet and images were taken (×20 magnification). Results are presented as mean 
+/− SEM (n=3) (A-D). P-value were determined by using GraphPad Prism: one-way 
ANOVA followed by least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, 
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Figure 5.  9b: 27OHC increases cell migration/invasion in ERα-negative breast cancer 
cells via ERβ: 
E) Scatterplot analysis of TCGA data of 504 invasive breast cancer carcinomas for mRNA 
expression of ERβ expressed as median expression of CYP27A1, where the horizontal line 
presents the mean. P-value was determined using GraphPad Prism: Mann–Whitney test.  
We confirmed these observations using an shRNA mediated ERβ knockdown in the MDA-
MB-231 cells. 27OHC was similarly unable to increase migration in the absence of ERβ 
(Fig. 5.9A). Knockdown of ERβ using shRNA constructs was confirmed by Western blot 




Figure 5.  10: 27OHC increases cell migration in ERα-negative breast cancer cells via 
ERβ: 
 MDA-MB-231 cell were stably transfected with shRNA for knockdown (ERβ) or control 
shRNA particles and dosed with 27OHC (0.1μM) for 48hrs. A)  A trans-well assay was 
used to detect migration after 6 hours. The migrated and invaded cells was stained with 
crystal violet and images were taken (×20 magnification). B) Western blotting was used to 
detect the abundance of ERβ with or without ERβ silencing. B-actin was used as loading 


























5.5.2.  The role of ERβ in the regulation of IGF-I and EGF receptors and associated 
signalling molecules. 
Based on the wealth of pre-clinical data suggesting a role for the EGF and IGF signaling 
pathways that are linked to ER signalling in breast cancer, we further investigated the role 
of ERβ in the regulation of IGF-I and EGF receptors. The activation of ERβ significantly 
increased the abundance of the IGF-I and EGF receptors (Fig. 5.10). As shown in figure 
5.10A and B, treatment with a synthetic ERβ agonist gradually increased levels of the IGF-
I receptor level from 1µM in comparison to control with a peak response observed at 
2.5µM; the percentage increases were respectively; (1µM 20.5%; ns), (2.5µM 120.7%; 
p < 0.01) in MCF7. A similar result was seen in MDA-MB-231 cells with a peak increase 
in IGF-I receptor level observed at 2.5µM (p < 0.001), and EGF receptor level observed at 
2.5µM (p < 0.05) (Fig. 5. 10C & D).  
Conversely, with all approaches of ERβ inhibition, we observed a loss of the IGF-I and 
EGF receptors (Fig.  5.10). With MCF-7 cells, we found that an ERβ inhibitor, PHTPP, 
significantly decreased the level of IGF-I receptor abundance with both concentrations at 
5 and 10 µM (p < 0.001 and p < 0.001 respectively) (Fig. 5. 10A&B). We also found the 
same results with MDA-MB-231 cells, with a reduction in the IGF-I receptor levels 
observed at 5 and 10µM (p < 0.01 and p < 0.01 respectively), and with EGF receptor levels 
observed at 10mM (p < 0.001) (Fig. 5. 10E & F). Further, the ERβ inhibitor, PHTPP also 
caused an inhibition in cell proliferation in MDA-MB-231 cells; from 2µM in comparison 
to control with a further decline in response observed at 10µM; the percentage decreases 
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were (2mM 12.7%; p < 0.001), (5mM 22.0%; p < 0.001) and (10mM 29.73%; p < 0.001) 
in MDA-MB-231 cells (Fig. 5.11A). Interestingly, using the publicly available 
METABRIC gene expression database, we found that tumours that had high mRNA levels 
of ERβ also had increased expression of the IGF-IR and EGFR and Ki-67, as a marker of 
proliferating cells (p <0.001, p <0.001 and p <0.01 respectively) (Fig. 5.11 B-D 
respectively). Conversely low tumour expression of ERβ was associated with lower 




Figure 5.  11: Effects of selective ERβ agonist and antagonist treatment on IGF-IR 
and EGFR levels in MCF-7 and MDA-MB-231:  
(A-C) MCF-7 and (D-F) MDA-MB-231 treated with ERβ agonist for 24hrs and antagonist 
for 48hrs and were immunoblotted with IGF-IR (A-F) and (D-G) EGFR antibody. GAPDH 
worked as loading control. (C, E&G) Quantitative densitometry analysis. (H) MDA-MB-
231 cells were treated with increasing doses of a selective ERβ antagonist for 48hrs and 
cell proliferation was assessed using a crystal violet assay. (I-K) Scatterplot analysis of 
TCGA data of 504 invasive breast cancer carcinomas for mRNA expression of IGF-I, 
EGFR and Ki67 represented as median expression of ERβ. Results are presented as mean 
+/− SEM (n=3) (A-D), P-value were determined by using GraphPad Prism: one-way 
Statistical analysis: one-way ANOVA test followed by least significant difference (LSD) 


















































































































































































































































































Figure 5.  11: The role of ERβ in the regulation of IGF-I, EGF receptors, Ki67 and 
cell proliferation.:  
(A) MDA-MB-231 cells were treated with increasing doses of a selective ERβ antagonist 
for 48hrs and cell proliferation was assessed using a crystal violet assay. (B-D) Scatterplot 
analysis of TCGA data of 504 invasive breast cancer carcinomas for mRNA expression of 
IGF-I, EGFR and Ki67 represented as median expression of ERβ. Results are presented 
as mean +/− SEM (n=3) (A), P-value were determined by using GraphPad Prism: one-
way Statistical analysis: one-way ANOVA test followed by least significant difference 







































































































































































































































































We also observed a loss of the IGF-I receptor with ERβ siRNA in MCF-7 (Fig. 5.11A), the 
IGF-I and EGF receptors with ERβ siRNA and shRNA in MDA-MB-231 (Fig. 5.11B &C 
respectively).  
 MCF-7 (A) and MDA-MB-231 (B) after being transfected with ERβ siRNA and non-
silencing RNA for 48hrs, (C) MDA-MB-231 after being transfected with ERβ shRNA and 
non-silencing shRNA and were immunoblotted with IGF-IR, ERβ (A,B&C) and EGFR 




Figure 5.  12: Effects of knocking down ERβ on levels of the IGF-IR in MCF-7 




























5.5.3. The involvement of the 27OHC in regulating molecules associated with IGF 
signalling pathway,  
Caveolae have a particular requirement for free cholesterol which intercalates with 
caveolin-1 (CAV-1) (Murata et al., 1995). CAV-1 has been shown to bind to the EGFR 
and IGF-1R and mediate their signaling. In our laboratory, we showed previously that 
CAV1 is a marker of an invasive, hormone-resistant phenotype and correlates with the 
beta1 integrin in TNBC cells (Zielinska et al., 2018). As we observed that the addition of 
LDL increased the abundance of key cell surface markers including the IGF-1R, we wished 
to determine if CAV1, and beta 1, which we have shown play important roles, were also 
involved. We examined the effect of 27OHC on the abundance of CAV1 (a marker of lipid 
rafts), the β1 integrin (that associates with CAV1) and fibronectin. The addition of 27OHC 
for 48hrs significantly increased the abundance of CAV-1, fibronectin and the β1 integrin 
(p < 0.05, p < 0.05 and p<0.05 respectively) (Fig. 5.12A &B and Fig. 5.13). Figure 5.13 
shows that the 27OHC-induced increase in the abundance of the fibronectin was blocked 





Figure 5.  13: The involvement of the 27OHC in regulating key signalling molecules 
in lipid rafts:  
(A) MDA-MB-231 were treated with 27OHC for 48hrs and were immunoblotted with 
indicated antibodies. GAPDH and B-actin were used as loading controls. (B) Quantitative 
densitometry analysis; the data are expressed as mean ± SEM (n=3), and P-value were 
determined by using GraphPad Prism one-way Statistical analysis: ANOVA test followed 

















































































































































Figure 5.  14: The effect of the ERβ on fibronectin levels in the present or absence of 
27OHC:  
MDA-MB-231 after being transfected with ERβ siRNA and non-silencing RNA treated with 
27OHC for 48hrs were immunoblotted with indicated antibodies. B-actin worked as 
loading control. Quantitative densitometry analysis: the data are expressed as mean ± 
SEM (n=3), and P-value were determined by using GraphPad Prism one-way Statistical 
analysis: ANOVA test followed by least significant difference (LSD) post-hoc test 

























































































5.6.   Discussion  
In the previous chapter, 27OHC was shown to promote cell growth in ERα-positive breast 
cancer cells and increased breast cancer cell migration and invasion in both ERα and β 
positive cell lines. When silencing the ERα in MCF-7, we found that only the effect of 
27OHC on cell proliferation was inhibited and not its ability to increase cell migration and 
invasion. Our data also suggested that the only receptor increased when silencing ERα in 
ERα-positive cell lines, was ERβ. This corresponds to previous reports whereby the role 
of ERβ depends on the relative ratio of expression of ERα to ERβ. ERβ  having a protective 
effect in the presence of ERα but in the absence of ERα recent data suggest that ERβ has a 
pro-tumourigenic role (Leygue and Murphy, 2013). Approximately 30% of TNBCs 
express ERβ. It has been demonstrated that ERβ target genes can regulate cancer cell 
survival/death, movement, growth and development as well as genes associated with G1/S 
cell cycle phase checkpoint pathways and the Wnt/β-catenin and these are elevated in 
TNBC (Shanle et al., 2013; Hamilton et al., 2015). Higher expression level of ERβ in 
TNBC makes it a logical pharmacological target due to its structural similarity to ERα 
(Novelli et al., 2008b). However, there have been conflicting results from studies of the 
role of ERβ in TNBC because of the fact that TNBC is a heterogeneous disease, and this 
is not reflected in in vitro studies when using TNBC cell lines (MDA-MB-231 and 
Hs578T). Furthermore, discrepancies in the reported results may also be because of a lack 
of standardized observation strategies, such as use of antibodies that have not been 
correctly validated, inconsistent cut-offs for specifying ERβ-positive cancers when using 
immunohistochemistry, and variable tissue processing and preparation methods 
(Andersson et al., 2017). To address these inconsistencies we used a certified TNBC cell 
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line (negative for ERα. PR, and HER2 overexpression) and validated ERβ antibodies 
(Andersson et al., 2017). 
We observed that 27OHC drives the invasion and migration of MDA-MB-231 TNBC cells. 
Whilst a recent report proposed that 27OHC acted as a negative modulator of ERβ (Starkey 
et al., 2018), we found effects of 27OHC in MDA-MB-231 cells were blocked by inhibiting 
ERβ using siRNA. 27OHC has both agonistic and antagonistic effects on ERα function 
depending upon on the target organs (Umetani et al., 2014). Therefore, it is also possible 
that 27OHC may also have both agonistic and antagonistic effects on ERβ function. Our 
data showing a positive correlation between 27OHC and ERβ is consistent with the results 
from the TCGA database: we found that tumours that had high mRNA levels of CYP27A1 
(and thus expected elevated 27OHC) also had increased expression of ERβ.  
To further understand the role of ERβ we inhibited ERβ in MDA-MB-231 TNBC cells 
using three different strategies (siRNA, shRNA or an ERβ inhibitor, 4-[2-phenyl-5,7- 
bis(trifluoromethyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenol, PHTPP). With all approaches 
of ERβ inhibition, we observed a loss of the IGF-I and EGF receptors and an inhibition in 
basal cell proliferation. The phenotype that we observed has been confirmed recently by 
others (Piperigkou et al., 2016). These data indicate that ERβ is a positive regulator of the 
IGF-I and EGF receptors. A link between ERβ and IGF and EGF signalling pathways was 
also indicated by silencing ERβ in TNBC cell lines, that reduced cell proliferation, 
migration and invasion that was associated with down-regulation of the IGF-I and EGF 
receptors. Conversely up-regulating ERβ, using an agonist, increased levels of the IGF-IR 
(Richardson et al., 2011; Hamilton et al., 2015). Some studies have indicated that ERβ 
found to be a biomarker linked with a more aggressive clinical outcomes (Novelli et al., 
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2008a), and relates to Ki-67, a proliferation marker. This is consistent with the results from 
the TCGA database, in which we found that tumours that had high mRNA levels of ERβ 
also had increased expression of the IGF-IR, EGFR and Ki-67, mRNA levels.  
The addition of 27-OHC for 48hrs increased the abundance of CAV1 and the β1 integrin. 
Depleting or sequestering cholesterol from the cell membrane leads to a shift in lipid raft 
and hormonal receptors and caveolar proteins such as CAV-1 to other parts of the plasma 
membrane. In our laboratory, Zielinska  et al. have illustrated that CAV1 is a marker of an 
invasive, hormone-resistant phenotype (Zielinska et al., 2018) and that CAV-1 associates 
with the β1 integrin in TNBC cells (Burrows et al., 2006). We found that the addition of 
27OHC increased the abundance of fibronectin and this was blocked in the absence of ERβ. 
This is also in agreement with a previous study indicating that ERβ suppression decreases 
the expression of the mesenchymal markers vimentin and fibronectin and decreases MDA-
MB-231 breast cancer cells migration and invasion (Piperigkou et al., 2016).  
Based on the wealth of pre-clinical data suggesting a role for the IGF signalling pathways 
in TNBC, different strategies were developed to target these systems. Monoclonal 
antibodies and small molecules, targeting the tyrosine kinase domain of the receptors 
(TKIs) have been major approaches to disrupt IGF signalling cascades (Christopoulos, 
Corthay and Koutsilieris, 2018a) and these strategies applied as monotherapies have had 
limited clinical success. We elucidated that the phenotypic effects of 27OHC involved the 
IGF-IR and that perhaps targeting ERβ in TNBC could be a different approach for down-
regulating IGF signalling. 
Statins also impact on the pathways activated by IGF and EGF. Simvastatin has been 
shown to inhibit the development of radioresistant esophageal cancer cells by reversing the 
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process of EMT via the PTEN-PI3K/AKT signalling cascades and this action was blocked 
by the addition of IGF-I (Li et al., 2014). This work further highlights the roles statins plays 
in aggressive breast cancer and can lead us to more promising therapeutics targeting 





5.7.   Conclusion  
In summary, our data elaborates a mechanism to support the clinical studies suggesting the 
link between obesity and high cholesterol with an increased risk of breast cancer 
progression: we identified a novel mechanism whereby 27OHC promotes cell migration 
and invasion through ERβ in TNBC cells. Our data also indicate that ERβ is a positive 
regulator of the IGF-I and EGF receptors. We observed that ERβ depletion decreased 






The effects of interactions between IGFs and 





6.1.   Introduction  
Obesity is correlated with an increase in cancer-specific deaths in women with breast 
cancer with IGF signalling and levels of cholesterol implicated. Metabolic syndrome and 
obesity are correlated with increased breast cancer risk and a worse outcome due to 
increased levels of  insulin-like growth factors (IGFs) (Creighton et al., 2008, 2012).  In 
humans, prospective epidemiology has found a significant correlation between circulating 
IGF-I levels and the subsequent risk of developing several types of cancer such as 
colorectal, prostate and premenopausal breast cancers (Pollak, Schernhammer and 
Hankinson, 2004b). Several studies indicate IGF-I/IGF-II pathway in breast cancer 
progression (Belardi et al., 2013; Mancini et al., 2014). 
The IGF-IR through subsequent phosphorylation of either one insulin receptor substrate-
1/-2 (IRS-1/ -2) serves as a scaffold to modulate and activate other important pathway 
proteins as PI3K/AKT/mTOR (Mirdamadi et al., 2015) and Ras/Raf/MAPK (Trefely et al., 
2015) and this function has been well-investigated in all molecular subtypes of breast 
cancer (Law et al., 2008). A study using global gene expression data from breast cancer 
patients who used neoadjuvant anastrozole treatment reported that several genes are 
associated with poor response to  therapy such as MAPK, IGF-I and obesity (Ellis et al., 
2012). Activation of IGF-IR downstream signalling pathways promotes tumorigenesis by 
activating cell survival and proliferation and the invasiveness of cancer cells (Shukla and 
Gupta, 2007; Courtney, Corcoran and Engelman, 2010; Lee, Loh and Yap, 2015). 
Increased expression of the IGF-IR and the IR strongly associates with poor patient clinical 
outcomes across all molecular subtypes of breast cancer (Law et al., 2008). Despite these 
associations, clinical results of anti-IGF-IR monoclonal antibody trials in breast cancer 
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have been unsuccessful (Ekyalongo and Yee, 2017) as there are currently no good 
biomarkers to indicate which patients will respond. Identifying potential biomarkers of 
response may enable a more targeted and therefore more successful approach to implement 
the anti-IGF-IR therapies.  
Cancer cells utilise glucose as a source of energy(Garber, 2004), and the negative 
association of obesity and type 2 diabetes with breast tumours may be indicating an 
elevated energy supply that would enhance breast carcinogenesis. Cholesterol biosynthesis 
(intracellular) is also dysregulated in cancer cells due to increased acetyl CoA levels via 
glycolysis, fatty acid biosynthesis or HMG-CoA reductase activity (Kwan et al., 2008; 
Ahern et al., 2011), which is significantly increased or up-regulated in several cancer types 
including breast tumour, and has been correlated with a more aggressive breast cancers 
(Azrolan and Coleman, 1989).  
 The LDL-R is abundant on TNBC cells and is important in the growth of TNBCs in the 
setting of elevated circulating LDL-C (Gallagher et al., 2017b). In both in vivo and in vitro 
models, it has been reported that the addition of LDL-cholesterol (100µg/ml) increased 
proliferation and migration and reduced adhesion of breast cancer cells, compared to 
untreated conditions. While in hypercholesterolemic mice, breast tumours were larger and 
more proliferative and metastasized to the lungs (dos Santos et al., 2014).  
There is emerging evidence to indicate that crosstalk exists between cholesterol 
metabolism and IGF signalling pathways. Lipid rafts are known to contain tyrosine kinase 
receptors, such as HER2, EGFR and the IGF-IR (Laurentiis, Donovan and Arcaro, 2007) 
and their signalling effects are dependent on the cholesterol abundance of the lipid-rafts 
(Chen and Resh, 2002). Disruption of lipid raft in TNBC breast cancer cell lines, applying 
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the cholesterol sequestering agent methyl-β-cyclodextrin, MβCD, reduced cell growth and 
induced apoptosis (Badana et al., 2018). Statins are 3-hydroxy-3-methylglutharyl-
coenzyme-A reductase (HMGCR) inhibitors that inhibit the rate limiting step in the 
production of cholesterol. Statins also impact on the pathways activated by EGF and IGF 





 6.2.   Aims and objective 
In this chapter, we aimed to delineate the involvement of the IGFs/IGF-IR in the effects of 
cholesterol on breast cancer cell growth and invasion. 
 
6.3.   Specific aims  
Aim 1: To examine the effect of LDL and 27OHC on the levels of IGFs in MCF-7 (ER-
positive) and MDA-MB-231 (ER-negative) cells 
Aim 2: To address if the effects of LDL on cell proliferation and migration in both ERα- 
positive and ERα-negative breast cancer epithelial cell lines were mediated through the 
IGF-1R. 
Aim 3: To examine the effects of LDL on IGF-I-induced activation of MAPK/AKT in both 




6.4.   Methods 
6.4.1.   Cell culture:  
The human breast cancer cell lines MCF7, and MDA-MB-231 were purchased from ATCC 
(Teddington, Middlesex, UK). All cell lines were cultured as described before in section 
2.1. 
6.4.2.   Dosing with exogenous 27OHC, LDL and an IGF-IR antagonist:  
For cell proliferation assays, cells were incubated in growth media DMEM for 24 hours, 
followed by 24 hours in serum-free media. The cells were then treated with different 
concentrations of 27OHC (0.1µM) and LDL (80 µg/ml) as optimised in chapters 3 and 4. 
To address the potential interactions of LDL with the IGF-I signalling pathway, we 
investigated the effects of LDL on cell proliferation and migration in the presence or 
absence of an IGF-IR inhibitor (AG1024). Different strategies have been developed to 
target this system, such as monoclonal antibodies and small molecule inhibitors, targeting 
the tyrosine kinase domain of the receptor(Christopoulos, Corthay and Koutsilieris, 
2018b). Firstly, I investigated the optimum concentration of a tyrosine kinase inhibitor 
(AG1024), by using a range of concentrations (0-5µM) for both MCF-7 and MDA-MB-
231; an effective reduction of the IGF-IR was shown by Western blotting (Fig 6.1). 
Figure 6.1 shows that based on loss of the IGF-IR, 5µM was the optimum dose for MCF-




 A) for MCF-7 and B) MDA-MB-231 dosed with an IGF-IR inhibitor (0-5 µM) for 24hrs. 
The protein abundance of the IGF-IR was measured, and β-actin was used as loading 







Figure 6. 1:  The optimum concentration of IGF-IR inhibitor in MCF-7 and 
MDA-MB-231 cell lines: 
A.   MCF-7 
IGF1 Inhibitor
CT 1 μM 2.5 μM 5μM
IGF1-R
Β-Actin










6.4.3.   Radioimmunoassay (RIA)  
Conditioned media levels of IGF-I were assessed using a radioimmunoassay as described 
in section (2.12).  
 
6.4.4.   Cell proliferation  
This was determined using a CV proliferation assay (Feoktistova, Geserick and Leverkus, 
2016a), as described in section 2.4.  
 
6.4.5.   Trans-well migration assay  
 Cells were prepared to migrate into the chemoattractant serum in the lower compartment 
as described in section 2.9, for 24 h (MCF-7) or 6 h (MDA-MB-231) with or without the 
addition of an IGF-IR antagonist (2.5-5µM) or LDL (100µg/ml). 
 
6.4.6.   Western blot  
Western blot analysis was performed as described previously in section (2.10). In brief, 
protein cell lysates (30μg), were subjected to SDS polyacrylamide gel electrophoresis 
(SDS-PAGE), transferred to nitrocellulose membrane and immunoblotted with the 
following antibodies: anti-IGF-IRβ (1:1000), MAPK and phospho-MAPK (1:1000; 
Thermo fisher), Phospho-IGF-I Receptor β (1:1000; Thermo fisher), AKT (1:1000; Cole-
Parmer Scientific experts), phospho-AKT(1:1000; Star Lab) GAPDH (1:5,000; Millipore) 
and β-actin (1:10,000; Sigma-Aldrich). After that the membranes were incubated with 
particular secondary antibodies (anti Mouse or Rabbit) conjugated to peroxidase (Sigma), 
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next proteins were detected by Clarity ECL substrate (BioRad) by using BioRad Chemidoc 
XRS + system and quantified using Image J 1.46r software (BioRad). 
6.4.7.   Targeted CYP27A1 gene knockdown: 
For experiments investigating the effects of LDL(80 µg/ml) on the production of IGF-I in 
the presence or absence of CYP27A1 in MCF-7 and MDA-MB-231 cells, siRNA was used 
for silencing the CYP27A1 as described in section 3.4.  
6.4.8.   Statistical analysis  
The whole experiments were repeated in triplicate, and also each experiment was repeated 
three times. Using GraphPad Prism 8.0.1 software for windows (La Jolla, CA, USA), to 





6.5.   Results 
6.5.1.   The effect of LDL and 27OHC on the levels of IGF-I in MCF-7 and MDA-MB-
231 cells 
As 27OHC and LDL induced migration and invasion in breast cancer cell lines, we next 
examined the effect of 27OHC on the IGF-I signalling pathway in both ERα-positive and 
ERα-negative breast cancer cell lines. Treatment with 27OHC (0.1µM) and LDL(80 
µg/ml) for 48hrs, increased the abundance of the IGF-IR in MCF-7 cells (p<0.001 and 
p<0.01 respectively) (Fig. 6.2A and B) and in and MDA-MB-231 (p<0.01 and p<0.001 
respectively) (Fig. 6.2C and D) in comparison to the controls. With the radioimmunoassay, 
the addition of 27OHC (0.1µM) and LDL(80 µg/ml) increased the production of IGF-I in 
MCF-7 (p<0.05 and p<0.001) respectively and increased the production of IGF-I in MDA-
MB-231 cells (p<0.01 and p<0.001) respectively (Fig 6.3). These results suggest that there 
is a link between IGF and cholesterol metabolism.   
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western blotting for A) MCF-7 and C) for MDA-MB-231 after being dosed with 27OHC 
(0.1µM) and LDL(80 µg/ml) for 48hrs.  Densitometry analysis of fold changes of IGF-IR 
against loading control β-actin in B) MCF-7 and D) MDA-MB-231. Data representative 
of mean ±SEM (n=3).  P-values were determined using GraphPad Prism one-way 
Statistical analysis: ANOVA test plus least significant difference (LSD) post-hoc test 
(*p < 0.05, **p < 0.01, ***p < 0.001). 
  
 






Figure 6. 3:  Radioimmunoassay to measure IGF-I concentrations:  
in A) MCF-7 and B) MDA-MB-231cells after being dosed with 27OHC (0.1µM) and LDL 
(80 µg/ml) for 48 hours. Data are representative of mean ±SEM (n=3). P-values were 
determined using GraphPad Prism one-way Statistical analysis: ANOVA test plus least 
significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.001 
6.5.2.   The effects of LDL on cell proliferation and migration in the presence or 
absence of an insulin-like growth factor receptor antagonist  
To address the potential interactions of LDL with the IGF-I pathway, the effects of LDL 
on cell proliferation and migration in the presence or absence of the IGF-IR were 
investigated. We used a tyrosine kinase inhibitor, AG1024, to inhibit the IGF-IR for both 
MCF-7 and MDA-MB-231. Cells were treated with LDL (80 µg/ml) for 48hrs, then 
changes in growth and migration were assessed. Figure 6.4A shows that LDL treatment 
increased MCF-7 proliferation (p < 0.001) in comparison to the control, whereas in the 
presence of the IGF-IR antagonist, LDL was unable to increase cell growth. LDL treatment 
significantly increased MCF-7 cell migration (p < 0.001), and this effect of LDL was also 





Figure 6. 4: The effects of LDL on cell proliferation and migration in the presence or 
absence of an insulin-like growth factor receptor antagonist:   
Cell proliferation for A) MCF-7 treated with (LDL 80µg/ml) in the presence or absence of 
a tyrosine kinase inhibitor (AG1024;5µM) for 48 hours, by using crystal violet 
proliferation assay. Cell migration for B) MCF-7 cells after being dosed with LDL 
(80µg/ml) with or without AG1024 (5µM). The migrated cells were stained with crystal 
violet and images were taken (×20 magnification). Data representative of mean ±SEM 
(n=3). P-values were determined by using GraphPad Prism one-way Statistical analysis: 
ANOVA test plus least significant difference (LSD) post-hoc test (*p < 0.05, **p < 0.01, 



















































The same results were found with MDA-MB-231: Figure 6.5A shows that LDL (80µg/ml) 
treatment increased cell proliferation (p < 0.001) in comparison to the control, whereas 
with the IGF-IR (2µM) antagonist, LDL was no longer able to increase cell growth. The 
ability of the LDL to increase MDA-MB-231 migration was also significantly inhibited in 
the presence of the IGF-IR antagonist (Fig. 6.5B). Inhibition of the insulin-like growth 
factor receptor using a tyrosine kinase inhibitor, AG1024, blocked the effects of cholesterol 




Figure 6. 5: The effects of LDL on cell proliferation and migration in the presence or 
absence of an insulin-like growth factor receptor antagonist:  
The cell proliferation for A) MDA-MB-231 after being treated with (LDL 80µg/ml) with or 
without a tyrosine kinase inhibitor (AG1024 2µM) for 48 hours, by using CV proliferation 
assay. Trans-well migration assay was used to perform the cell migration for  B)  MDA-
MB-231 after being dosed with (LDL 80µg/ml) in the presence or absence of AG1024 
(2µM): the migrated cells were stained with CV and images were taken (×20 
magnification). Data representative of mean ±SEM (n=3). P-values were determined by 
using GraphPad Prism; ANOVA test plus least significant difference (LSD) post-hoc test 

















































6.5.3 .  The effect of LDL on the MAPK/AKT transduction pathways in the presence 
or absence of an insulin-like growth factor receptor antagonist  
In MCF-7 cells, the LDL-induced increase in MAPK and AKT activation (p < 0.01) was 
blocked when the insulin-like growth factor receptor was disrupted using a tyrosine kinase 
inhibitor (Fig. 6.6A-C). The western blots show effective downregulation of the IGF-IR 
and inhibition of phospho-IGF-IR (p < 0.001) in MCF7 cells (Fig. 5.6B and C). Similarly, 
with MDA-MB-231 cells, LDL-induced an increase in the phosphorylation of MAPK and 
AKT and these effects were inhibited when the insulin-like growth factor receptor was 
blocked using a tyrosine kinase inhibitor (Fig. 6.7). This indicates that the inability of LDL 
to enhance activation of MAPK/AKT pathway upon the disruption of IGF-IR suggesting 




Figure 6. 6: Levels of the IGF-IR, p-IGF-IR, MAPK, p-MAPK, AKT, p-AKT were 
determined using western blotting in the presence or absence of LDL with or without 
an insulin-like growth factor receptor antagonist:  
A&B) MCF-7 cells, after being treated with (LDL 80µg/ml) and a tyrosine kinase inhibitor 
(AG1024 2µM) for 48 hours, were assessed the levels of IGF-IR, p-IGF-IR, MAPK, p-
MAPK, AKT, p-AKT and GAPDH was used as a loading control for IGF-IR and p-IGF-
IR, but AKT and MAPK for p-AKT and p-MAPK respectively. C) Densitometry analysis of 
fold changes of IGF-IR against loading control β-actin, MAPK against p-MAPK and AKT 
against p-AKT. Data representative of mean ±SEM (n=3).  P-values were determined by 
using GraphPad Prism one-way Statistical analysis: ANOVA test plus least significant 




Figure 6. 7: The levels of the IGF-IR, p-IGF-IR, MAPK, p-MAPK, AKT, p-AKT were 
determined using western blotting of LDL in the presence or absence of an insulin-
like growth factor receptor antagonist:  
in A&B) MDA-MB-231 cells, C) Densitometry analysis of fold changes of IGF-IR against 
loading control β-actin, p-MAPK against MAPK and p-AKT against AKT. Data 
representative of mean ±SEM (n=2). 
In chapter 3, it was shown that LDL induced the proliferation, invasion and migration of 
both MCF-7 (ERα-positive) and MDA-MB-231 (ERα-negative) cells and this was 
inhibited when the enzyme that converts cholesterol into 27OHC (CYP27A1) was silenced 
using siRNA.  
Furthermore, it was determined that the effects of LDL on the production of IGF-I in the 
presence or absence of CYP27A1 were inhibited in both ERα-positive (Fig. 6.8A) and 
negative (Fig. 6.8B) breast cancer cell lines. It also reduced the abundance of the IGF-IR 





















Interestingly, using the publicly available METABRIC gene expression database, we also 
demonstrated that tumours with high levels of CYP27A1 (and thus expected elevated 
27OHC) also had increased expression of IGF-I (p <0.001) (Fig. 6.8C). Conversely low 
tumour expression of CYP27A11 was associated with lower expression of IGF-I (Fig. 
6.8C). 
 
Figure 6. 8: Levels of IGF91 in the presence or absence of CYP27A1: 
 in A) MCF-7 and B) MDA-MB-231 after being dosed with LDL (80µg/ml) in the presence 
or absence of CYP27A1 for 48 hours. C) The protein expression of the IGF-IR and 
CYP27A1 were assessed using western blot analysis. GAPDH was used as a loading 
control. D) Scatterplot analysis of TCGA data of 504 invasive breast cancer carcinomas 
for mRNA expression of IGF-I represented as median expression of CYP27A1. Results are 
presented as mean +/− SEM (n=3) (A-C), and D) where the horizontal line presents the 
mean. P-values were determined by using GraphPad Prism: one-way Statistical analysis: 
one-way ANOVA test followed by Tukey’s post-hoc test (*p < 0.05, **p < 0.01, 
***p < 0.001) (A-C), and D) Mann–Whitney test.  
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6.6.    Discussion  
Growth factor signalling is often deregulated in cancer cells. One of the most common 
activators of PI3K and its downstream target Akt is IGF-I via its receptor IGF-IR, which 
can modulate cell survival (Chimento et al., 2019b). In overweight women, it has been 
shown that IGF signalling and levels of cholesterol, specifically LDL-C are up-regulated. 
Recently it has been found that LDL-R abundance is important in the growth of TNBCs in 
the setting of increased circulating LDL-C and is thought to be a major contributing factor 
to the increased mortality and recurrence in overweight women with TNBC (Gallagher et 
al., 2017b). Recent meta-analyses reported that breast cancer patients who use statins, show 
improved recurrent-free, overall and cancer- specific survival (Manthravadi, Shrestha and 
Madhusudhana, 2016; Li et al., 2018).  
We found that the addition of LDL increased the production of IGF-I by MCF-7 and MDA-
MB-231 cells. It also increased the abundance of the IGF-IR in MCF-7 and MDA-MB-231 
cells, and this phenotype has been confirmed recently in prostate cancer, PC-3 cells. These 
data indicated that simvastatin treatment deregulated IGF-IR expression (Sekine et al., 
2008) and impeded both basal IGF-I and IGF-I-induced ERK and Akt activation (Sekine 
et al., 2018). Breast cancer (MCF-7, MDA-MB231) and prostate cancer (PC-3, LNCaP) 
cells are more sensitive to cholesterol sequestering than normal-like prostate and breast 
cell lines (PZ-HPV7 and MCF-10A, respectively) (Li et al., 2006). In fact, raft modulating 
agents are more efficient in cells with high content of lipid rafts, such as, breast cancer cell 
lines MCF-7 and MDA-MB231, than normal-like breast cell lines  (Sekine et al., 2018).  
 The data also clearly indicate that LDL increased the proliferation of MCF-7 and MDA-
MB-231 cells and increased their cell invasion. Inhibition of the insulin-like growth factor 
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receptor using a tyrosine kinase inhibitor, AG1024, blocked the effects of cholesterol on 
cell growth and invasion of MCF-7 and MDA-MB-231 cells. The inhibition of migration 
and growth that we found was consistent with results in the other reports in different cell 
lines (Li et al., 2014).  
Statins can influence the signalling pathways activated by IGF and EGF. Simvastatin has 
been proposed to inhibit the IGF-IR in bile duct cancer cells (Laurentiis, Donovan and 
Arcaro, 2007), suppress esophageal cancer cell growth and can lead to the development of 
radioresistance by reversing the process of epithelial-to-mesenchymal (EMT) transition 
through the PTEN-PI3K/AKT signalling pathway and this phenotypic effect was blocked 
by the addition of IGF-I (Li et al., 2014).   
Several data suggest that statins reduce tumour growth and migration (Livingstone et al., 
2014; Cardwell et al., 2015; Borgquist et al., 2019), deregulate IGF-1R expression (Sekine 
et al., 2008) and inhibit both basal IGF-I  and IGF-I-induced ERK and Akt activation 
(Sekine et al., 2018). Conversely, it has been shown that alteration of circulating 
cholesterol using high cholesterol diets in mice, promoted prostate tumor proliferation and 
survival, as a result of activated Akt signalling pathway through cholesterol-rich lipid rafts 
(Zhuang et al., 2005). Although MAPK pathway has been associated with growth and 
survival responses, we indicated that after 48hrs of treatment with LDL, both AKT and 
MAPK were activated, and these effects of cholesterol were blocked with an IGF-IR 
inhibitor. The inhibition of insulin-like growth factor-1 receptor attenuated cholesterol- 
induced AKT and MAPK activation. This suggests that AKT and MAPK are associated 
with LDL actions in breast cancer cell lines. The same effect has been investigated but in 
different cancer type such as prostate cancer cell lines (Sekine et al., 2018). Activated 
 
197 
PI3K/Akt controls cell survival, growth and tumorogenesis, and abnormal activation of this 
pathway participates in the invasiveness and development of cancer cells (Shukla and 
Gupta, 2007; Courtney, Corcoran and Engelman, 2010).  
There have been different explanations for the mechanism by which cholesterol associates 
with the IGF-I signalling pathway (Araya, Tang and Wikvall, 2003; Sekine et al., 2008).   
In vitro experiments in human cells, hepatocytes (HepG2) cells, reported a role for growth 
hormone, IGF-I, and glucocorticoids in the regulation of the enzyme CYP27A1 activity 
(Araya, Tang and Wikvall, 2003). Considering this it is interesting that LDL increased the 
production and secretion of IGF-I and this was inhibited when the enzyme CYP27A1 was 
silenced in both ERα-positive and -negative breast cancer cell lines. It also reduced the 
abundance of the IGF-IR in MCF-7 cells. These data were consistent with the results from 
the publicly available METABRIC gene expression database, which together suggested 
that CYP27A1 is a positive regulator of IGF-I receptors. These phenotypic effects that we 
observed have been confirmed recently by others with different methods of targeting 
cholesterol metabolism (Laurentiis, Donovan and Arcaro, 2007; Lee et al., 2016). There 
are some limitations; we evaluated the association of MAPK and AKT pathway with the 
action of LDL in breast cancer cell lines, but we did not investigate if AKT or MAPK were 
involved in the effects of LDL and 27OHC. The data show that blocking the IGF-1R with 
a tyrosine kinase inhibitor, inhibited the effects of LDL on activating AKT and MAPK, 
and its ability to increase levels of the IGF-1R and IGF-I. Blocking CY27A1, had similar 
effects, suggesting that LDL via 27OHC is a positive regulator of IGF signalling. 
Considering the upregulation of other membrane proteins in the previous chapter, such as 
CAV1 and the beta 1 integrin, it would be interesting to investigate if an association existed 
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between these molecules at the cell membrane and if this played a part in regulating the 
downstream signalling that we observed. Since IGF-1R activation needs ligand binding 
that lead to elevate IGF-1 levels, decreasing IGF1 level may be a reasonable approach for 
future to test the potential hypothesis that LDL promotes IGF1 expression which in turn 




 6.7.   Conclusion  
Our data suggest that the actions of LDL on the growth, invasion and activation of the 
AKT/MAPK pathway of breast cancer cells are mediated by the IGF-IR. These results 
advise that the combination of cholesterol lowering drugs and agents targeting the IGF-IR 










7.1.  General discussion 
Epidemiological studies indicate that cholesterol metabolites have a role in enhancing 
tumour growth and invasion and increase the risk of breast cancer in postmenopausal 
women (DuSell et al., 2008; Wu et al., 2013; Nguyen et al., 2015; He and Nelson, 2017). 
This is probably due to elevated oxysterol production which associates with 
hypercholesteremia. Increased concentrations of cholesterol metabolites have also been 
associated with breast cancer (Nelson et al., 2013a; Wu et al., 2013; Gallagher et al., 
2017a). Cholesterol-lowering drugs (such as statins) have a protective effect against breast 
cancer deaths and recurrence (Beckwitt et al., 2018), suggesting that lowering cholesterol 
and 27OHC may have therapeutic benefit against breast cancer development. Nevertheless, 
the definite mechanism as to how cholesterol affects breast cancer pathogenesis, 
particularly with regard to the ERβ, is still not clear (Lipovka and Konhilas, 2016).  
We evaluated the significance of high cholesterol-LDL on the growth and migration of 
breast cancer cell lines and found that LDL drives the proliferation of ERα-positive and 
ERα-negative cells, and this is consistent with a previous study examining the importance 
of the LDL-R in the growth of TNBCs (Gallagher et al., 2017a). The inhibition of 
CYP27A1 blocked the action of LDL, suggesting that the exogenous of 27OHC can 
contribute to the risk of breast cancer by mediating the effect of cholesterol LDL.  
The phenotype that we observed has been confirmed by others (Nelson et al., 2013a; Wu 
et al., 2013) in addition to clinical evidence supporting a role of the 27OHC/CYP27A1 
metabolic signalling pathway in breast cancer (Nelson et al., 2013a; Baek et al., 2017; Le 
Cornet et al., 2020). Moreover, a recent study has demonstrated the correlation between 
CYP27A1 expression, high grade tumours, and an increased risk for aggressive disease 
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which suggests that CYP27A1 can be a biomarker of late lethal disease in postmenopausal 
women who have ER-positive breast tumours (Kimbung et al., 2020). Additionally, a study 
in bladder cancer cells showed that blocking CYP27A1 can reduce the cellular cholesterol 
levels in androgen receptor-positive cell lines (Liang et al., 2019) and the same result was 
found in prostate cancer cell lines (Alfaqih et al., 2017).  
LDL induced proliferation in ERα-negative cells, MDA-MB-231, but despite siRNA to 
CYP27A1 blocking the effects of LDL, exogenous addition of 27OHC did not induce 
proliferation. There are other metabolites of cholesterol that can also mediate effects of 
cholesterol. This may mean that the effects of LDL in MDA-MB-231 cells may be 
mediated through other metabolites. 25-hydroxycholesterol has been shown to promote 
bladder cancer cell proliferation and the EMT markers in human bladder cancer cells 
(Wang, He and Fang, 2020). Therefore, it will be helpful for future work to investigate how 
CYP27A1 impacts breast cancer progression as it may be a useful strategy to treat or 
prevent breast cancer. These data indicate that cholesterol lowering treatments such as 
statins could also be a good strategy to control the risk of breast cancer, since it has been 
reported that statins can decrease 27OHC concentrations in breast cancer tumours 
(Kimbung et al., 2017b).  
We found that 27OHC promoted cell growth in ERα positive, but not in ERα negative cell 
lines, and this effect was mediated via the ERα, as has been observed previously (DuSell 
et al., 2008; He and Nelson, 2017; Starkey et al., 2018). Interestingly, we found that 
27OHC was able to promote breast cancer cell migration and invasion in both cell lines. 
We elucidated that the proliferative effects of 27OHC involved the ERα and that perhaps 
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targeting ERα with lowering cholesterol treatment in ERα-positive breast cancer cells 
could be a targeted approach for decreasing breast cancer growth. 
However, silencing the ERα in the ERα-positive cells had no effect on the ability of 27OHC 
to promote migration and invasion. In an attempt to understand what was mediating the 
effects of 27OHC, we silenced the ERα in the ERα-positive cells and observed an increase 
in the abundance of the ERβ. It is consistent with previous data whereby the role that 
27OHC plays depends on the relative ratio of expression of ERα to ERβ (Leygue and 
Murphy, 2013), and this suggested that ERβ can mediate the metastatic actions of 27OHC 
in the absence of ERα. High expression of ERβ in TNBCs and its structural similarity to 
ERα have suggested that it is a logical therapeutic target (Abe et al., 1998; Novelli et al., 
2008a). There have been conflicting findings about the role of ERβ in breast cancer (Jensen 
et al., 2001; Hamilton et al., 2015; Bialesova et al., 2017; Austin et al., 2018), due to 
differences between the studies; this could relate to the lack of standardized detection 
methods and insufficiently validated antibodies (Carder et al., 2005). Moreover, ERβ has 
five different isoforms, which could also complicate the investigation of the physiological 
role of ERβ and its participation in the carcinogenesis of breast cancer (Girgert, Emons and 
Gründker, 2019). It has been shown that ERβ1, ERβ2 and ERβ5 have been expressed in 
breast cancer tissue (Yan et al., 2020). To address these differences we used a certified 
TNBC cell line (negative for ERα. PR, and HER2 overexpression) and validated ERβ 
antibodies (Andersson et al., 2017). Moreover, we have successfully used three different 
strategies to silence ERβ in MDA-MB-231 TNBC cells. 
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In future studies, it will be important to determine the ratio of ERβ1, ERβ2 and ERβ5 in a 
large sample of TNBC and to associate the cholesterol/oxysterol level with treatment 
outcome (Murphy and Leygue, 2012). 
We found that 27OHC-induced cell migration and invasion and increased the abundance 
of an EMT marker fibronectin, through ERβ, suggesting that 27OHC can act via both the 
ERα and ERβ in our models, dependent on the context. This is supported by the observation 
that 27OHC increases cell proliferation in prostate cancer cell lines via ERβ activation 
(Raza et al., 2017). This is also in agreement with a previous study indicating that 27OHC 
can promote breast cancer migration and invasion and EMT markers (Jiao et al., 2020) and 
that ERβ suppression decreased the expression of vimentin and fibronectin, and decreased 
MDA-MB-231 breast cancer cell migration and invasion (Piperigkou et al., 2016). In 
contrast, recent studies indicate that 27OHC acts as a negative modulator of ERβ in 
Ishikawa uterine cancer cells, and they explained that this effect was because of the 
concentration of etradiol (E2) was higher than in previous reports (Starkey et al., 2018). 
They suggested that 27OHC may function as a competitive ligand in smooth muscle and 
vascular endothelial cells (Umetani et al., 2007).  Since 27OHC shows both agonistic and 
antagonistic actions on ERα functions depending on target organs (Umetani, 2016), 
27OHC may also function as both an antagonist and agonist for ERβ dependent on specific 
tissues/cells or the presence or absence of the ERα (Skliris et al., 2006b). These novel 
results and the previous studies suggest that endocrine treatment in combination with 
lowering cholesterol drugs may be beneficial for improving ER-positive breast cancer 
outcomes. As a previous study showed, a combination of cholesterol lowering drug and 
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adjuvant endocrine therapy may improve the outcome of patients with ER-positive breast 
cancer (Borgquist, Giobbie-Hurder, Thomas P. Ahern, et al., 2017). 
In TNBC, ERβ1 expression associates with Ki-67, a cell growth biomarker, indicating that 
ERβ1 can have a role in driving growth (Yan et al., 2013), and this is consistent with the 
results from the TCGA database, in which we found that tumours with high mRNA levels 
of ERβ also had increased expression of Ki-67.  
Functional crosstalk exists between ERs and  growth factor receptors, such as EGFR and 
IGF-IR. Growth factor pathways can activate estrogen, and estogen can activate IGF 
signalling (Yee and Lee, 2000). Treatment of ERα-positive breast cancer cells with 
tamoxifen can lead to resistance, and IGF-IR and/or EGFR are critical for breast cancer 
resistance to endocrine therapy (Ignatov et al., 2010). The role of ERβ in  breast cancer 
growth was shown in ERα-negative tumours, but not ERα-positive tumour (Yan et al., 
2013). Additionally, ERβ associates with cancer growth and progression in lung 
cancer(Hershberger et al., 2009) and prostate cancer (Raza et al., 2017). 
With ERβ inhibition, we observed a suppression of IGF-I and EGF receptors and an 
inhibition of basal cell proliferation. The phenotype that we observed has been confirmed 
recently by others in TNBC, but they observed an interaction between ,ERβ and insulin-
like growth factor-II (IGF-II) in TNBC(Hamilton et al., 2015; Piperigkou et al., 2016). 
Conversely, we used a different approach to confirm this finding and found that up-
regulating ERβ, using an agonist, increased levels of the IGF-I and EGF receptors in MDA-
MB-231 cells. These data indicate that ERβ is a positive regulator of the IGF-I and EGF 
receptors. A link between ERβ with IGF and EGF signalling pathways has also been 
reported previously where silencing ERβ in TNBC cell lines reduced cell proliferation, 
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migration and invasion that was associated with down-regulation of the IGF-I and EGF 
receptors (Richardson et al., 2011; Hamilton et al., 2015). Some studies have indicated that 
ERβ found to be a biomarker linked to a more aggressive breast cancer (Novelli et al., 
2008a).This is consistent with the results from the TCGA database, in which we found an 
association between the levels of ERβ with IGF-IR and EGFR mRNA levels and that may 
suggest that ERβ is a positive regulator of IGF-IR, EGFR and Ki-67. We elucidated that 
the phenotypic effects of LDL and 27OHC involved the IGF-IR and EGFR and that 
perhaps targeting ERβ in TNBC could be a different approach for down-regulating IGF 
signalling.  
The wealth of pre-clinical studies indicate a role for  EGF and IGF signalling pathways in 
TNBC tumours, and these pathways are correlated with poor response to therapy, reduced 
overall survival and higher rates of recurrence (Cox et al., 2015; Christopoulos, Corthay 
and Koutsilieris, 2018a). Several strategies were developed to target the IGF and EGF 
signalling pathway and these strategies were applied as monotherapies and had limited 
success(Christopoulos, Corthay and Koutsilieris, 2018b). This indicated the need to 
identify a good biomarker to be able to select those patients most likely to respond. Based 
upon our results, we suggest that potentially the ERβ may be investigated as biomarker of 
response to anti-IGF-IR and EGFR therapies, such as inhibitors of the tyrosine kinase 
domains of these receptors (TKIs).  
 In the presence of 27OHC or LDL, doxorubicin was less effective in inducing cell death, 
suggesting they can act as survival factors in MDA-MB-231, TNBC. This result was 
consistent with previous work where doxorubicin significantly downregulated HMG-CR, 
and this led to a decrease in the level of the EGFR, and thus enhanced doxorubicin-induced 
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cell death. In addition, knockdown of HMG-CR in the presence of DOX enhanced PARP 
cleavage, which is an indicator of caspase-3 activation and consequent apoptosis (Yun et 
al., 2019). We determined that the phenotypic effects of LDL involved the IGF and EGF 
signalling, and as previous studies have demonstrated, this pathway is associated with poor 
response to therapy. We suggested that the phenotypic effects of LDL decreasing 
doxorubicin cytotoxicity, may involve the IGF and EGF signalling pathways. Therefore, 
perhaps inhibiting cholesterol metabolism in TNBC may be an effective approach in 
addition to chemotherapy treatment to lower the dose and reduce the side effects of 
chemotherapy treatment. The same result was reported for MCF-7 breast cancer cells, and 
it indicated that simvastatin reduced cell growth and increased the rate of  cell death in 
doxorubicin treated cells, and it has been suggested that simvastatin may promote 
doxorubicin cytotoxicity in ERα-positive breast cancer cells (Buranrat, Suwannaloet and 
Naowaboot, 2017). 
Depleting or sequestering cholesterol in cells from the membrane leads to a shift in raft and 
hormonal receptors and caveolar proteins to other parts of the plasma membrane (Garnett 
and Greenhough, 2013). We found that the addition of 27OHC increased the abundance of 
CAV1, the β1-integrin and the IGF-IR. In our laboratory, Zielinska  et al. have indicated 
that CAV1 is a marker of an invasive, hormone-resistant phenotype (Zielinska et al., 2018) 
and that CAV1 associates with the β1 integrin in TNBC cells (Burrows et al., 2006).  
Moreover, it has been indicated that CAV1 regulates IGF-I and EGF-R signalling. 
(Laurentiis, Donovan and Arcaro, 2007). Since we determined that the effects of LDL 
involved modulation of IGF and EGF, it will be helpful in future study to determine if 
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CAV1, EGFR and IGF-IR play an important role in the phenotype induced by LDL and 
27OHC.  
IGF signalling and levels of cholesterol are frequently up-regulated in overweight women 
and this is thought to be important contributing factors to the increased mortality and 
recurrence in overweight women with TNBC breast cancer(Gallagher et al., 2017b).  The 
insulin family of growth factors mediates effects of metabolic disturbances (Belardi et al., 
2013). IGF expression is strongly increased in invasive breast cancer through downstream 
activation of  the mTOR pathway leading to  TNBC cell migration (Mancini et al., 2014).  
Our findings show that the addition of LDL increased the production of IGF-I and the 
abundance of the IGF-IR in MCF-7 and MDA-MB-231 cells. The same phenotype has 
been confirmed recently in breast cancer patients, these data indicated that the increase of 
serum IGF-I is correlated with high levels of metabolic syndrome markers, including LDL-
cholesterol, triglyceride and high BMI and this increased the risk of breast cancer 
progression (Khaddour et al., 2020).  Moreover, simvastatin treatment deregulated IGF-IR 
expression through inhibition of the AKT pathway (Sekine et al., 2008, 2018) and inhibited 
both basal IGF-I and IGF-IR expression (Sekine et al., 2018). We found that inhibition of 
the IGF-IR blocked the effects of cholesterol on cell growth and invasion of MCF-7 and 
MDA-MB-231 cells consistent with other reports in  different cell lines (Li et al., 2014). 
The same results were found in bile duct cancer cells, with a report that the statin, 
simvastatin was able to influence the signalling pathways activated by IGF and EGFR. 
(Laurentiis, Donovan and Arcaro, 2007). Moreover, in a prostate cancer cell line, PC-3s,  
simvastatin inhibited cell proliferation and migration through inhibiting activation of the 
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IGF-I/AKT pathway (Sekine et al., 2018). This suggests that cholesterol is associated with 
the IGF-I pathway to promote cancer proliferation, migration, and invasion.  
My study indicated that inhibition of the IGF-IR attenuated cholesterol-induced AKT and 
MAPK activation. This suggests that AKT and MAPK are associated with LDL actions in 
breast cancer cell lines. The same effect has been reported previously (Sekine et al., 2018). 
Activated PI3K/AKT controls cell survival, proliferation and tumorogenesis, and the 
abnormal activation of the PI3K/AKT pathway due to the development and invasiveness 
of cancer cells (Shukla and Gupta, 2007; Courtney, Corcoran and Engelman, 2010). These 
data are consistent with our results from the TCGA gene expression database, and this 
implies that the CYP27A1 may function as a positive regulator of IGF-I receptors. The 
effects that we observed have been confirmed recently by others with different methods of 
targeting cholesterol metabolism (Laurentiis, Donovan and Arcaro, 2007; Lee et al., 2016). 
It will be a helpful in future work, performing inhibitor studies, to investigate if AKT or 
MAPK pathways are involved and not just associated with their action in the effects of 
LDL and 27OHC. There are some limitations: we evaluated the effects of 27OHC and LDL 
on changes of gene expressions only at a single time point instead of performing a time-
course experiment.  Although, we selected breast cancer cell lines, that possess some of 
the characteristics associated with particular breast cancer subtypes, these cell lines are not 
ideal models as they do not reflect the pathophysiological process which are observed in 
human breast cancer tissue. A single cell line does not represent the cellular diversity and 
heterogeneity associated with breast tumours. Improvements could be made with single 
cell line models, by growing them in 3D cell culture as opposed to 2D cell culture, with 
the addition of specific matrices and perhaps with other cell types to closer represent breast 
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cancer. Although preliminary, our study could guide future directions upon which to focus 
using clinical samples to validate our in vitro associations.   
Another limitations of this study was only performing optimisation studies once and not in 
triplicate, despite the fact that the doses selected were repeated more than three times in 
the critical experiments.  
In summary, our data elaborate a mechanism to support the clinical studies suggesting the 
link between obesity and high cholesterol with an increased risk of breast cancer 
progression. LDL and 27OHC promote cell proliferation, migration and invasion through 
a novel mechanism in human breast cancer cells. This study shows that ERβ is a positive 
regulator of IGF-I and EGF pathways, that via their respective receptors can activate the 
MAPK/PI3K/AKT signalling pathways. The overall alterations in these pathways may 
contribute to increased proliferation rates and invasiveness of breast cancer cells and may 






Figure 7. 1: Schematic illustrating the potential signalling pathways which underlie 
the phenotypic and metabolic changes that occur when breast cancer cells are exposed 
to high LDL:  
Cholesterol metabolism in breast cancer is enhanced with LDL and 27OHC supporting 
breast cancer progression. The ERβ is central to these effects on invasion and migration 
and impacts on the IGF and EGF axes. This results in intrinsic activation of oncogenes 
such as IGF-I, which can bind to the IGF-IR and activate MAPK/ PI3K/AKT signalling 
pathways. The overall alterations in these pathways may contribute to increased 




7.2.  Future direction 
Work detailed in this thesis showed novel effects of LDL, which may contribute to 
increased growth, migration and invasion. In particular, LDL was demonstrated to regulate 
cross-talk between the ERβ and the IGF/EGF signalling pathway. Therefore, it will be 
important to further understand the underlying mechanistic role for ERβ in mediating the 
effects of LDL in TNBC, that use LDL to promote metastasis.  This may identify new drug 
targets and optimise treatment regimens for this sub-set of TNBC patients. 
- To assess whether ERβ expression correlates with disease free-survival and 
overall survival and if this affected by statin use and/or correlation with 
CAV-1, IGF-IR and EGF-R using tissue from TNBC patients. 
- To determine whether the LDL-induced migratory and invasive phenotype 
of ERβ expressing TNBC cells is modulated in the presence of statins. 
- To illustrate whether depleting cholesterol in cells causes a shift in raft and 
hormonal receptors and caveolar proteins to other parts of the plasma 
membrane. As ERα has previously been found to bind to CAV-1 (Schlegel 
et al., 2001), ERβ may be present in the same signalling complex in TNBC.  
- To investigate the role of other cholesterol metabolites on breast cancer 
progression such as 25-hydroxycholesterol.  
- To understand how CYP27A1 impacts breast cancer progression as this 
may be a useful strategy to prevent or treat breast cancer, by using other 
types of experiments. 
 
213 
- To use Mendelian Randomization to determine whether CAV1, integrins 
and ERβ, which are associated with a TNBC metastatic phenotype, are 
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